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SUMMARY
Cancer belongs to the most life-threatening diseases in humans and represents in a simplified
manner the destruction of healthy tissue and organs by uncontrolled cell proliferation and
subsequent formation of a tumor. The most dangerous step of this disease occurs when cancer
cells gain the ability to invade into the surrounding tissue and to disseminate via the blood
system or the lymphatics throughout the body to form at distant sites secondary tumors, a
process named metastasis. To gain motility and invasiveness, cancer cells are known to
undergo an epithelial-mesenchymal transition (EMT). EMT is well known from non-
pathological processes like development and wound healing and describes the temporal
transition of non-invasive epithelial cells into motile, invasive mesenchymal cells.
To gain new and more detailed insights into the complex process of EMT and to identify new
potential markers for ongoing metastasis, we established different in vitro EMT model
systems and tracked changes in global gene expression occurring during EMT. By comparing
these gene expression profiles we identified the neural cell adhesion molecule (NCAM) and
the homeobox transcription factor distal-less homeobox 2 (Dlx2) to be upregulated during
EMT.
Employing different in vitro systems such as the normal murine mammary gland (NMuMG)
cells which undergo a progressive EMT upon transforming growth factor (TGFβ) treatment,
in combination with transgenic and syngeneic mouse models, we investigated the role of
NCAM and Dlx2 during the process of EMT. 
Our investigations revealed that NCAM expression is required and sufficient to induce EMT
in NMuMG cells. We show that during EMT NCAM undergoes a functional switch by
changing both its subcellular localization and its interactions partners. A subset of
upregulated NCAM breaks down its complex formation with the fibroblast growth factor
receptor (FGFR) and translocates into lipid rafts where it interacts with the member of the Src
family kinase (SFK) p59Fyn. In association with p59Fyn NCAM induces the phosphorylation of
focal adhesion kinase (FAK), leading to stabilization of β1-integrin-mediated focal adhesion,
increased cell spreading and migration. In line with this observation, we found NCAM
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expression at the invasive front of human and murine tumors. 
In contrast, Dlx2 function is not required and its expression is not sufficient to induce EMT in
NMuMG cells. Instead, we found that Dlx2 function protects from TGFβ-induced cell-cycle
arrest and apoptosis by two major modifications namely, inhibition of the apoptotic,
canonical TGFβ-signaling pathway and the activation of mitogenic, survival-ensuring
mitogen-activated protein kinase (MAPK) -and phosphoinositide 3-kinase (PI3K) pathways.
The canonical apoptotic TGFβ signaling is inhibited by transcriptional repression of the
TGFβ receptor II (TGFβRII) gene, leading to reduced TGFβRII protein levels, decreased
activation of the signal transducers Smad2/4 and reduced transcriptional activation of the
cell-cycle inhibitors such as p21CIP1. Proliferation and survival is mediated by the cooperated
activation of the MAPK and PI3K pathways triggered by epidermal growth factor receptor
(EGFR). Supporting the importance of Dlx2 function during tumor development and
progression, we show that (i) loss of Dlx2 function in B16 melanoma cells significantly
impairs their ability to form primary tumors and metastatic lesion in the lung of transplanted
syngeneic mice and (ii) expression of Dlx2 correlates significantly with invasiveness of
human melanoma, lung and prostate cancers.
In summary, we identified the cell-adhesion molecule NCAM and the transcription factor
Dlx2 as important key players of EMT by promoting invasion and survival, respectively.
Whether these genes can be used as prognostic markers for EMT-driven tumor invasion
requires further investigations. 
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ZUSAMMENFASSUNG
Krebs gehört zu den gefährlichsten Krankheiten des Menschen. Krebs sind entartete Zellen,
die durch unkontrolliertes Wachstum und Vermehrung gesundes Gewebe und Organe
zerstören. Dabei erfolgt der lebensbedrohlichste Schritt dieser Krankheit, wenn Krebszellen
sich im Gewebe ausbreiten, invasiv werden und durch das Blut- und Lymphsystem in
verschiedenen Körperregionen transportiert werden, um dort zu sekundären Tumoren
auszuwachsen. Dieser  Prozess wird als Metastasenbildung bezeichnet.
Damit Krebszellen mobil und invasiv werden können, vollziehen sie ein sogenanntes
Epithelial-Mesenchymal Transition (EMT). EMT ist ein Vorgang, der bei nicht-
pathologischen Prozessen wie z.B. der Embryonalentwicklung oder Wundheilung stattfindet
und die temporäre Umwandlung nicht-invasiver Epithelzellen in invasive, fibroblastoide
Zellen beschreibt. 
Um neue und tiefere Einblicke in die komplexen Prozesse des EMT zu bekommen und um
neue potentielle Marker für die Metastasenbildung identifizieren zu können, haben wir
verschiedene in vitro EMT-Modelle etabliert und die Veränderungen der Genexpression, die
während EMT stattfinden, verfolgt. Durch das Vergleichen dieser Genexpressionsprofile
konnten wir unter anderem das neuronale Zelladhesionsmolekül NCAM und den
Transkriptionsfaktor distal-less homeobox 2 (Dlx2) als in EMT erhöht exprimierte Gene
identifizieren.
Unsere Untersuchungen haben ergeben, dass die Funktion von NCAM für EMT benötigt
wird. Darüber hinaus reicht seine alleinige Überexpression aus, um EMT auszulösen. Wir
zeigten, dass NCAM während EMT eine funktionelle Wandlung durchmacht, indem es
sowohl seine subzelluläre Lokalisation als auch seine molekularen Interaktionspartner
wechselt. Ein Teil des hochregulierten NCAM löst sich von seiner Interaktion mit dem
Fibroblasten Wachstumsfaktor-Rezeptor (FGFR) und wandert in sogenannte "lipid rafts", wo
es mit der Src-Kinase p59Fyn interagiert. In Kooperation mit p59Fyn induziert NCAM die
Phosphorylierung der Fokalen Adhäsions-Kinase (FAK), wodurch β1-integrin vermittelte,
fokale Adhäsion stabilisiert und somit Zelladhäsion und Zellmigration verstärkt wird. In
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Übereinstimmung mit diesen Ergebnissen konnten wir die Lokalisation von NCAM in der
invasiven Front von Tumoren bei Mensch und Maus zeigen.
Im Gegensatz zu NCAM wird die Funktion von Dlx2 für EMT nicht benötigt und ist nicht
ausreichend, um EMT auszulösen. Stattdessen schützt Dlx2 vor dem transformierenden
Wachstumsfaktor beta (TGFβ) vermittelten Zellzyklusarrest und Zelltod. Dlx2 ist in der Lage
sowohl die durch TGFβ ausgelöste Signalkaskade als auch die Mitogen-aktivierte Protein-
Kinase (MAPK) und Phosphoinositide-3 Kinase (PI3K) Signaltransduktionkaskaden zu
verändern. Die durch TGFβ induzierte apoptotische Signaltransduktion wird durch die
transkriptionelle Repression des TGFβ-Rezeptors II (TGFβRII) inhibiert, wodurch dieser die
Signalüberträger Smad2/4 nicht mehr aktivieren kann, was wiederum zu einer verminderten
Expression des Zellzyklusinhibitors p21CIP1 führt. Komplementär wird die Teilungsfähigkeit
und das Überleben der Zelle durch die kooperative Aktivität der MAPK and PI3K
ermöglicht, die durch den Epidermalen Wachstumsfaktor-Rezeptor (EGFR) kontrolliert
werden. Die Wichtigkeit der Dlx2 Funktion während der Tumorentwicklung und -
progression wir durch folgende Beobachtungen gestützt: (i) Der Verlust der Dlx2 Funktion
schränkt die Fähigkeit von B16 Melanomzellen sowohl Tumore als auch Lungenmetastasen
zu bilden signifikant ein und (ii) die Expression von Dlx2 korreliert signifikant mit der
Aggressivität von humanem Prostatakrebs und Melanomen. 
Somit konnten wir zeigen, dass sowohl das Zelladhäsionsprotein NCAM als auch der 
Transkriptionsfaktor Dlx2 eine wichtige regulatorische Rolle während EMT spielen. Dabei 
ist NCAM entscheidend für die Ausbreitung der Krebszellen in umliegendes Gewebe, 
während Dlx2 das Wachstum und Überleben der Zellen in Gegenwart von TGFβ ermöglicht. 
Ob NCAM und/oder Dlx2 als diagnostische Marker für Tumorprogression und 
Metastasenbildung im humanem Krebs genutzt werden können, bedarf weiterer 
Untersuchungen.
Zusammenfassung
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1. Introduction
1.1. Hallmarks of cancer
Cancer represents in a simplified manner the destruction of healthy tissue and organs by
uncontrolled cell proliferation and subsequent formation of a tumor. Multiple intrinsic (e.g.
reactive oxygen species) as well extrinsic factors (e.g. UV light) can provoke cancer
formation by inducing DNA damages leading to inactivation of tumor-suppressors or the
arise of oncogenes. Cells which transform into a cancer cell have to acquire distinct
"hallmarks of cancer" to grow out into a tumor (Hanahan and Weinberg, 2000): 
• Self-sufficiency in growth signals. Growth factors which are required for proliferation are
limited and have to be supplied by external sources. Cancer cells break down this limitation
by either producing growth factors in an autocrine manner and/or by overexpressing growth
factor receptors to become hyperresponsive towards ambient growth factor concentrations
(Fedi et al., 1997). 
• Insensitivity to antigrowth signals. Within normal tissue, multiple anti-proliferative signals
operate to maintain cellular quiescence and tissue homeostasis. Tumor cells block
antigrowth signaling by inactivating cell-cycle inhibiting pathways such as the
retinoblastoma (pRb) pathway or by overexpressing mitogenic proteins such as c-Myc
(Weinberg et al., 1995).
• Resistance towards apoptosis. Several intrinsic factors (e.g. genomic instability) as well as
extrinsic factors (e.g. hypoxia) induce apoptosis of untransformed cells. Tumor cells
prevent apoptosis by overexpressing anti-apoptotic genes such as Bcl-2 or by silencing
tumor-suppressors such as p53 (Butt et al., 1999, Harris et al., 1996).
• Limitless replicative potential. Untransformed cells are limited in their replicative potential
by the length of their telomeres. Shortening of telomeres below a certain length induces
cell-cycle arrest, senescence and apoptosis. Tumor cells prevent this by expressing the
telomerase enzyme (Shay and Bacchetti et al., 1997)
Introduction: Hallmarks of Cancer
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• Sustained angiogenesis. The growth of untransformed cells is limited by nutrients and
oxygens supplied by blood vessels. Tumor cells bypass this limitation by inducing
angiogenesis via release of angiogenic factors such as vascular endothelial growth factor
(VEGF) and/or fibroblast growth factor (FGF) (Folkman et al., 1997).
• Tissue invasion and metastasis. Non-transformed epithelial cells are embedded via tight
intercellular junctions into a tissue, which is limiting in space and nutrient supply. Tumor
cells break down this limitation by gaining invasiveness and the ability to metastasize to
distant sites (Sporn et al., 1996). For more details see Chapter 1.2 "Distinct mechanisms of
tumor invasion and metastasis" and Chapter 1.4 "EMT, the cytoskeleton, and cancer cell
invasion.
Introduction: Hallmarks of Cancer
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1.2. Distinct mechanisms of tumor invasion and metastasis (Review)
Mahmut Yilmaz, Gerhard Christofori, and Francois Lehembre: "Distinct mechanisms of
tumor invasion and metastasis" Trends in Molecular Medicine 2007, 13(12), 535-41
Purpose of the review
Cancer cells utilize different types of migration to leave the primary tumor in order to reach
distant sites within the body. This review highlights the characteristics of each type of
migration and summarizes the current knowledge about the strategies used by invasive cancer
cells to establish secondary tumors at distant sites.
Summary
Cancer cells are able to invade into the surrounding tissue utilizing different types of
migration namely (i) collective migration, including coordinated as well as cohort migration
and (ii) single cell migration, including mesenchymal as well as amoeboid migration. Due to
their intrinsic plasticity, cancer cells are able to switch between different modes of migration
and thus are able to adapt to changes in their environment. 
1.2.1. Introduction
Metastasis is the cause of 90% of all deaths from cancer and it displays a remarkably diverse
set of clinical features. In principle, metastatic secondary tumors are formed by cancer cells
that have left the primary tumor mass and traveled, mainly via blood and lymphatic vessels,
to seek out new sites throughout the body where they seed new colonies. To achieve this
journey, cancer cells employ numerous strategies that all lead to the same goal, the
establishment of secondary sites. In order to leave the primary tumor and to disseminate to
distant organs, metastatic cancer cells first lose adhesion to neighboring tumor cells and gain
migratory and invasive capabilities. Such epithelial-mesenchymal-transition (EMT) is
accompanied by a variety of changes in gene expression and functions, such as the loss of
epithelial markers and the gain of mesenchymal markers (Thiery and Sleeman, 2006). Cancer
cells are then able to permeate the basement membrane, to invade into surrounding tissue and
to gain direct access to blood and lymphatic vessels. After successful intravasation into
Introduction: Distinct mechanisms of tumor invasion and metastasis
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vessels they need to survive in the blood or lymphatic circulation, to disseminate in the whole
body to then recognize specific target organs and extravasate into a new environment where
they seed and grow as secondary tumors. The ability to grow in secondary sites is of
particular importance, since the ‘foreign’ tissue environment does not necessarily provide
cancer cells with the familiar collection of growth and survival factors that allowed them to
thrive in the primary ‘home’ tumor. Depending on the features of the primary tumors, their
stroma and the intrinsic ability of a given metastatic cell to adapt to a new stroma, cancer
cells will use distinct mechanisms to proliferate, survive and spread. Thus, the multiple steps
of metastases encompass many biological functions. To achieve these functions, cancer cells
frequently hijack gene expression programs employed by non-transformed cells during
embryonic development, such as EMT and a variety of signaling pathways underlying
morphogenetic processes.
1.2.2. Cancer cells use multiple strategies of invasion
Depending on the tumor type and the surrounding tissue, cell migration involves different
cellular strategies to overcome the physical resistance of three-dimensional tissue networks
(Figure 1). Accordingly, various patterns of invasion can be observed upon morphological
analyses of different human cancer types (Friedl, 2004). For example, squamous cell
esophageal cancers predominantly invade by forming cone-like structures, lobular breast
cancers migrate in indian-file patterns through the extra-cellular matrix (ECM), and
anaplastic thyroid cancers mainly show invasion of single, sparse cells. Based on histological
criteria, there are two fundamentally different patterns of invasion: single cell invasion and
collective cell invasion. On histological sections, single cell migration is characterized by the
presence of isolated and dispersed tumor cells in an adjacent tissue. This is in contrast to what
is observed during collective cell invasion where the cancerous tissue pushes forward as a
whole, thereby displacing the healthy surrounding cells.
Introduction: Distinct mechanisms of tumor invasion and metastasis
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Figure 1: Different strategies of tumor invasion. (A) Individual cancer cells detach from the primary tumor and invade the
surrounding tissue by amoeboid invasion. Characteristics for the amoeboid invasion are the weak interactions with the ECM
and the protease -and calpain independency. (B) The mesenchymal invasion is initiated by an epithelial-mesenchymal
transition (EMT) of individual cancer cells at the invading front of the primary tumor. Characteristics for the mesenchymal
invasion are the spindle shaped morphology of the cancer cells and the expression of proteases and certain set of integrins.
Its is also assumed that the invading cancer cells are able to switch between both the amoeboid and mesenchymal invasion
depending on the composition of the microenvironment they meet. (C) In the coordinated collective invasion cancer cells
invade the surrounding tissue without loosing the contact to their neighbour cells and the primary tumor. This type of
invasion is protease dependent. (D) The collective invasion as a cohort of 6-10 cells is characterized by the remaining
contact between the invading cells and the lost contact to the primary tumor. This type of invasion is protease dependent. 
1.2.3. Single migrating cells
Cancer cells migrating and invading as single cells can either employ a fibroblast- or a
leukocyte-like strategy to passage through the ECM:
1.2.3.1. The fibroblast strategy: mesenchymal migration
When individual malignant cells detached from the primary tumor mass at the periphery of
carcinomas they frequently display many hallmarks of EMT (Brabletz et al., 2005b). The
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essential features of EMT are the disruption of intercellular contacts, the acquisition of a
spindle-shape fibroblast-like morphology, the enhancement of cell invasiveness and cell-
stroma interaction and a slow division rate (Lee et al., 2006). Altogether, these features lead
to the release of “mesenchymal” cells from the parent epithelial tissue. The resulting
mesenchymal-like phenotype is amenable to migration and, by extension, to tumor invasion
and metastatic dissemination. Interestingly, a typical feature of some cancers might
correspond to an in vivo EMT: neural crest tumor and also melanoma cells migrate one-by-
one in single Indian-files through channels they have carved in the adjacent stroma (Friedl,
2004). These invading cells often lose E-cadherin expression and show several characteristics
of active invasion, including expression of integrins and surface proteases (Figure 1).
While numerous markers of mesenchymal cells, such as vimentin, N-cadherin or fibronectin
are readily identified in cells undergoing EMT in vitro, very few of these markers are
detected in invading cells in cancer biopsies in vivo, except the loss of E-cadherin expression
and the gain of a nuclear β-catenin signal (Brabletz et al., 2005a). Moreover, in vivo,
epithelial markers are frequently maintained in invading cancer cells, including the
expression of cytokeratins that are routinely used for cancer diagnosis. The failure of readily
detecting full EMT in cancers of patients has lead to a debate whether EMT actually occurs
in patient carcinogenesis (Tarin et al., 2005; Thompson et al., 2005). However, since the loss
of E-cadherin expression is observed in almost all epithelial cancers and other morphological
and genetic hallmarks of EMT can be detected with varying frequency, major efforts are
ongoing to dissect the molecular pathways underlying the transition from an epithelial to a
mesenchymal phenotype during tumor progression (Christofori and Semb, 1999). Profiling
gene expression of primary cancers and metastasis as well as of cancer cells undergoing EMT
will certainly help to settle this issue and to identify novel markers of tumor malignancy. 
1.2.3.2. The leukocyte strategy: amoeboid migration
Amoeboid migration is a very efficient invading mode where tumor cells use a crawling type
of movement that is driven by weak interactions with the stroma (Hlubek et al., 2007). Such
highly deformable cells have been observed in vivo using intravital imaging of carcinoma
cells (Sahai, 2005). Proteases are not required for this movement because cells are able to
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squeeze through gaps in the ECM (Figure 1). Accordingly, amoeboid migration was recently
described by its extracellular proteases- and calpain-independent mechanism of action (Wolf
et al., 2003a; Sahai et al., 2007). This type of migration is retained in leukocytes and certain
cancer cells, including hematological cancers and neuro-endocrine tumors, such as small-cell
lung cancer (Friedl, 2004).
1.2.4. Collectively migrating cells
A hallmark of collective invasion is the maintenance of cell-cell adhesion by the continuous
expression of adhesion molecules and other components of the adhesive apparatus by
invading cells. A subset of highly motile cells at the invading front of the cell sheet (referred
to as path-generating cells) provides the migratory traction and via cell-cell junctions pulls
the following cells in their rear (Carragher et al., 2006). Collectively migrating cells engage
and cluster integrins in anterior protrusions towards the ECM and show a high expression of
specific matrix-metalloproteases (MT1-MMP, uPA/uPAR, MMP-2) for remodeling of the
ECM (Hegerfeldt et al., 2002). The molecular mechanisms involved in collective cell
invasion are likely to resemble that of morphogenetic collective cell movements observed
during embryonic development.
1.2.4.1. The morphogenesis strategy: coordinated invasion
Coordinated invasion consists of cell sheets that extend into tissue, yet maintain contact with
the primary tumor. Cells present at the migrating front produce MMPs that generate a path
for the cells to follow. This type of movement is observed in invasive epithelial cancer such
as oral squamous cell carcinoma, basal cell carcinoma, melanoma, mammary carcinoma and
colon carcinoma (Nabeshima et al., 2000). This mass movement is similar to what is
observed in embryonic morphogenesis, where complex multi-cellular sheets formed by cells
that are linked to each other by cell-cell junctions move along surrounding tissue substrates
(Figure 1). The precise molecular mechanisms underlying this coordinated invasion are still
largely unknown, mainly due to the difficulties to model this complex type of migration in
vitro. Our laboratory has recently reported that the cells in the leading front of collectively
invading squamous cell carcinomas express high levels of podoplanin, a transmembrane
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glycoprotein implicated in the remodeling of the actin cytoskeleton (Friedl et al., 2004).
Notably, when expressed in epithelial breast cancer cells, podoplanin is able to induce
filopodia formation and cell migration and invasion without the downregulation of E-
cadherin expression, indicating a mode of cell migration that clearly does not involve EMT
(Wicki et al., 2006).
1.2.4.2. The border-cell strategy: cohort migration
This specific pattern of migration and invasion is manifested by cell-clusters that collectively
detach from the primary tumor to generate migrating cell nests. During this process, cells
continue to adhere to each other by adherens junctions and leave behind large gaps in the
matrix, indicating that they are able to degrade the ECM (Figure 1). Leading edge cells
express integrins, which enable their attachment to the ECM ahead of the cell nests. This type
of invasion is frequently found in a subset of melanomas and in rhabdomyosarcomas
(Nabeshima et al., 2000). This phenomenon is also observed in primordial germ cell
migration and in Drosophila border-cell migration, where a group of 6–10 cells specified at
the anterior of the egg chamber migrate towards the developing oocyte (Wicki and
Christofori, 2007). That the genes playing a key role during primordial germ cell and border-
cell migration are also regulating cohort migration in human cancers is an attractive thought,
yet remains to be determined.
1.2.5. Tumor cell plasticity
Several lines of evidence suggest that tumor cells exhibit high plasticity in modulating their
type of invasion in order to progress through the multiple stages of the metastatic process.
For example, to intravasate collectively invading cells have to break away from their
neoplastic neighbors before being able to enter the blood stream. Thus, an adaptive switch in
migration mechanisms must occur, allowing cells to survive in different environments.
Supporting this hypothesis, cells not only undergo EMT during tumor metastasis but also
progress from a mesenchymal to an amoeboid type of invasion. For example, mesenchymal
cells subjected to protease inhibitor treatment in 3-D culture undergo a mesenchymal-
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amoeboid transition, allowing efficient migration in the absence of protease activity (Sahai et
al., 2007). Friedl and co-workers have also shown in a melanoma explant model of human
cancer that cells can switch from one invasion pattern to another, depending on the tumor
environment and particularly on the selective pressure exerted by cancer drugs (Carragher et
al., 2006). In addition, adherens junction components, such as E-cadherin, are known to be
lost in primary tumors but are re-expressed in distant metastases suggesting that
mesenchymal cells can re-differentiate into an epithelial phenotype upon reaching sites of
metastases (Brabletz et al., 2005b). These experimental data suggest a highly efficient
cellular and molecular plasticity in tumor cell migration strategies (Montell, 2003). 
1.2.6. Acid-mediated tumor invasion
The vast majority of cancers exhibit increased glucose flux compared to normal tissue (Friedl
and Wolf, 2003a). This glycolytic phenotype plays a critical role for the survival of tumor
cells exposed to a hypoxic environment (Gambhir, 2002). Interestingly, it has been proposed
that elevated glycolysis and with it higher acid production leads to cell necrosis and
apoptosis. Cell death produces gaps and spaces into which migratory cancer cells could
invade. In addition, necrotic cells release proteolytic enzymes that further support
extracellular matrix degradation (Gatenby and Gillies, 2004).
1.2.7. Establishment of secondary sites
In most cancers, metastases are seeded via either hematogenic or lymphogenic dissemination.
It is estimated that several million cells per gram of tumor can be shed daily into the
lymphatic system or in the bloodstream (Pennacchietti et al., 2003; Gatenby et al., 2006).
However, the actual process of cancer cell intravasation is only poorly understood.
Intravasation into blood vessels may be an active phenomenon where tumor cells migrate
towards nutrient or chemokine gradients or a passive phenomenon that does not involved
active cancer cell migration but rather simple cancer cell shedding into the highly permeable
tumor vasculature (Liotta et al., 1976). A potential mechanism of chemoattraction has been
recently suggested: tumor cells can secrete both CCR7 receptor and its ligands, CCL21 and
CCL19. The ligands are then drained towards lymphatics by the flow of tissue fluid and
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concentrate downstream of cancer cells ensuring that they migrate towards lymphatic vessels
(Butler and Gullino, 1975). The dissemination of tumor cells has characteristic patterns of
organ tropism that reflects their heterogeneity and depends on the cancer type (Bockhorn et
al., 2007). While the circulatory pattern can explain the location of certain metastases, it is
not sufficient to explain the incidence of metastases in most secondary organs(Shields et al.,
2007). More than a hundred years ago, Paget proposed that disseminating tumor cells (seed)
need to find the appropriate microenvironment in distant organs (soil) for metastatic
outgrowth ('seed and soil' hypothesis; (Nguyen and Massague, 2007)). More recently,
cytokines have been shown to play crucial roles in the homing of tumor cells to distinct
organs. For example, the chemokine-receptor CXCR4 is highly expressed in malignant breast
cancers and their metastases. Organs representing the first destinations of breast cancer
metastases express high levels of SDF1/CXCL12, the bona fide ligand of CXCR4 receptor,
suggesting an attraction of the receptor-expressing tumor cells toward an SDF1/CXCL12
gradient. Neutralizing the interactions between SDF1/CXCL12 and CXCR4 in a transgenic
mouse model in vivo significantly impairs metastases of breast cancer cells to regional lymph
nodes and lung (Fidler, 2003). Thus, specific expression of a set of genes may direct
metastases to distinct secondary sites. Accordingly, in examining breast cancer cell with
varying propensity to metastasize to different target organs, specific gene expression
signatures have been identified, for example a lung-metastasis signature and a bone
metastasis signature (Paget, 1889; Muller et al., 2001) (see also below). In addition to
seeding de novo metastasis, invasive tumor cells may also contribute to primary tumor
growth: disseminated cells may return to their original site leading to progressive
accumulation of very aggressive cells in the primary tumor and thus local recurrence, a self-
seeding hypothesis that is support by a number of experimental and clinical observations
(Minn et al., 2005).
1.2.8. Circulating tumor cell extravasation
Before establishing metastases, cancer cells need to extravasate from the blood stream. To do
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so, cancer cells adhere to the vascular endothelium, transmigrate across the endothelial cells
and invade the surrounding tissue. The molecular mechanisms underlying these processes are
only poorly understood. Besides specific adhesion of cancer cells to surface receptors on
endothelial cells, platelets have been proposed to facilitate this process through several
mechanisms. Actually, Armand Trousseau proposed already in 1865 that a visceral
carcinoma could cause thrombophlebitis, an inflammation of the vessels due to blood clotting
(Trousseau’s sign) (Kang et al., 2003). Circulating cancer cells may use platelets as shields in
order to promote their survival (Norton and Massague, 2006). Platelets also protect tumor
cells from the cytotoxic effects of circulating TNFα, and enhance tumor embolization in the
microvasculature. Furthermore, platelets facilitate cancer cell adhesion to the endothelium
and are able to induce neoangiogenesis enabling growth in the secondary site (Philippe et al.,
1993; Nieswandt et al., 1999; Kang et al., 2003; Gupta and Massague, 2004). In a transgenic
mouse model of liver carcinogenesis, caused by the expression of the c-MET oncogene,
venous thromboses (Trousseau’s sign) develop apparently dependent on the upregulation of
plasminogen activator inhibitor type 1 (PAI-1) and cyclooxygenase-2 (COX-2) (Mehta,
1984). Indeed, administration of aspirin to mice reduces the metastatic potential of cancer
cells, presumably both by reducing the incidence of cancerous emboli and the αVβ3 integrin-
mediated angiogenesis (Karpatkin and Pearlstein, 1981; Nash et al., 2002; Boccaccio et al.,
2005). Colonization of a secondary organ by disseminated cancer cells, however, may not
only be achieved by embolization in a capillary field, but also by adhesive interactions
between surface receptors and ligands on cancer and endothelial cells. For example, α3β1
integrins and a novel receptor called metadherin are implicated in homing to the
microvasculature of the lung (Gasic et al., 1972; Dormond et al., 2001). For the actual
extravasation process, both the motility of the cancer cells and the permeability of the
vascular endothelium are important. Ablation of the cytoskeletal adaptor protein ezrin in
osteosarcoma cells reduces the escape of cancer cells from the vasculature (Wang et al.,
2004). The angiogeneic factor VEGF, highly expressed by most cancer cells, increases the
permeability of the endothelium and thus facilitates extravasation (Brown and Ruoslahti,
2004). Therefore, several pathway may be involved alone or in combination in cancer cell
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extravasation, yet the molecular details remain to be elucidated. Recently, Massagué and
coworkers reported that four genes (epiregulin, COX2, MMP-1 and MMP-2) collectively
contribute to vascular remodeling functions by supporting the formation of vasculature in
mammary tumors, the entry of tumor cells into the circulation and the exit of tumor cells
from the bloodstream into the lung parenchyma. When any of these genes is singly
inactivated in breast cancer cells, either by pharmacological inhibition or by RNAi-mediated
knock-down technology, there is only a moderate inhibition of primary-tumor growth and
lung metastasis. However, when all four genes together are inactivated, an almost complete
abrogation of both primary-tumor growth and lung metastasis is observed (Khanna et al.,
2004).
1.2.9. Establishment of a pre-metastatic niche
Another attractive hypothesis to explain how cancer cells recognize and colonize specific
organs is the generation of a permissive microenvironment in the metastatic target organ for
incoming cancer cells (pre-metastatic niche) (Weis and Cheresh, 2005). Recently, employing
syngeneic tumor transplantation models of organ-specific metastasis, it has been shown that
bone-marrow-derived, VEGF receptor-1-expressing progenitor cells first home to pre-
metastatic sites in target organs before the arrival of tumor cells. One of the cues for
incoming cancer cells seems to be an increase in the deposition of fibronectin (Gupta et al.,
2007). However, the actual signals that lead to the tissue-specific recruitment of progenitor
cells are unknown. Another study has shown that the release of VEGF, TGFβ and TNFα by
primary tumors induces expression of the chemoattractants S100A8 and S100A9 by lung
endothelium and myeloid cells which in turn facilitates the colonization of pre-metastatic
sites within the lung parenchyma by cancer cells (Kaplan et al., 2007).
1.2.10. Are cancer initiating cells seeds for metastasis?
The morphological resemblance of the metastatic lesions to the primary tumor and the
presence of metastatic poor prognosis gene expression pattern in primary tumors led to the
hypothesis that the development of metastatic cancer cells is rather an early than a late event
during tumor progression (Ramaswamy et al., 2003; Kaplan et al., 2005; Hiratsuka et al.,
Introduction: Distinct mechanisms of tumor invasion and metastasis
- 19 -
2006). In the last years, cancer stem cells (CSC) or better cancer initiating cells (CIC) have
been suggested to play a critical role during the metastatic process (Sorlie et al., 2001). CIC
are defined as cancer cells that are able to self-renew and to initiate tumor formation. Since
metastases seem to recapitulate the heterogeneous phenotype of their primary tumor, it has
been suggested that CICs escaping from the primary tumor could be the seed for metastasis
(van 't Veer et al., 2002). This notion is supported by the observation that only a subset of the
cancer cells from a primary tumor or from a metastatic site can induce new metastatic lesions
(clonal event). In addition, the pathological features of metastatic cancer cells resembles in
great parts characteristics of bona fide stem cells (Table I). At the moment there are different
models attempting to explain the origin and nature of CIC ((Sorlie et al., 2001); Figure 2): (i)
CIC derive from normal stem cells that upon oncogenic transformation accumulate mutations
over time, due to their self-renewal capacity, (ii) transient amplifying progenitor cells which
are more abundant and retain partial self-renewal capacity are transformed and acquire
additional mutations over time, (iii) fusion of stem cells with transformed cells gives rise to
transformed cells with self-renewal capacity, which could explain the detection of fusogenic
markers (e.g. CD44 or CD47) and aneuploidy in neoplastic transformation, (iv) normal
cancer cells regain self-renewal capacity and de-differentiate due to specific mutations or
environmental cues (stem cell niche). Therefore, the term 'cancer initiating cell' probably
relates to a broad group of cells that share some common properties. Identification of these
cells in tumors and metastases will provide novel insights into tumor biology in general and
into the metastatic process in particular. 
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Figure 2: Different models for the development of a cancer initiating cell (CIC). (A) The inappropriate fusion of a
normal cell and tumorigenic cell can give rise to a CIC. Fusion can occur either between a normal stem cell and a cancer cell
or between a mutated stem cell and a normal cell. Both scenarios lead to a hybrid CIC, which unites features of both
fusogenic partners and could mark the onset of tumor development and metastasis. A third, more unlikely scenario could be
the fusion of both a mutated stem cell and a cancer cell. (B) Single or multiple mutations within a differentiated cell,
immediate progenitor cell or stem cell could give rise to a CIC.
1.2.11. Relevance for patients 
The risk of metastatic spread and/or recurrence can sometimes be predicted from certain
features of the primary tumor, as in the case of breast cancer, for which tumor size,
histological grade, and gene expression pattern are indicative of the risk of relapse
(Goldhirsch et al., 2006). However, these approaches are still limited in their prognostic
value, and we need to learn more about the molecular mechanisms underlying the multiple
stages of tumor metastasis in order to substantially improve the cancer patients’ condition.
Recent studies showed that 70 to 80% of breast cancer patients receiving adjuvant treatment
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would have survived without it. These patients currently are not identified, and their
treatment protocols may be inappropriate(Group., 1998a; Group., 1998b). The failure to
distinguish bona fide metastases from inert disseminated cells thus has important
implications. It seems important to develop novel surrogate markers of tumor progression
that may identify the state of the metastatic process in cancer patients. Moreover, depending
on the invasion program used by cancer cells, molecular mechanism-based therapies should
be developed. Hence, morphological and molecular features of the invasive tumor front are
important for therapeutic considerations, not only for choosing the right therapeutic approach
but also for its pharmacological characteristics. For example, collective invasion coincides
with intact cell junctions and thus higher cancer cell density, which in turn affects the
penetration of drugs into solid tumors (Minchinton and Tannock, 2006). Moreover, patient
diagnosis based on certified molecular markers of distinct tumor invasion or metastatic
programs could go along with the use of specific drugs in a more accurate way (Sotiriou and
Piccart, 2007). In the near future, gene expression analysis will be routinely employed for
deciphering a patient’s prognosis. For example, in breast cancer, several existing gene
expression signatures have been shown to be equally informative, and it has been suggested
that combining them might be even more powerful(Massague, 2007). Obviously, the main
challenge in the future will be the development of drugs (and/or combinatorial treatment) that
not only target rapidly dividing but also slowly dividing, highly malignant cancer cells. The
molecular understanding of the early steps of cancer cell invasion will thus provide novel
therapeutic opportunities. 
1.2.12. Concluding remarks
It is now well established that various cancer types use distinct and complex strategies to
disseminate in the whole body. Future studies of these mechanisms will involve the
establishment of robust in vitro 3-dimensional invasion systems. This challenging endeavor
needs to consider that depending on the tumor location the tumor stroma has different
characteristics. For example, malignant breast cancer cells can revert to a non-transformed
phenotype when exposed to a non-permissive stroma(Albini and Sporn, 2007). Moreover,
irradiated tissue can induce non-transformed cells to acquire malignant potential. Models
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combining in vitro cell culture experiments together with in vivo imaging in appropriate
mouse models will be one of the solutions to address this challenge (Wyckoff et al., 2007).
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1.3. TGFβ - its role in tissue homeostasis and cancer cell invasion
1.3.1. The two faces of TGFβ
TGFβ plays a central role in various biological processes including development, tissue
homeostasis and cancer. During developmental processes, such as gastrulation or neural crest
formation, TGFβ induces motility and invasiveness, enabling cells to migrate to distant sites
within the developing body. In contrast, in differentiated epithelial tissue TGFβ is mainly
known to maintain tissue homeostasis by inducing growth arrest and apoptosis, thus
functioning as a tumor-suppressor (Derynck et al., 2001; Siegel and Massague, 2003;
Massague, 2008). This complex and ambivalent nature of TGFβ signaling plays also a critical
role in cancer development and progression. Here, TGFβ acts at early stages of tumorigenesis
as a tumor-suppressor by inducing cell cycle arrest and apoptosis. During later stages of
tumorigenesis, TGFβ functions as an oncogene by inducing the production of mitogenic
factors, evasion of immunity and the transition of non-invasive epithelial cells into invasive
mesenchymal cells, a process named epithelial-mesenchymal transition (EMT) (Roberts and
Wakefield, 2003; Thiery and Sleeman, 2006; Pardali and Moustakas, 2007; Massague, 2008;
Yang and Weinberg, 2008). Cancer cells which have undergone EMT are able to detach from
the primary tumor and to invade into the surrounding tissue to form metastatic lesions at
distant sites.
1.3.2. TGFβ signaling
TGFβ is the prototype of the TGFβ superfamily of morphogenetic factors, including bone
morphogenetic protein (BMPs), growth differentiation factors (GDFs), Müllerian Inhibiting
Substance (MIS), activins and others. All these cytokines are well known to regulate various
biological processes like cell proliferation, apoptosis, differentiation, angiogenesis and
migration. Each ligand presents unique features of action, while they all share a common
machinery to transmit intracellular signals, the TGFβ receptor complex.
TGFβ is secreted and bound in an inactive form to the latent TGFβ binding proteins (LTBPs)
in the extracellular matrix. The mature, bioactive TGFβ is produced upon proteolytic
cleavage of the latent complex by different proteases. The bioactive TGFβ binds to two
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related receptors, namely TGFβRI and TGFβRII, the latter also named activin receptor-like
kinase 5 (ALK5). Both receptors are serine/threonine kinases. Upon TGFβ binding, TGFβRI
and TGFβRII form hetero-tetrameric complexes of two identical TGFβRI/TGFβRII receptors
heterodimers. This leads to specific phosphorylation of serine and threonine residues in the
juxtamembrane region of TGFβRI by TGFβRII. Subsequently, a conformational change of
TGFβRI leads to the activation of its dormant catalytic domain and phosphorylation of
TGFβRI associated effector proteins such as the receptor-associated Smad proteins (R-
Smads). The activated R-Smads subsequently interact with the common mediator Smad 4,
translocate into the nucleus and control the transcriptional expression of various genes.
Besides the well characterized canonical TGFβ signaling pathways is TGFβ also able to
transmit signals via non-canonical signal transduction. This complex signaling machinery
relies on the ability of the TGFβ-receptor complex to interact with various non-Smad
interaction partners like receptor tyrosine kinases (RTKs) and diverse adapter proteins. Both,
canonical as well as non-canonical TGFβ signaling can operate independently from each
other, but mostly cooperate during TGFβ induced signaling. This leads to the immense
complexity and variability of TGFβ signaling and its ability to control various cellular
processes. 
1.3.3. Canonical TGFβ signaling
Canonical TGFβ signaling utilizes Smad proteins to submit signals from the TGFβ-receptor
complex to the nucleus. Ligand binding and activation of the TGFβ-receptor complex leads
to the phosphorylation of Smad2/3 (R-Smads) at specific serine residues. These activated R-
Smads form a trimeric complex with the common mediator Smad4, to enter the nucleus and
interact with various transcriptional co-activators or co-repressors to control cellular
processes like differentiation, cell-cycle arrest and apoptosis (described below). Within this
basic signal transduction pathway, an intrinsic negative feedback loop is engaged to control
canonical TGFβ signaling. This negative feedback is exerted primarily by three types of
proteins: (i) the inhibitory Smads (i-Smads), (ii) ubiquitin ligases of the Smurf family and
(iii) phosphatases like the SH2 domain-containing inositol 5-phosphatase (SHIP). The
inhibitory Smad7 and the ubiquitin ligases Smurf1/2 are targets of canonical TGFβ signaling
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and are rapidly upregulated. Smad7 is recruited to the activated TGFβ-receptor complex and
inhibits TGFβ signaling by competing with R-Smads and by recruiting phosphatases like
SHIP, which dephosphorylate and inactivate the TGFβ-receptor complex. Furthermore,
Smad7 binds and activates Smurf ubiquitin ligases, leading to ubiquitinylation of the
TGFβRI, thus provoking its endocytosis and lysosomal degradation (Di Guglielmo et al.,
2003). 
1.3.3.1. Canonical TGFβ signaling mediated cell-cycle arrest
In epithelial cells, TGFβ relays its cytostatic function via transcriptional activation of cyclin-
dependent kinase (CDK) inhibitors, such as p21CIP1 or p15INK4B. The cytostatic function of
both CDK inhibitors relies on their ability to inhibit the cell-cycle progression from the G1 to
the S phase. This is achieved by preventing the complex formation and activation of cyclinD-
cdk4/6 and cyclinE/A-cdk2 complexes by p21CIP1 and p15INK4B, respectively (Pardali et al.,
2000; Gomis et al., 2006). Simultaneously, TGFβ inhibits cell-cycle progression by
repression of c-Myc transcription, which plays an important role in cell growth and cell
division. Upon canonical TGFβ signaling, c-Myc is downregulated by the coordinated
activity of Smad3/4, retinoblastoma-like 1 (p107) and the transcription factors E2F4/5 and C/
EBPβ (Chen et al., 2002; Gomis et al., 2006). 
1.3.3.2. Canonical TGFβ signaling mediated apoptosis
Among the genes, which are regulated by TGFβ and are responsible for the induction of
apoptosis, are GADD45β, the Bcl-2 homolog domain-only factor Bim, the death-associated
protein kinase (DAPK) and SHIP. All these factors, except SHIP, promote apoptosis by
inducing the release of mitochondrial cytochrome C and subsequent activation of caspase-
mediated apoptosis. For example, GADD45β activates via mitogen-activated kinase kinase 4
(MKK4) the MAPK p38 and the pro-apoptotic protein Bad, which both cooperate to trigger
mitochondrial cytochrome C release and the activation of caspase-mediated apoptosis. The
lipid phosphatase SHIP promotes apoptosis by inhibiting PI3K activity, thereby blocking its
survival promoting signaling (Zhang, 2009). 
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1.3.4. Non-canonical TGFβ signaling
The TGFβ-receptor complex interacts with various non-Smad signaling proteins, including
receptor tyrosine kinases (RTKs), cytoplasmic adapter proteins and G-protein-coupled
receptors. Each of these interaction partners can be activated upon TGFβ binding to the
TGFβ-receptor complex and emit signals which can act independently or can interfere with
canonical TGFβ signaling. Among well known signaling pathways which are triggered by
non-canonical TGFβ signaling are the MAPK, PI3K and Rho-like GTPase signaling
pathways (Zhang et al., 2009). 
1.3.4.1. TGFβ-induced MAPK activation
Binding of TGFβ to the TGFβ-receptor complex leads to the trans- and autophosphorylation
of TGFβRI and TGFβRII on multiple sites. These phosphorylation sites can be recognized by
adapter proteins such as growth factor receptor binding protein 2 (Grb2) and Src homology
domain 2 containing protein (Shc). Subsequent activation of Grb2 and/or Shc leads to
activation of the small G-protein Ras, which in turn leads to the activation of the MAPK
signaling pathway. Activation of the MAPK Erk1/2 during TGFβ-induced EMT was shown
to be important for the disassembly of cell adherens junctions, modulation cell-matrix
interactions, increased motility and endocytosis (Zavadil et al., 2001).
1.3.4.2. TGFβ-induced JNK/p38 activation
Another interaction partner of the activated TGFβ-receptor complex is the adapter protein
and E3 ligase TRAF6. Binding of TRAF6 to the activated TGFβ-receptor complex induces
polyubiquitination of TRAF6, and promotes its interaction with the TGFβ-activated kinase 1
(TAK1), followed by TAK1 polyubiquitination and its activation (Sorrentino et al., 2008;
Yamashita et al., 2008a). TAK1 is than able to activate the MAPKKs MKK4 and MKK3/6,
which in turn induce c-Jun N-terminal kinase (JNK) and MAPK p38 activation. This TRAF6-
TAK1-JNK/p38 pathway is known to cooperate with canonical TGFβ signaling to induce
apoptosis or EMT (Weston et al., 2007). 
1.3.4.3. Rho-like GTPases in TGFβ-mediated EMT
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Par6, a scaffold protein regulating epithelial cell polarity, interacts with TGFβRI at tight
junctions. TGFβ stimulation induces the assembly and accumulation of the TGFβ receptor
complexes at tight junctions, where TGFβRII phosphorylates Par6. Upon phosphorylation,
Par6 recruits the E3 ubiquitin ligase Smurf1 to the activated receptor complex and mediates
ubiquitination and turnover of RhoA, which finally enables TGFβ-dependent dissolution of
tight junctions, a prerequisite for EMT (Ozdamar et al., 2005).
1.3.4.4. TGFβ-induced PI3K activation
TGFβRII was found to be continuously associated with p85, the regulatory subunit of PI3K.
Upon TGFβ binding of the TGFβ-receptor complex, PI3K becomes activated leading to the
phosphorylation of the PI3K target protein PKB and the activation of mammalian target of
rapamycin (mTOR). mTOR is a key regulator of protein synthesis via phosphorylation of S6
kinase (S6K) and eukaryotic initiation factor 4E-binding protein (4E-BP1). The activation of
S6K and 4E-BP1 by mTOR enhances translational capacity and protein synthesis, which is
important for TGFβ-induced EMT. Furthermore, activation of PI3K protects from TGFβ
induced death by (i) interfering with the apoptotic, canonical TGFβ signaling via
phosphorylation and inhibition of the R-Smad Smad3 or (ii) inhibition of the transcription
factor FoxO, which is essentially involved in TGFβ mediated cell-cycle arrest (described
below) (Shin et al., 2001). 
1.3.5. TGFβ as a pro-invasive factor
1.3.5.1. Myofibroblast Generation
The mobilization of myofibroblasts plays an important role in the pro-invasive function of
TGFβ. TGFβ stimulates the generation of highly motile myofibroblasts from mesenchymal
precursor cells, which possess features of fibroblasts and smooth muscle cells. These
myofibroblasts, also described as cancer-associated fibroblasts, promote cancer cell invasion,
aniogenesis and proliferation by producing pro-invasive and pro-angiogenic factors such as
matrix metalloproteases, cytokines like interleukin 8 (IL-8), vascular endothelial growth
factor (VEGF), and chemokines like CXCL12 (De Wever and Mareel, 2002; Allinen et al.,
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2004). 
1.3.5.2. Production of Autocrine Mitogens
TGFβ is able to promote tumor growth and invasion by stimulating the production of
mitogenic factors. Gliomas which were able to attenuate the tumor-suppressive function of
TGFβ benefit from an TGFβ-induced autocrine PDGF-B positive feedback loop. This is
achieved by Smad-dependent transcriptional activation of the PDGF-B gene (Jennings and
Pietenpol, 1998; Bruna et al., 2007). 
1.3.5.3. Evasion of Immunity
TGFβ was shown to inhibit the anti-tumoral activity of cytotoxic CD8+ T cells, by inhibiting
their ability to produce cytolytic factors such as pore-forming protein perforin, the caspase-
activating secreted factors granzyme A and B, and the pro-apoptotic cytokines Fas-ligand. In
human glioma patients, TGFβ decreases the expression of the activating immunoreceptor
NKG2D on CD8+ T cells and natural killer (NK) cells, which leads to reduced CD8+ T cells
mediated cancer-directed cytotoxic response. Knockdown of TGFβ synthesis in a glioma cell
lines prevented NKG2D repression and enhanced glioma killing by cytotoxic T cells and NK
cells (Thomas and Massague, 2005). 
1.3.5.4. Epithelial-Mesenchymal Transition 
TGFβ belongs to most potent inducers of the epithelial-mesenchymal transition (EMT).
Epithelial cells which undergo EMT loose E-cadherin-mediated intercellular connections,
detach from the cell collective and change into individual, motile, protease-expressing
mesenchymal cells. Cancer cells cells which undergo EMT are able to detach from the
primary tumor, invade into the surrounding tissue and form metastatic lesions at distant sites.
Interestingly, besides promoting invasiveness, TGFβ-induced EMT was shown to induce the
transition of transformed and immortalized human mammary epithelial cells into
mesenchymal cancer cells with stem cell traits, thus linking EMT to tumor cell plasticity
(Shipitsin et al., 2007; Mani et al., 2008)  . 
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1.4. EMT, the cytoskeleton, and cancer cell invasion (Review)
Mahmut Yilmaz and Gerhard Christofori: "EMT, the cytoskeleton, and cancer cell invasion".
Cancer Metastasis Review 2009, 24.
Purpose of the review
The EMT-mediated gain of invasiveness requires a complex modulation of diverse biological
processes such as intercellular adhesion, cell-matrix adhesion, extracellular matrix (ECM)
production and cytoskeletal remodeling. In this review, we highlight new insights into
various molecular and cellular processes occurring during EMT with the focus on the
formation of invasive structures which are utilized by invading tumor cells to migrate and
metastasize. 
Summary
There is an increasing functional correlation between the formation of migratory and invasive
membrane protrusions and the process of EMT. The structural as well as signaling molecules
which are required for the formation of lamellipodia, filopodia and invadopodia are also
found to be essentially required and to be active during EMT. Still, a direct link between the
cellular and molecular processes underlying the formation of lamellipodia, filopodia and
invadopodia on one hand, and EMT and tumor metastasis on the other hand, still remains to
be established. If such link can be ascertained, the molecular mechanisms and genes and
factors underlying the cellular organization of the cytoskeleton and the formation of
membrane protrusions move into the spotlight of medical relevance, i.e. the design and
development of innovative therapeutic approaches to interfere with cancer cell invasion and
metastatic dissemination.
1.4.1. Epithelial-mesenchymal transition (EMT) and metastasis
Metastasis, the spread of tumor cells from a primary tumor to a secondary site within the
human body remains one of the most life-threatening pathological events. In the last years,
major efforts have been taken to understand the molecular mechanism underlying the distinct
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steps of metastasis, which are (i) detachment of tumor cells from the primary tumor, (ii)
invasion into surrounding tissue, (iii) intravasation into blood or lymphatic vessels, (iv)
dissemination in the blood stream or the lymphatic system and, finally, (v) extravasation and
outgrowth at a secondary site. Each of these steps requires a distinct molecular program in
which the modulation of the adhesive and migratory and, thus, the cytoskeletal properties of
the disseminating tumor cells play essential roles. To detach from the primary tumor and to
invade into the surrounding tissue, tumor cells have to break down cell-cell contacts, remodel
cell-matrix adhesion sites, and follow a chemoattractive path through the extracellular matrix,
mined by secreted proteinases. These processes are commonly observed in various non-
pathological conditions, such as in developmental processes like gastrulation or neural crest
cell migration, where differentiated, epithelial cells dedifferentiate, move to a distant site, and
then re-differentiate to form a new structure. This temporary and reversible phenomenon is
known as the epithelial-mesenchymal transition (EMT), a process that is currently in the
limelight of investigating the onset of cancer cell migration, invasion and metastatic
dissemination (Grunert et al., 2003; Thiery and Sleeman, 2006). During EMT, non-motile,
polarized epithelial cells, embedded via cell-cell junctions in a cell collective, dissolve their
cell-cell junctions and convert into individual, non-polarized, motile and invasive
mesenchymal cells. Thereby, the molecular repertoire of a cell experiences dramatic changes.
For example, the function and expression of the epithelial cell-cell adhesion molecule E-
cadherin is lost, whereas the expression of the mesenchymal cell-cell adhesion molecule N-
cadherin is induced, a process also known as the cadherin switch. EMT can be prompted by
various intrinsic signals (e.g. gene mutations) as well extrinsic signals (e.g. growth factor
signaling). Among the growth factors known to induce EMT are transforming growth factor
β (TGFβ)(Zavadil and Bottinger, 2005), hepatocyte growth factor (HGF)(Savagner et al.,
1997), members of the epidermal growth factor (EGF) family (Lo et al., 2007), insulin-like
growth factor (IGF)(Graham et al., 2008), and fibroblast growth factor (FGF)(Lee et al.,
2006; Acevedo et al., 2007). Recently, also Notch signaling has been implicated in EMT in
human breast cancer cells by activating the transcription factor Snail2 (Slug), a potent
repressor of E-cadherin gene expression (Leong et al., 2007). Changes in the composition of
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the extracellular matrix (ECM) are also able to induce EMT, as shown for collagen I and
hyaluronan (Zoltan-Jones et al., 2003; Shintani et al., 2008b). With the diversity of signals
inducing EMT the complexity of the interactive downstream effector pathways increases.
Among the candidates which are engaged by TGFβ-induced EMT are the small GTPases
RhoA and Rac1 (Bhowmick et al., 2001a; Bakin et al., 2002), Ras (Janda et al., 2002),
phosphoinositol-3 kinase (PI3K)(Bakin et al., 2000), Mitogen-activated protein kinase
(MAPK)(Bakin et al., 2002), integrin-linked kinase (ILK)(Lee et al., 2004), and the Jagged1/
Notch signaling pathway(Zavadil et al., 2004). With increasing interest in microRNAs,
miR-200 and miR-205 have been recently shown to play an important role in TGFβ-induced
EMT by modulating the function of ZEB1 (δEF1) and ZEB2 (Sip1), transcriptional
repressors of E-cadherin gene expression (Gregory et al., 2008). Such complexity of
interactive signaling upstream and downstream of the induction of EMT also explains why
EMT is not a simple matter of changes in a cell’s adhesive capabilities or its cytoskeletal
organization, it rather represents a fundamental reprogramming of almost every aspect of a
cell’s biology. Still, the different signaling cascades underlying EMT can be grouped into
biological programs and, apparently, tumor cells undergoing EMT hijack programs that are
central for developmental processes. The actual occurrence of EMT in patients is still highly
debated, yet with more detailed molecular and histopathological analysis and the advent of
novel markers there is increasing evidence identifying EMT in various human cancers
(Brabletz et al., 2005a; Sarrio et al., 2008). Still, many aggressive, invading tumors do not
exhibit a molecular signature of EMT, suggesting that EMT may not be involved in every
type of single cell invasion and that some tumors may undergo a partial or incomplete EMT
(Tarin et al., 2005). In fact, cancer cells can invade in the absence of EMT and have a broad
repertoire for invasion, including amoeboid or collective cell invasion (Friedl, 2004; Wicki et
al., 2006). This review highlights recent novel insights into EMT research with a specific
focus on the remodeling of the actin cytoskeleton and the formation of invasive structures
during EMT and tumor cell invasion. 
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1.4.2. Epithelial cell-cell adhesion
The formation of a stable, polarized epithelium requires tight cell-cell and cell-matrix
connections. E-cadherin is the major component of epithelial adherens junctions (AJ) which
mediate, along with tight junctions, intercellular adhesion. AJ are located basal to the apical
tight junctions (TJ) and form a belt-like structure which tie neighboring cells together (zonula
adherens). E-cadherin is the prototype family member of classical cadherins, single-span
transmembrane glycoproteins that interact in a calcium-dependent, homophilic manner with
E-cadherins on neighboring cells. E-cadherin-mediated cell-cell adhesion complexes are
anchored to the actin cytoskeleton via its cytoplasmic domain and β-catenin and α-catenin
(Figure 3A). Thus, the formation of E-cadherin-mediated cell-cell adhesion fundamentally
modulates the organization of cytoskeleton. This classical view of a direct connection
between the E-cadherin/β-catenin/α-catenin complex and the actin network has been
challenged by recent studies demonstrating that a reconstructed cadherin-catenin complex
fails to bind actin filaments in vitro (Yamada et al., 2005), and that E-cadherin, localized in
electron-dense microdomains called spot adherens junctions (SAJs), binds to actin in an α-
catenin-independent manner (Cavey et al., 2008). Here, the authors describe a model in
which two distinct actin populations are involved in the zonula adherens architecture (Figure
3A). One population represents stable, non-dynamic patches of highly organized actin to
which the E-cadherin/β-catenin complex is attached in an α-catenin-independent manner
(SAJs). The second population of actin is an underlying, dynamic actin framework to which
the SAJs are linked and correctly positioned by α-catenin. One protein replacing α-catenin in
the E-cadherin/β-catenin complex to SAJ could be eplin, a newly identified actin-binding
protein(Abe and Takeichi, 2008). The juxtamembrane domain of E-cadherin binds to p120-
catenin which is important in surface tracking, lysosomal degradation and correct membrane
localization of E-cadherin (Thoreson et al., 2000; Ireton et al., 2002; Davis et al., 2003;
Stehbens et al., 2006). Furthermore, p120-catenin plays an elementary role in the stability of
epithelial cell-cell adhesion by repressing the activity of RhoA and activating Rac and Cdc42
(Noren et al., 2000; Noren et al., 2001; Wildenberg et al., 2006). All three GTPases are key
regulators of actin assembly and play an essential role in the stability of cell-cell adhesion by
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enforcing actin stress fibers (RhoA) and the formation of migratory membrane protrusions,
such as lamellipodia and filopodia (Rac and Cdc42, respectively), as discussed below.
Besides its adhesive function, E-cadherin also encompasses signaling capabilities, transduced
predominantly by proteins interacting with its intracellular domain, such as β-catenin, or
receptors that form multimeric complexes with E-cadherin, such as c-Met, the cognate
receptor for HGF, IGF1R or integrins (Comoglio et al., 2003). Notably, E-cadherin has been
shown to interact with a multimeric complex that consists of α3β1-integrin, the tetraspanin
CD151, which recruits protein kinase C-βII (PKCβII), receptor of activated protein kinase
C-1 (RACK1), and the transmembrane protein tyrosine phosphatase PTPµ (Chattopadhyay et
al., 2003) (Figure 3A). This multimeric complex promotes association of the cadherin-
catenin complex with the actin cytoskeleton and supports cadherin mediated cell-cell
adhesion. CD151 appears to be important for the filopodia-based "adhesion zipper
formation", a process by which initial filopodia-mediated contacts of epithelial cells develop
into mature cell-cell junctions (Vasioukhin et al., 2000; Shigeta et al., 2003). Moreover,
CD151 expression accelerates E-cadherin-mediated intercellular adhesion by inducing
Cdc42-induced filopodia extensions which form initial cell-cell contacts. Consistent with
these observations, E-cadherin colocalizes and interacts with cortactin, a key regulator of
actin-cytoskeleton assembly and remodeling (Helwani et al., 2004). E-cadherin also
associates with c-Met, IGF1R and αv-integrin at the plasma membrane (Reshetnikova et al.,
2007; Canonici et al., 2008). Interestingly, in the absence of α-catenin the E-cadherin/IGF1R
complex does not form, suggesting that α-catenin besides its function as actin-anchoring
protein also exerts a function as an important scaffolding protein. Upon stimulation with IGF-
I, αv-integrin dissociates from the cell-cell adhesion complex and translocates to focal contact
sites of invasive structures, such as invadopodia (see below). These findings expand E-
cadherin’s functional repertoire beyond its adhesive functions and emphasize the critical role
of E-cadherin as a regulator of signaling complexes.
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Figure 3. Differentiated, polarized epithelial cells are tightly attached to their neighboring cells by E-cadherin-mediated cell-
cell adhesion complexes and to the extracellular matrix via integrins. (A) Epithelial cell-cell adhesion. E-cadherin is
connected via β-catenin and Eplin to stable, electron-dense actin microdomains called spot adherens junctions (SAJ) in an α-
catenin-independent manner. These E-Cadherin-SAJs complexes are attached and correctly positioned to an underlying
dynamic actin framework via α-catenin. E-cadherin-mediated cell adhesion is stabilized by (i) p120-catenin recruited
p190RhoGAP, which stabilizes the actin cytoskeleton underlying the adhesion complex by balancing the activities of RhoA
and Rac1/Cdc42, and by (ii) protein tyrosine phosphatase PTPµ, which keeps β-catenin in an dephosphorylated state thereby
preventing its degradation. PTPµ is correctly positioned to β-catenin by a multimeric protein complex consisting of receptor
of activated protein kinase C-1 (RACK1), protein kinase C-βII (PKCβII), the tetraspanin CD151 and α3β1-integrin. (B)
Epithelial cell-matrix adhesion. Integrin-mediated cell-matrix adhesion and linkage to the actin cytoskeleton is
accomplished by a multiprotein complex consisting of the adaptor proteins talin, paxillin, vinculin and the ternary complex
of pinch, parvin and integrin-linked kinase (ILK), called tIPP complex. The interaction and phosphorylation status of focal
adhesion kinase (FAK) and the non-receptor tyrosine kinase Src is critical for integrin complex assembly and turnover.  
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1.4.3. Loss of E-cadherin function and its consequences
Loss of E-cadherin gene expression or of E-cadherin protein is frequently found during tumor
progression in most epithelial cancers. Hence, loss of E-cadherin function is a clinical
indicator for poor prognosis and metastasis (Perl et al., 1998; Bissell and Radisky, 2001;
Cavallaro and Christofori, 2004). Since E-cadherin plays a key role in epithelial structure and
homeostasis its expression underlies a strict control. As many other proteins, E-cadherin can
be regulated at the transcriptional as well as at the post-translational level, yet both
mechanisms usually cooperate for an efficient repression of E-cadherin function.
1.4.3.1. Transcriptional control of E-cadherin
Transcriptional repression of E-cadherin is mediated by a list of transcription factors, among
them intensely studied factors like Snail1 (Snail), Snail2 (Slug), ZEB1 (δEF1), ZEB2 (Sip1),
E47, and Twist (Peinado et al., 2007) (Figure 4A). The expression of these repressors can be
induced by a variety of stimuli, including activation of the TGFβ, HGF, EGF, Wnt, and
Notch signaling pathways. Moreover, they seem to regulate each other’s expression in
positive and negative feedback loops. Engagement of these transcriptional repressors at the
E-cadherin gene promoter eventually leads to epigenetic silencing of the gene by histone
modifications (acetylation, methylation, phosphorylation, ubiquitinylation, sumoylation) and
subsequently by DNA hypermethylation (Jenuwein and Allis, 2001; Zhang and Reinberg,
2001; Kouzarides, 2007). Such silencing of the E-cadherin promotor is a complex process
(Herranz et al., 2008). As a first step, Snail1 recruits the histone deacetylase HDAC to the E-
cadherin promotor complex, thereby inducing histone deacetylation. Subsequently, the
polycomb repressor complex 2 (PRC2) is recruited to the site and methylates histones, thus
supporting E-cadherin repression. Upon initial down-regulation of E-cadherin gene
expression, Snail1 induces ZEB1 expression, which in turn engages a second, PRC2-
independent repressor complex that further inhibits E-cadherin expression. In addition, new
interaction partners of Snail1 have been identified, such as the LIM-domain protein Ajuba
which recruits the protein arginine methyltransferase 5 (PRMT5) to support Snail1-mediated
transcriptional repression (Hou et al., 2008). In a large variety of human cancers, the E-
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cadherin gene is found to be highly hypermethylated, yet how the initial silencing of the gene
promoter converts into a more long-term repression by DNA hypermethylation remains to be
resolved (Berger, 2007). In the context of EMT and the metastatic dissemination of tumor
cells, the molecular basis of the reversibility or irreversibility of E-cadherin’s epigenetic
silencing is thus a future challenge. This complexity and/or variability in E-cadherin
regulation indicates that the cell has a dynamic range of E-cadherin expression and depending
on the actual need can either totally suppress or temporally attenuate its expression.
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Figure 4. Induction of epithelial-mesenchymal transition (EMT) (A) Repression of E-cadherin gene expression.
Growth factor stimulation induces various signaling cascades leading to the induction of EMT. Among the regulated genes
are transcription factors that repress E-cadherin gene expression and induce expression of genes such as matrix
metalloproteinases (MMP). (B) Loss of E-cadherin function. The E-cadherin cell-cell adhesion complex is destabilized by
Src and/or FAK- mediated phosphorylation of either E-cadherin or β-catenin. The phosphorylation of the cytoplasmic E-
cadherin domain induces its proteasomal degradation mediated by the E3-ubiquitin-ligase Hakai. Phosphorylation of β-
catenin induces its detachment from E-cadherin and relocalization into the nucleus, where together with Tcf transcriptions
factors modulates the expression of pro-invasive genes. Intracellular cleavage of E-cadherin by γ-secretase also results in a
loss of E-cadherin function, yet its newly generated C-terminal fragment (CTF2) together with p120-catenin translocates into
the nucleus, where it modifies the activity of the transcriptional repressor Kaiso. (C) Integrin-mediated support of EMT.
Enrichment of collagen I in the extracellular matrix supports EMT via the coordinated signaling of β1-integrins and the
collagen receptor DDR1. These signals converge via FAK and Pyk2 kinases on the p130Crk-associated scaffold (CAS)
protein, resulting in the induction of N-cadherin expression. (D) The formation of protrusive membrane structures. Upon
PDGF stimulation, N-cadherin co-localizes with PDGFR in membrane ruffles. The interaction of both N-cadherin and
PDGFR relies on Na+/H+ exchanger regulatory factor-2 (NHERF-2) which is recruited to the complex by p120-catenin.
Localized in membrane ruffles, N-cadherin contributes to actin cytoskeleton remodeling (i) by recruiting p190RhoGAP and
thereby favoring Rac1 and or Cdc42-mediated actin remodeling and (ii) by employing p120-catenin to recruit the non-
receptor tyrosine kinase Fer. Fer in turn phosphorylates and activates cortactin which induces actin assembly. Morover, Fer
stabilizes the N-cadherin complex by phosphorylating and activating protein tyrosine phosphatase PTP1B, thus preventing
β-catenin phosphorylation and degradation.
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1.4.3.2. Post-translational control of E-cadherin
On the post-translational level, the transport of newly synthesized E-cadherin to the cell
membrane can be inhibited via O-glycolysation (Zhu et al., 2001) or mature, membrane-
bound E-cadherin can be degraded by proteolytic cleavage or endocytosed from the plasma
membrane (Lochter et al., 1997; Steinhusen et al., 2001; Marambaud et al., 2002; Maretzky
et al., 2005). The proteolytic cleavage of E-cadherin can also produce E-cadherin fragments
which exert signaling functions. For example, γ-secretase-mediated cleavage of E-cadherin
produces a C-terminal, cytoplasmic fragment (CTF2) that is transported into the nucleus in a
p120-catenin-dependent manner (Figure 4B). In the nucleus, CTF2 modulates the interaction
between p120-catenin and Kaiso, a transcriptional repressor, thereby affecting for example
cell survival (Ferber et al., 2008). Destabilization of the E-cadherin adhesion complex is also
accomplished by receptor tyrosine kinase or Src-mediated phosphorylation of E-cadherin,
followed by its ubiquitylation by the E3 ligase Hakai and subsequent degradation (Gumbiner,
2000; Fujita et al., 2002) (Figure 4B). Moreover, integrin-activated focal adhesion kinase
(FAK) can phosphorylate β-catenin and thus induce its ubiquitylation and degradation and
the disassembly of the E-cadherin cell adhesion complex (Koenig et al., 2006). Endocytosis
of E-cadherin can occur via clathrin or caveolin-dependent mechanisms (Akhtar and Hotchin,
2001; Lu et al., 2003; Janda et al., 2006). A key player in clathrin-mediated E-cadherin
endocytosis is Arf6, a Ras-related small GTPase. It promotes endocytosis via recruitment of
Nm23-H1, a nucleoside diphosphate kinase (and the first metastasis suppressor gene ever
identified (Steeg et al., 1988)), which in turn activates dynamin-dependent fission of vesicles
and destabilization of cortical actin by recruiting the guanine nucleotide exchange factor
(GEF) Tiam1, a Rac1 inhibitor (Palacios et al., 2002). Recently, a new GTPase activating
protein (GAP) for Arf6, Smap1, has been identified, which plays an essential role in E-
cadherin endocytosis, revealing a new player in post-translational E-cadherin control (Tanabe
et al., 2005; Kon et al., 2008). The downregulation of E-cadherin not only leads to a
mechanical disruption of AJ, it also liberates proteins from the cytoplasmic cell adhesion
complex which exert ambivalent functions depending on their subcellular localization. The
probably most prominent cytoplasmic interaction partner of E-cadherin is β-catenin, well
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known for its dual role in cell adhesion and Wnt signaling (Clevers, 2006). Stabilized by
active Wnt signaling or by mutations in the β-catenin phosphorylation/degradation pathway,
β-catenin accumulates in the cytoplasm and enters the nucleus where it interacts with
members of the Tcf/Lef family of transcription factors and modulates expression of a large
number of genes involved in cell proliferation, migration, invasion, and morphogenesis,
including cyclin D1, the cell adhesion molecule L1-CAM, matrix metalloproteases (MMP)
and the metastasis gene S100A4 (Arce et al., 2006) (Wong and Pignatelli, 2002). Another
recently discovered target of β-catenin/Tcf signaling is Fascin, a actin-bundling protein which
is essential for filopodia formation and cancer cell invasion (Vignjevic et al., 2006; Vignjevic
et al., 2007). Similar to β-catenin, upon loss of E-cadherin function, p120-catenin is also
freed from the cytoplasmic cell adhesion complex and accumulates in the cytoplasm. In
addition to its functions on Rho family GTPases and the actin cytoskeleton (see above),
p120-catenin can traffic to the nucleus where it binds to the transcriptional repressor Kaiso.
In contrast to β-catenin/Tcf-mediated transcription, where β-catenin acts as a transactivator,
p120-catenin has no transactivation domain and rather releases Kaiso from its promoter
binding sites and thus activates gene expression by de-repression. However, the nature of
p120/Kaiso target genes is still poorly defined (van Roy and McCrea, 2005).
1.4.4. The cadherin switch and its consequences
The loss of epithelial E-cadherin and the gain of mesenchymal N-cadherin expression is a
major hallmark of EMT. This cadherin switch leads to a drastic change in the adhesive
properties of a cell, as it loses its affinity for epithelial neighbors and gains affinity for
mesenchymal cells, such as fibroblasts or vascular endothelial cells. Besides the change of
the adhesive repertoire, the gain of N-cadherin expression also provokes increased cell
migration and invasion (Nieman et al., 1999; Hulit et al., 2007). Like E-cadherin, N-cadherin
belongs to the family of classical cadherins and forms homophilic cell-cell adhesion
junctions. N-cadherin is normally expressed in nervous tissue, in vascular endothelial cells,
and in skeletal and cardiac muscle cells. Its expression is upregulated in the cells of the
primitive streak during mesoderm formation and during progression of a variety of cancers,
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where its expression correlates with poor prognosis (Hazan et al., 2004; Gravdal et al., 2007;
Hulit et al., 2007). Investigations into the molecular mechanisms underlying the induction of
N-cadherin expression during EMT have only recently begun. It has been shown that N-
cadherin can be upregulated by collagen I via the coordinated engagement of the collagen
receptor discoidin domain receptor 1 (DDR1) and α2β1-integrin based on a p130Crk-associated
substrate (CAS) scaffold (Shintani et al., 2008a; Shintani et al., 2008b) (Figure 4C). On the
transcriptional level, the transcriptional repressor Twist appears to be involved in the
induction of N-cadherin gene expression in an β1-integrin-dependent manner (Alexander et
al., 2006; Niu et al., 2007; Yang et al., 2007). Like its epithelial counterpart, N-cadherin is
connected via α-catenin and β-catenin to the cytoskeleton and functions as both a mechanical
cell adhesion component and a signaling molecule. Recently, it has been reported that during
neurite extension the traction forces generated by retrograde actin flow are directly
transmitted to N-cadherin adhesions, thereby mechanically linking N-cadherin with the
formation of motile structures (Bard et al., 2008). Interestingly, the authors show that the
mechanical engagement of N-cadherin induces local actin polymerization and thereby
ensures the integrity of the adhesion complex. Engagement of N-cadherin activates the
RhoGTPase Rac1, which in turn recruits the actin remodeling protein cortactin to the N-
cadherin adhesion complex (El Sayegh et al., 2005) (Figure 4D). Within this complex, the
non-receptor tyrosine kinase Fer associates with N-cadherin via p120-catenin (Kim and
Wong, 1995). Fer then phosphorylates and activates cortactin, thereby inducing actin
remodeling, and increasing the mobility of N-cadherin molecules to extend the adhesion zone
and, finally, to promote the formation of stable cell-cell adhesion. In line with these
observations, N-cadherin is found to be localized in the lamellipodia of adjacent, contacting
myoblasts (Comunale et al., 2007). Fer also phosphorylates the phosphatase protein tyrosine
phosphatase 1B (PTP1B) and promotes its binding to N-cadherin. The PTP1B/N-cadherin
interaction protects β-catenin from degradation by keeping it in a dephosphorylated state and
thereby ensures the stability of the N-cadherin-mediated cell-cell junctions (Xu et al., 2002;
Xu et al., 2004) (Figure 4D). Also similar to E-cadherin, N-cadherin interacts with a number
of signal transduction molecules and contributes to various signaling pathways. For example,
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Na+/H+ exchanger regulatory factor (NHERF)-2 has been shown to physically link N-
cadherin to PDGF receptor (PDGFR) by binding both β-catenin in the N-cadherin/β-catenin
complex and PDGFR (Theisen et al., 2007) (Figure 4D). PDGFR activation is known to
induce actin reorganization and cell proliferation and differentiation and to play an important
role in EMT (Heldin et al., 1998; Kong et al., 2008). Interestingly, PDGF stimulation of
NIH3T3 cells leads to colocalization of N-cadherin, p120-catenin and p190RhoGAP in dorsal
circular ruffles (DCRs), structures known to depend on growth factor-induced Rac activity
and subsequent RhoA inhibition (Ridley et al., 1992; Sander et al., 1999; Pertz et al., 2006).
This is interesting because p120-catenin is not only important for the recruitment of Fer to the
N-cadherin complex, but together with p190RhoGAP also coordinates the antagonistic
functions between Rac and RhoA (Nimnual et al., 2003; Wildenberg et al., 2006). This
antagonism plays a critical role in defining the structure of the actin cytoskeleton. The active
form of RhoA stimulates focal-adhesion (FA) formation and contractility via assembly of
predominantly radially-oriented actin stress fibers (ASF), whereas Rac activation induces cell
spreading, migration and membrane ruffling via actin polymerization at the cell periphery.
Moreover, Rac activation inhibits Rho activity, which can also be achieved by p120-catenin
over-expression (Anastasiadis et al., 2000) (Figure 4D). Besides PDGR, N-cadherin also
interacts with FGF receptors (FGFR) in a complex with neural cell adhesion molecule
(NCAM), a immunoglobulin domain cell adhesion molecule (Cavallaro et al., 2001;
Cavallaro and Christofori, 2004). The interaction between N-cadherin and FGFR leads to
stabilization of FGFR at the membrane surface by preventing its internalization upon ligand
binding. As a result, sustained MAPK pathway activation and increased cell motility and
MMP secretion promote invasiveness of N-cadherin-expressing cells (Hazan et al., 2000;
Williams et al., 2001; Suyama et al., 2002). NCAM accomplishes a similar induction of cell
migration and invasion by directly binding and stimulating FGFR via its fibronectin type III
domains (Cavallaro et al., 2001). Thereby, NCAM-mediated stimulation of FGFR signaling
differs substantially from FGF-induced FGFR signal transduction resulting into different
cellular outcomes, such as increased cell-substrate adhesion, migration and invasion by
NCAM and cell proliferation by FGF (Francavilla et al., 2007). The interaction between N-
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cadherin and NCAM with FGFR relies on a CAM-domain proximally located to the acid box
region of the FGFR, which is not required for FGF ligand binding (Sanchez-Heras et al.,
2006). Such complex interactions between different cell adhesion molecules and tyrosine
kinases raise another level of complexity in the regulation of cell migration, invasion and
metastasis formation. For a more detailed insight into specific aspects of cell adhesion and
signaling complexes at the invasive cancer front we refer the reader to recently published
reviews (Cavallaro and Christofori, 2004; Christofori, 2006). Like E-cadherin, N-cadherin is
also proteolytically processed to generate shedded extracellular domain and intracellular
domain fragments with potential signaling functions. In neurons, N-cadherin is cleaved by
ADAM10 and by PS1/γ-secretase to produce a cytoplasmic fragment of N-cadherin, N-Cad/
CTF2, for example stimulated by bone morphogenic protein-4 (BMP4) (Marambaud et al.,
2003; Shoval et al., 2007). N-Cad/CTF2 is able to interfere with the CPB/CREB transcription
complex, by binding the transcription factor CBP and inducing its proteasomal degradation.
N-Cad/CTF2-induced repression of CPB/CREB-mediated transcriptional control suppresses
expression of genes important for proliferation and differentiation, such as c-Fos. N-Cad/
CTF2 also promotes migration of neural crest cells by increasing the expression of β-catenin
and therewith inducing the expression of β-catenin target genes like cyclin D1. Interestingly,
N-Cad/CTF2 facilitates β-catenin-dependent signaling (i) by inhibiting β-catenin
phosphorylation, (ii) by increasing β-catenin transcription and (iii) by reducing full-length N-
cadherin protein levels to prevent sequestration of β-catenin to cell-cell junctions (Uemura et
al., 2006). These data describe N-cadherin as a critical protein in the regulation of EMT and
cell invasiveness. Besides simply exercising a cell adhesion function that changes a cell’s
affinity from epithelial cells to mesenchymal cells, it is actively involved in delineating a
cell’s migratory state by modulating growth factor signaling and remodeling the actin
cytoskeleton. Such pleiotropic functions certainly warrant detailed future experimental
investigations.
1.4.5. Integrin-mediated cell-matrix adhesion and signaling
The extracellular matrix (ECM) is a constantly remodeled 3D structure consisting of a variety
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of specialized proteins and proteoglycans which are able to regulate many cellular processes,
including cell proliferation, survival, differentiation, and migration. This control is mainly
based on a constant communication between the adhesive adaptors of a cell, integrins, and
the ECM. Changes of a cell’s integrin repertoire or the composition of the ECM can have
drastic consequences for the cell and, in extremis, can lead to cell death as well as
transformation. Besides its scaffolding function, the ECM is also able to bind and sequester
diverse growth factors and chemokines which can be retrieved by local proteolysis and,
dependent on activation or inactivation, affect cell behavior. Integrins are heterodimeric type-
I transmembrane proteins consisting of an α-and a β-chain. Mammals have 18 α and 8 β
chains which are combined to generate 24 different combinations which bind in a specific,
yet partially overlapping, manner various components of the ECM. Similar to cadherins, also
integrins function as both mechanical adhesion and signaling molecules. Importantly,
integrins switch between an inactive, low ligand-affinity conformation and an active, high
ligand-affinity conformation. Activation can be achieved by binding of intracellular proteins
to integrins, such as talin, or by MMP-mediated proteolytic cleavage (Deryugina et al., 2000;
Tadokoro et al., 2003). Integrins are linked to the actin cytoskeleton and signal via the ternary
complex of integrin-linked kinase (ILK), pinch and parvin, also named the tIPP complex
(Legate et al., 2006) (Figure 3B). In the tIPP, integrins are linked through ILK to the actin
cytoskeleton, either via parvin itself or via a paxillin/vinculin/parvin complex. ILK plays a
major role as a scaffold protein in assembling the multimeric protein complex which is
necessary for the integrin-actin cytoskeleton linkage (via parvin, paxillin and vinculin).
Moreover, ILK is required for the formation of signaling complexes with receptor tyrosine
kinases via pinch. The signaling cascades triggered by the activation of integrins and its
cytoplasmic partners are complex. Among the direct targets downstream of integrins are
FAK, Src-family kinases, glycogen synthase-kinase-3β (GSK3β) and protein kinase B (AKT/
PKB). Effectors of these signaling cascades include MAPK, NFκB, Jun, β-catenin and others
and together they modulate cell proliferation, cell survival, cell migration and invasion.
Among the mitogenic integrins are α6β4 or αvβ3-integrins which cooperate with diverse
growth factor receptors, including EGFR, ErbB2, and c-Met (Gambaletta et al., 2000;
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Mariotti et al., 2001; Mercurio and Rabinovitz, 2001; Trusolino et al., 2001). On the other
hand, growth inhibitory signals can be transmitted, for example via α2β1-integrin, which in
turn activates p38-MAPK-mediated cell-cycle inhibition (Ellinger-Ziegelbauer et al., 1999;
Ivaska et al., 1999). Integrin αvβ6 or αvβ8 engagement leads to the activation of latent TGFβ
thereby executing its cytostatic effect (Munger et al., 1999; Mu et al., 2002). Faced by this
dichotomy of integrin signaling, cancer cells switch their integrin expression to a pro-
oncogenic repertoire in order to invade and survive in the surrounding tissue. 
1.4.5.1. Integrins in EMT and cell invasion
The function of integrins during EMT is diverse and dynamic as they are able to initiate and
enforce EMT and invasion. For example, engagement of integrins α1β1 or α2β1 by collagen
type I results in a loss of E-cadherin mediated cell-cell contacts, along with the activation of
the β-catenin/Tcf pathway in pancreatic cancer cells (Koenig et al., 2006; Wipff and Hinz,
2008). Furthermore, as described above, collagen type I is also able to induce N-cadherin
expression upon activation of the integrin α2β1 together with the collagen receptor discoidin
domain receptor 1 (DDR1), a receptor tyrosine kinase (Shintani et al., 2008a). Both, the
downregulation of E-cadherin and upregulation of N-cadherin play important roles in the
initiation and execution of EMT. Interestingly, Snail1, the transcriptional repressor of E-
cadherin expression and a potent inducer of EMT, is able to induce the expression of αvβ3-
integrin which is well known for its pro-invasive functions and its localization in the invading
front of cancers (Sharma and Henderson, 2007; Haraguchi et al., 2008). Along with their
function as mechanical anchor proteins for cell migration and invasion, integrins play an
important role in the correct localization of proteases. Several reports demonstrate that the
colocalization and cooperation of β1-integrin and MT1-MMP1 is necessary for cancer cell
invasion into a collagen matrix and that both MT1-MMP and β1-integrins have important
roles in EMT (Pulyaeva et al., 1997; Bhowmick et al., 2001b; Ellerbroek et al., 2001; Wolf et
al., 2003b; Cao et al., 2008). The localization of MT1-MMP to β1-integrins is an exocytic
event dependent on the activity of the GTPase Rab8 (Bravo-Cordero et al., 2007). Integrin-
mediated recruitment of ECM remodeling proteases is also responsible for the liberation and/
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or activation of matrix bound growth factors and chemokines. As described above, the
cooperation of MT1-MMP and αvβ8-integrin leads to the activation of latent TGFβ (Mu et al.,
2002; Sheppard, 2005). TGFβ usually acts as a cytostatic, tumor suppressing factor, but it
promotes tumor progression and invasion, if the tumor cells overcome its cytostatic and
apoptotic effects (Roberts and Wakefield, 2003). In fact TGFβ is one of the most potent
inducers of EMT in cultured cells in vitro and in animal models in vivo (Thiery and Sleeman,
2006). Other integrins which are upregulated during EMT, such as αvβ6-integrin, are also able
to increase protease expression and to liberate and activate TGFβ (Bates et al., 2005; Bates,
2005; Araya et al., 2006). Also, the activities of the cytoplasmic interaction partners of
integrins, ILK and pinch, have been implicated in the process of EMT (Oloumi et al., 2004;
Bagnato and Rosano, 2007; Li et al., 2007). 
1.4.6. EMT and the actin cytoskeleton
The actin cytoskeleton is a highly dynamic structure, which is constantly remodeled in a
living cell. This dynamics are based on a well-balanced and highly controlled equilibrium of
local assembly and disassembly of actin filaments. Obviously, such regulation is a
prerequisite for processes like endocytosis, cell motility, and cancer cell invasion. 
1.4.7. RhoGTPases and EMT
The members of the Rho GTPase family are mainly responsible for integrating and
transmitting signals from chemokine and growth factor receptors and from adhesion receptors
to effector proteins of actin remodeling. RhoGTPases are activated upon GTP binding and
inactive in their GDP-bound form. RhoGTPase activation is tightly controlled by three
groups of regulatory proteins, guanine nucleotide exchange factors (GEF), GTPase-activating
proteins (GAP), and guanine nucelotide dissociation inhibitors (GDI). GEF are responsible
for the activation of RhoGTPases by promoting the exchange of Rho-bound GDP by GTP.
This is counteracted by GAP which raise the intrinsic GTPase activity of RhoGTPases and
the hydrolysis of bound GTP to GDP. Finally, GDI bind inactive Rho-GDP and prevent the
interaction with RhoGEFs and thus its activation. RhoA, Rac1 and Cdc42 are best studied
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among the 23 family members of RhoGTPases. The complexity of RhoGTPase signaling
arises not only from the size of its family members and number of effector proteins (~ 70
proteins), but also from the numbers of GEF (~ 70 members), GDI (~3 members) and GAP
(~ 60 members) which modulate their activity. Depending on which GEF, GDI or GAP is
interacting with the RhoGTPase the biological response can be different. In the GTP-bound
form, RhoGTPases activate effector proteins, which are often serine/threonine kinases, such
as the p21-activated kinases (PAK) for Rac1 and Cdc42 and the ROCK kinases for RhoA. In
general, RhoGTPases affect almost all cell biological processes in a cell’s life (Etienne-
Manneville and Hall, 2002; Sahai and Marshall, 2002; Burridge and Wennerberg, 2004).
With regard to migration and invasion and in a simplified view, RhoA induces actin stress
fiber formation and regulates cytoskeletal changes affecting cell-cell or cell-matrix adhesion,
Rac1 is involved in lamellipodia and membrane ruffle formation, and Cdc42 is involved in
filopodia formation (Hall, 2005; Ridley, 2006). Based on their central function in actin
remodeling and their ability to induce MMPs, Rho GTPases play an important role in EMT
as well (Lozano et al., 2003),. During growth factor-induced EMT, tight control of the
activities of RhoGTPases is critical. As mentioned above, depending on the presence of
epithelial or mesenchymal cadherins, the localization and function of p120-catenin and thus
the activity of RhoGTPases change dramatically (Cozzolino et al., 2003). In epithelial cells,
p120-catenin localizes at the cell membrane and associates with E-cadherin where it controls
the activity of RhoA and Rac1. RhoA activity, which is required for the initial cell-cell
contact formation, is downregulated in established, mature cell adhesions. Both, activation
and inactivation of RhoA require the p120-catenin-dependent recruitment of RhoGEFs, like
Vav2, or RhoGAPs, like p190-RhoGAP, respectively. The recruitment of p190-RhoGAP
results in the activation of Rac1 which leads to a stabilization of E-cadherin junctions by
inhibiting the activities of IQ-domain GTPase-activating protein 1 (IQGAP1), a Rac1 effector
protein and a mediator of E-cadherin endocytosis (see also below). Moreover, the actin
cytoskeleton underlying cell contacts is reorganized and stabilized (Anastasiadis, 2007).
During EMT, p120-catenin binds to mesenchymal cadherins at the cell membrane but is also
found localized in the cytoplasm. Cytoplasmic p120-catenin functions as a RhoA-GDI that
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binds and represses RhoA activity (Bellovin et al., 2005). Simultaneously, p120-catenin
bound to mesenchymal cadherins at the cell membrane promotes Rac1 activity and induces
the formation of motile, protrusive membrane structures, such as lamellipodia. Thus, both
cytoplasmic and membrane-sequestered p120-catenin cooperate to induce cell motility during
EMT. Interestingly, Rac1 inhibits RhoA activity by inducing the production of reactive
oxygen species (ROS), which in turn activate p190RhoGAP by inhibiting the low-molecular
weight protein tyrosine phosphatase (LMW-PTP)(Sander et al., 1999; Zondag et al., 2000).
Moreover, the expression of Snail1, the transcriptional repressor of E-cadherin gene
expression and potent inducer of EMT, is is increased upon Rac1-mediated ROS production
(Radisky et al., 2005). The importance of RhoGTPases in EMT is also underscored by the
notions that Rac1b, a splice variant of Rac1, is highly expressed in malignant breast tissue,
that RhoA downregulation is required for EMT in colon carcinoma progression, and that
RhoC activity is critical for cell migration, invasion and metastasis after EMT (Clark et al.,
2000; Bellovin et al., 2005; Hakem et al., 2005). The activity of RhoA during EMT not only
effects cell-cell adhesion but also microtubule-mediated cell-matrix adhesion and basement
membrane integrity (Nakaya et al., 2008). RhoA, when localized at the cell-basement
membrane (BM) gets in contact with Net1, a RhoA-specific GEF, thereby exerting an
important function for the integrity of the BM in epiblasts. During gastrulation, a process
resembling EMT, RhoA at the cell basis loses its activity, which leads to microtubule
destabilization, cell-BM contact disruption and BM breakdown. Notably, destabilization of
the cell-BM contacts precedes breakdown of cell-cell adhesions. Tiam1, a GEF for Rac1, also
exerts a critical function in both E-cadherin-mediated cell-cell junction stability and during
EMT. Loss of Tiam1 activity is required for the induction of EMT; forced expression of
constitutive-active forms of Rac1 (RacV12) or Tiam-1 prevents HGF-induced EMT in
epithelial cells (Hordijk et al., 1997; Malliri et al., 2004). Interestingly, ablation of Tiam-1 in
a mouse model of chemical-induced skin carcinogenesis reduces tumor incidence yet
increases tumor malignancy, demonstrating the ambivalent role of Rac1 in tumor formation
and tumor progression (Malliri et al., 2002). Despite major progress, the detailed role of Rho
family GTPases in EMT and tumor progression still remains unresolved. The sophistication
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of tumor cell motility and invasion on one side and the immense complexity of the regulation
of RhoGTPases on the other side obscure a simple solution. The formation of membrane
protrusions and other RhoGTPase-dependent activities during EMT are not linear processes,
and rather depend on the integrated activities of many members of the RhoGTPase family
and their interaction with various regulatory proteins which will eventually determine the
time and localization of their specific activities. 
1.4.8. Membrane ruffles
The onset of motility requires a relaxation of static actin structures in order to form pliable
membrane protrusions. Rigid actin stress fibers are disassembled upon dorsal circular ruffle
(DCR) formation leaving a fine cortical actin meshwork behind, from which cell membrane
protrusions like lamellipodia can emerge (Ballestrem et al., 1998; Krueger et al., 2003).
DCRs are short-lived actin structures formed at the dorsal surface of growth factor (PDGF,
HGF, EGF)-stimulated cells. DCRs, formed at the leading edge of growth factor-stimulated
cells, are also able to secrete MMP (e.g. MMP-2), revealing their potential role for the onset
of cell invasion (Suetsugu et al., 2003). Besides relaxing static membrane structures, DCRs
are also important for macropinocytosis in growth factor-stimulated epithelial cells (Vieira et
al., 1996; Orth and McNiven, 2006). Macropinocytosis plays an important role in the
modulation of cell signaling; it may either inhibit signal transduction via degradation of
growth factor receptor complexes or it may potentiate signaling, as shown in the case of EGF
(Vieira et al., 1996). DCRs are enriched with actin assembly proteins, such as Arp2/3, WASP
and cortactin, suggesting that DCR formation requires actin assembly. As mediators of
growth factor signaling, RhoGTPases, like Rac1 or Cdc42, are required for DCRs formation
as well (Dharmawardhane et al., 2000). Other reports indicate the involvement of protein
kinase A (PKA) and the cytoplasmic tyrosine kinase Abl in DCR formation (Plattner et al.,
1999). Both, PKA and Abl, are known to be involved in EMT (Srinivasan and Plattner, 2006;
Yang et al., 2006; Finn et al., 2007). β-catenin in a complex with APC is also found to be
localized at the leading edge of migratory cells, implying an important role for cell
polarization and migration by linking microtubules to the actin cytoskeleton (Etienne-
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Manneville and Hall, 2003; Watanabe et al., 2004; Sharma et al., 2006). Notably, β-catenin
seems to exert its function at the leading edge of cells by co-localizing with N-cadherin and
IQGAP1 in membrane ruffles (Sharma and Henderson, 2007). IQGAP1, an effector of Cdc42
and Rac1, here acts as a key regulator of internalization of N-cadherin and APC. The fact that
PDGFR also co-localizes with N-cadherin in membrane ruffles suggests an interesting
overlap of proteins known to be important in both EMT and ruffle or podosome formation
(Theisen et al., 2007). Other newly identified players in DCR formation and important for
motility are palladin and its interaction partner Eps8 (Goicoechea et al., 2006; Goicoechea et
al., 2008). Palladin binds F-actin and crosslinks actin filaments into bundles. It also interacts
with Src, thereby affecting Src-mediated actin remodeling (Ronty et al., 2007). Both proteins
are also involved in podosome formation which highlights the kinship between DCRs and
podosomes (Goicoechea et al., 2008). The cancer relevance of Eps8 and palladin is
underlined by their increased expression in various human cancers, including breast and
thyroid cancer (Matoskova et al., 1995; Ryu et al., 2001; Wang et al., 2004; Griffith et al.,
2006; Yao et al., 2006). Interestingly, palladin expression appears to be induced by treatment
of myofibroblasts with TGFβ1, suggesting a link between TGFβ signaling, a major inducer of
EMT, and the formation of ruffles and podosomes (Ronty et al., 2006).
1.4.9. Lamellipodia and filopodia
To be able to leave the primary tumor and to disseminate to secondary sites, tumor cells have
to break down cell-cell and cell-matrix junctions, as described above, and they have to invade
into the surrounding tissue by gaining motility and forming invasive, matrix degrading
structures. On planar two-dimensional culture substrates, cells utilize two well-known
organelles to explore and move into the surrounding environment, filopodia and lamellipodia.
Both are actin-rich membrane protrusions that are formed upon remodeling of the actin
cytoskeleton beneath the plasma membrane. Lamellipodia are flat, sheet-like protrusion and
they are the main organelle for cell locomotion. The unbranched, long actin filaments at the
base of the lamellipodium are progressing into a highly, lateral branched actin network at the
leading edge, giving lamellipodia their typical structure (Figure 5B). Here, actin assembly
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and lateral branching (dendritic nucleation) are mainly controlled by the Arp2/3 complex, a
seven subunit protein and major initiator of actin assembly. The activity of the Arp2/3
complex itself is controlled by actin nucleation-promoting factors, such as the N-WASP or
the Scar/WAVE complexes which are themselves recruited to and activated at the membrane
by Rac1 (Innocenti et al., 2004; Ibarra et al., 2005; Le Clainche and Carlier, 2008). Increased
expression of Arp2/3 and WAVE2 has been shown to correlate with poor prognosis in breast
and liver carcinomas underlining the relevance of lamellipodia-like structures in cancer
progression (Iwaya et al., 2007a; Iwaya et al., 2007b). Furthermore, the formation of
lamellipodia is also observed upon ErbB2-driven EMT in epithelial cells, indicating that the
formation of lamellipodia-like structures underlies the increased invasiveness observed
during EMT (Khoury et al., 2001). Lamellipodia interact and attach to their environment via
different adhesion molecules, including integrins and cadherins (Comunale et al., 2007;
Wang et al., 2008). Also, CD44, the hyaluronan receptor was identified to be in a complex
with the protease MT1-MMP in lamellipodial protrusions (Mori et al., 2002). Here, MT1-
MMP binds directly to CD44 and mediates its proteolytic cleavage, thereby stimulating
migration (Figure 5B). In contrast, filopodia are rod-like extension consisting of tight
bundled actin fibers which penetrate into the surrounding environment originating from the
basis of lamellipodia. Filopodia can be considered as a sensory organ of the cell that are used
to detect and assimilate signals like chemoattractants or nutrients released from e.g. blood
vessels. Interestingly, metastatic cells are rich in filopodia-like structures, which correlates
with their invasiveness (Coopman et al., 1998; Wang et al., 2002). Filopodia formation is
based on non-branched, processive actin assembly, controlled by fascin, diaphanous and Ena/
VASP (Svitkina et al., 2003; Le Clainche and Carlier, 2008) (Figure 5B). Actin bundling via
fascin, diaphanous and Ena/VASP, on the other hand, is controlled by Rac and Cdc42. Fascin
upregulation correlates with poor prognosis in different cancer types, including gastric
cancer, lung cancer and breast cancer (Pelosi et al., 2003; Hashimoto et al., 2004; Rodriguez-
Pinilla et al., 2006). Notably, fascin is a direct target the β-catenin/Tcf signaling pathway,
which is active in the process of EMT as well (Vignjevic et al., 2007). Recently, it has been
reported that filopodia can transform into lamellipodia by initiating dendritic actin nucleation,
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characteristic for lamellipodia formation, demonstrating that both filopodia and lamellipodia
are highly interactive, inter-convertible structures (Mongiu et al., 2007). 
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Figure 5. Upon completion of EMT, spindle-shaped, invasive cells migrate and invade into the surrounding environment by
utilizing (i) membrane protrusion like lamellipodia and filopodia for horizontal cell movement and (ii) podosome-derived
invasive structures, invadopodia, for ventral invasion. (A) Invadopodia-mediated invasion. Invadopodia are actin and
phosphotyrosine-rich membrane protrusions with a high extracellular matrix degrading capacity. Invadopodia consist of an
outer adhesive ring and a central actin-rich core. The non-receptor tyrosine kinase Src, the actin binding protein cortactin and
the membrane bound matrix metalloproteinase MT1-MMP play an essential role in the formation and function of
invadopodia. Integrins (like αvβ3-integrin), along with their cytoplasmic interaction partners, are positioned in the adhesive
ring where they mediate adhesion. The actin organization and nucleation is controlled by the Arp2/3 protein complex
(adapted from Block et al., 2008). (B) Lamellipodia/filopodia-mediated migration. Lamellipodia are the major organelles
for cell movement and build upon highly branched dendritic actin networks, which are initiated by the nucleation promoting
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factors WASP/N-WASP and the Arp2/3 complex. Lamellipodia interact with their environment via N-cadherin, β1-integrin
or the hyaluronan receptor CD44, the latter also important for the correct positioning of the membrane-bound MT1-MMP.
Filopodia are stiff, rod-like extension formed by tightly bundled actin filaments. They function as sensory organs of cells
that penetrate into the surrounding microenvironment. They originate from the root of lamellipodia and are initiated and
controlled by the concerted activity of the RhoGTPase Cdc42 and nucleation-promoting factor ENA/VASP. The major
determinant for actin bundling and filopodia morphology is fascin. Filopodia interact with their environment via the cell
adhesion molecules N-cadherin, NCAM, and β1-integrins. 
1.4.10. Podosomes and invadopodia
To move into or through a three-dimensional matrix, the real life situation, cells have to gain
the capability to remodel the ECM via the expression of proteinases. In the last few years,
actin-rich protrusion with ECM proteolytic activity, called invadopodia, have drawn
particular attention in the context of cancer cell invasion. Invadopodia are considered the
transformed counterparts of podosomes, which are formed by non-transformed yet highly
migratory cells, such as macrophages, dendritic cells, osteoclasts, and activated smooth
muscle and endothelial cells. The exact functions of podosomes are still rather elusive, yet it
seems that they are formed when cell adhesion junctions and matrix needs to be
concomitantly degraded. This may be the case, when immune cells like monocytes or
dendritic cells have to cross tissue boundaries or during bone resorption by osteoclasts for the
control of bone homeostasis (Saltel et al., 2004). The similarities or non-similarities of
podosomes and invadopodia are still under debate, yet the most striking differences between
both lies in the degree of ECM degradation and their half-lives. Invadopodia are strong
degraders of ECM and persist for up to one hour, whereas podosomes exhibit less ECM
degradation activity and are stable only for minutes. Common for invadopodia and
podosomes is their architecture. They share an actin filament-rich core containing the actin
assembly machinery (WASP, cortactin and Arp2/3) and a multimeric protein complex
surrounding the actin core, consisting of integrins and integrin-associated proteins like
vinculin, talin and paxillin (Figure 5A). The multimeric adhesive ring complex is connected
to the actin core via radial actin filaments (Linder and Kopp, 2005; Ayala et al., 2006; Linder,
2007; Block et al., 2008). Invadopodia of invading tumors cells mediate proteolysis of the
ECM via the expression of different MMP, the most prominent being MT1-MMP collagenase
and one of its direct targets, MMP2 gelatinase (Kelly et al., 1998). Invadopodia have been
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identified in numerous cancer cell lines, including malignant melanoma, breast cancer,
glioma, and head and neck cancer (Angers-Loustau et al., 2004; Tague et al., 2004; Artym et
al., 2006; Clark et al., 2007). The formation of invadopodia can be initiated by various
signals, for example by EGF, HGF or TGFβ-induced signal transduction (Tague et al., 2004;
Yamaguchi et al., 2005; Oxmann et al., 2008) or by α6β1-integrin engagement (Nakahara et
al., 1996). Invadopodia-inducing growth factors are not only produced by cancer cells
themselves but are frequently supplied by tumor-associated macrophages (TAM), which
themselves are attracted to the tumor microenvironment by tumor-released chemokines, such
as colony stimulating factor 1 (CSF-1) or placental growth factor (PlGF). TAM are well-
known to increase cancer cell invasion for example by inducing EGF driven invadopodia
formation in the cancer cells (Wyckoff et al., 2004; Yamaguchi et al., 2006). Besides their
important role in primary tumor invasion and tumor cell intravasation into the blood or the
lymphatic circulation, invadopodia are also critical for extravasation at secondary sites.
Thereby, the chemokines S100A8 and S100A9, produced by endothelial or myeloid cells at
the premetastatic niche, attract circulating tumor cells and facilitate their extravasation and
invasion at the secondary site by inducing the formation of tumor cell invadopodia (Rafii and
Lyden, 2006). The formation of invadopodia follows distinct steps (Artym et al., 2006). First,
a local enrichment of actin and cortactin at sites of cell-ECM contact initiates the recruitment
of MT1-MMP. This stage is named the pre-invadopodia stage and is then followed by further
recruitment of actin, cortactin and MT1-MMP, which leads to matrix degradation and the
formation of mature, invading invadopodia. Late invadopodia are defined by dispersal of
actin and cortactin leaving an MT1-MMP enriched structure that maintains matrix
degradation. A recent report proposes important roles for the calcium-dependent protease
calpain-2, protein tyrosine phosphatase PTP1B, and Src for the onset of invadopodia
formation and the regulation of invadopodia turnover (Cortesio et al., 2008). Apparently,
activation of integrins and/or EGF receptor leads to increased calpain-2 activity, which
subsequently proteolytically processes and activates PTP1B. Activated PTP1B wields
dephosphorylation of an inhibitory phospho-tyrosine of Src resulting in increased Src
tyrosine kinase activity, Src-mediated phosphorylation of cortactin and, subsequently, to actin
Introduction: EMT, the cytoskeleton, and cancer cell invasion
- 56 -
assembly. Conversely, activated Src phosphorylates calpain-2, resulting in proteolytic
cleavage and inactivation of cortactin and, thus, invadopodia disassembly. Both Src and
cortactin are essential for invadopodia formation and their increased activity can be used as a
potential marker for the onset of invadopodia formation (Bowden et al., 2006; Webb et al.,
2007). Downstream targets of activated Src which are known to be essential for invadopodia
formation and maintenance include cortactin, N-WASP, ArfGAPs like AMAP1/AMAP2,
paxillin and Tks5/Fish (Seals et al., 2005; Yamaguchi et al., 2005; Bharti et al., 2007;
Badowski et al., 2008; Oikawa et al., 2008). Invadopodia are known to be enriched with
integrins of the β1-integrin family (α3, α5, α6) or with αvβ3-integrin (Mueller and Chen, 1991;
Deryugina et al., 2001; Badowski et al., 2008). β1-integrins are receptors for laminin,
collagen and fibronectin, αvβ3-integrins preferentially bind to vitronectin. Furthermore, the
interaction of αvβ3-integrin with MT1-MMP leads to the activation of immature MMP2,
thereby promoting collagen proteolysis in invasive breast carcinomas (Deryugina et al.,
2001). Each of both proteins, αvβ3-integrin as well as MT1-MMP, have been shown to be
important for EMT (Pulyaeva et al., 1997; Galliher and Schiemann, 2007). The co-expression
and most likely co-operation of MT1-MMP and β1-integrin in EMT-driven invasiveness,
under the control of the transcription factor Twist, suggests that proteins relevant for
invadopodia formation are important for EMT as well (Terauchi et al., 2007). Besides their
function as mechanical anchors in the ECM, integrins actively participate in invadopodia
formation. For example, engaged α6β1-integrin induces phosphorylation of p190RhoGAP and
promotes its localization in invadopodia, where it represses RhoA activity and supports the
formation of membrane protrusions (Nakahara et al., 1998). As key regulators of actin
assembly, the major RhoGTPases RhoA, Rac1, and Cdc42 play essential roles in invadopodia
formation. Elimination of the activities of Rac1 or Cdc42 results in a reduction of
invadopodia formation in glioma cells and mammary carcinoma cells, respectively (Chuang
et al., 2004; Yamaguchi et al., 2005). On the other hand, RhoA is known to be important for
actin assembly and exocytosis of MMP in invadopodia by controlling IQGAP1 activity
(Sakurai-Yageta et al., 2008). For more detailed insights into invadopodia formation and
function, we refer the reader to several excellent recent reviews (Buccione et al., 2004;
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Linder, 2007; Gimona et al., 2008; Vignjevic and Montagnac, 2008).  
1.4.11. Lamellipodia, filopodia and their overlap with invadopodia
The kinship between the two-dimensional filopodia and lamellipodia with three-dimensional
invadopodia is still under debate. It seems that invadopodia represent a hybrid of both
structures. Like lamellipodia, invadopodia are built upon a branched actin network, yet they
employ N-WASP for actin assembly instead of WAVE-2 used by lamellipodia. On the other
hand, both invadopodia and filopodia engage Cdc42 for the induction of membrane
protrusions which are long and thin in their appearance, suggesting that actin bundling could
play an important role in invadopodia formation. However, whether filopodial actin-bundling
proteins like fascin are located in invadopodia remains to be determined (Weaver, 2008). 
1.4.12. Invadopodia and their role in EMT
As illustrated above, EMT leads to increased motility and invasiveness of epithelial cells by
dissolving epithelial cell-cell adhesion, modulating cell-matrix adhesion and by inducing the
secretion of ECM degrading proteinases. Thus, it can be assumed that EMT provokes the
formation of podosome or invadopodia-like structures. Surprisingly, up to date there is no
experimental evidence that directly links EMT with the formation of invadopodia or
podosomes. Nonetheless, a number of proteins that are important for invadopodia formation
and for the execution of EMT have been identified, strongly suggesting that invadopodia
formation could be involved in EMT-driven cell invasion. Both EMT and invadopodia
formation can be stimulated by various growth factors, including EGF, HGF, PDGF, and
TGFβ (Yamaguchi et al., 2005; Lo et al., 2007), (Varon et al., 2006). The engagement of
these growth factors leads to the activation of the non-receptor tyrosine kinase Src. The
potency of Src to induce EMT and/or invadopodia formation is well established (Frame,
2004; Bowden et al., 2006; Cortesio et al., 2008). Moreover, downstream targets of Src-
signaling, such as calpain, are upregulated during TGFβ-induced EMT and are required for
invadopodia formation (Xie et al., 2003; Cortesio et al., 2008). Another protein, able to
induce invadopodia and also involved in EMT, is endoglin, a cell surface adhesion molecule
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and co-receptor for TGFβ signaling (Fonsatti et al., 2003). Endoglin is needed for EMT
during heart development, and its expression correlates with increased invasiveness of breast
cancer cells via the increased formation of invadopodia (Mercado-Pimentel et al., 2007;
Oxmann et al., 2008). Most likely, invadopodia and podosomes are not only matrix degrading
structures but also function as guidance organelles that provide a cell with the ability to probe
its microenvironment by exploring potential cell-cell and cell-matrix adhesions and by
sensing chemoattractive cues. Interestingly, PDGF induces the translocation of cortactin to
podosomes via the GAP BPGAP1 and Rac1, indicating that PDGF receptor is involved in the
formation of podosomes (Head et al., 2003; Lua and Low, 2004). As described above,
PDGFR colocalizes with N-cadherin in membrane ruffles, and both N-cadherin and cortactin
are found in the growth cones of emerging neuronal axons and exert a crucial role in neuron
guidance (Lee, 2005; Bard et al., 2008). The co-localization of cortactin with the N-cadherin/
NCAM/FGFR complex and NCAM-mediated FGFR signaling have been shown to contribute
to neurite outgrowth (Cavallaro et al., 2001). Thus, consistent with its upregulated expression
during EMT (the cadherin switch, see above), N-cadherin is likely to be involved in the
formation of invadopodia.
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2. AIM OF THE STUDY
Epithelial-mesenchymal transition (EMT) is a critical process underlying the onset of cancer
cell invasion and has been identified at the invasive front of murine and human tumors.
Hence, the identification of reliable prognostic markers and the intervention with EMT-
driven invasion is of major interest in cancer diagnostics and therapy. To achieve these goals,
we need to gain new and detailed insights into the molecular processes regulating EMT. 
For this purpose, we induced EMT in different in vitro model systems and followed changes
in gene expression profile to investigate:
• which genes are master regulatory genes of EMT
• which cell biological processes are controlled by these master regulators
• are these master regulators required for tumor progression and metastasis formation in vivo
• are these master regulators potential markers for invasion and metastasis in human tumors 
Here, we identified the cell adhesion molecule NCAM and the transcription factor Dlx2 as
master regulatory genes of EMT and investigated there cell biological functions as well as
their contribution to tumor progression and metastasis formation in vivo.
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3. RESULTS
3.1. NCAM-induced focal adhesion assembly: a functional switch upon loss of E-
cadherin (Article)
Francois Lehembre, Mahmut Yilmaz, Andreas Wicki, Tibor Schomber, Karin Strittmatter,
Dominik Ziegler, Angelika Kren, Phillip Went, Patrick WB Derksen, Anton Berns, Jos
Jonkers and Gerhard Christofori. EMBO 2008, 27(19), 2603-15. 
3.1.1. Abstract
Loss of expression of the cell-cell adhesion molecule E-cadherin is a hallmark of epithelial-
mesenchymal-transition (EMT) in development and in the progression from epithelial tumors
to invasive and metastatic cancers. Here, we demonstrate that the loss of E-cadherin function
up-regulates expression of the neuronal cell adhesion molecule NCAM. Subsequently, a
subset of NCAM translocates from fibroblast growth factor receptor (FGFR) complexes
outside of lipid rafts into lipid rafts where it stimulates the non-receptor tyrosine kinase p59Fyn
leading to the phosphorylation and activation of focal adhesion kinase (FAK) and the
assembly of integrin-mediated focal adhesions. Ablation of NCAM expression during EMT
inhibits focal adhesion assembly, cell spreading and EMT. Conversely, forced expression of
NCAM induces epithelial cell delamination and migration, and high NCAM expression
correlates with tumor invasion. These results establish a mechanistic link between the loss of
E-cadherin expression, NCAM function, focal adhesion assembly and cell migration and
invasion.
3.1.2. Introduction
When cancer cells disseminate from a primary tumor and infiltrate the surrounding tissue,
they leave the tumor mass not only by gaining migratory and invasive capabilities but also by
dissolving cell-cell contacts, known as tight and adherens junctions (Friedl and Wolf, 2003b).
Consistent with this notion, the calcium-dependent cell-cell adhesion molecule E-cadherin, 
the prototype adhesion molecule of epithelial adherens junctions, is found absent or
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dysfunctional in the majority of epithelial cancers (carcinomas) (Cavallaro and Christofori,
2004). Inhibition of E-cadherin activity by specific neutralizing antibodies or shRNA-
mediated down-regulation of its expression in epithelial MDCK cells leads to increased
motility and invasiveness (Behrens et al., 1989; Qin et al., 2005). Conversely, the invasive
behavior of carcinoma cells can be blocked by forced expression of E-cadherin (Frixen et al.,
1991). Using a transgenic mouse model of pancreatic β cell carcinogenesis (Rip1Tag2), we
have previously demonstrated that the loss of E-cadherin is a rate-limiting event during tumor
progression (Perl et al., 1998). 
In many cancer types, the loss of E-cadherin coincides with a gain of expression of the
mesenchymal cadherin, N-cadherin. This ‘cadherin switch’ is thought to be required for
tumor cells to gain invasive properties (Cavallaro, 2004). Interestingly, the cadherin switch is
also a hallmark of EMT, a process characterized by the combined loss of epithelial cell
junction proteins, including E-cadherin, α-catenin, β-catenin, and claudins, and the gain of
mesenchymal markers, such as N-cadherin, vimentin and fibronectin (Thiery, 2003; Thiery
and Sleeman, 2006). EMT is a critical process during embryonic development and it is
thought to play an important role in the progression of cancer, although this hypothesis is still
under debate (Lee et al., 2006). 
Here, we have investigated the functional consequences of the loss of E-cadherin in various
cellular systems and transgenic mouse models and report that expression of the neuronal cell
adhesion molecule NCAM, a member of the immunoglobulin superfamily of genes, is up-
regulated concomitant with the loss of E-cadherin function. NCAM has been previously
implicated in tumor progression and in lymph node metastasis, mainly by modulating β1
integrin-mediated cell-matrix adhesion (Cavallaro et al., 2001; Christofori, 2003). In neurons,
NCAM triggers distinct signal transduction pathways. Within lipid rafts, NCAM associates
with and activates p59Fyn kinase leading to the phosphorylation of focal adhesion kinase
(FAK) and focal adhesion assembly, whereas in the non-raft compartment NCAM facilitates
FGFR–activated signaling (Beggs et al., 1997; Niethammer et al., 2002). Here, we
demonstrate that the up-regulation of NCAM expression is a direct result of the loss of
adherens junctions. As a consequence, NCAM clusters in lipid rafts together with p59Fyn,
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leading to FAK phosphorylation and focal adhesions assembly, activities required for cell
motility and EMT.
3.1.3. Results 
3.1.3.1. EMT induced by the loss of E-cadherin 
We have employed several different experimental systems to investigate the functional
impact of the loss of E-cadherin function on cell behavior and cell signaling. First, TGFβ-
treatment of NMuMG murine mammary gland epithelial cells, a well-characterized EMT
model, induced a loss of E-cadherin expression accompanied by a complete EMT (Miettinen
et al., 1994; Bhowmick et al., 2001a) (Figure 6A). Second, shRNA-mediated knock-down of
E-cadherin in MCF7 human epithelial breast carcinoma cells substantially reduced E-
cadherin expression (MCF7-shEcad; Figure 6A,B). Third, genetic ablation of E-cadherin
function was achieved by establishing a cell line from mammary tumors of MMTV-Neu
transgenic mice (Muller et al., 1988), in which both E-cadherin alleles were flanked by LoxP
recombination sites (MTflEcad cells) (Derksen et al., 2006). Expression of Cre-recombinase
in MTflEcad cells led to a complete abrogation of E-cadherin expression (MTdeltaEcad;
Figure 6A,B). The lack of E-cadherin expression in both MCF7-shEcad and MTflEcad cells
resulted in a loss of epithelial morphology and a gain of a fibroblast-like appearance (Figure
6A). Reduced expression of E-cadherin in MCF7 cells was accompanied by decreased
expression of other epithelial markers, such as β−catenin, and an increased expression of the
mesenchymal markers N-cadherin and vimentin. The lack of E-cadherin in MTflEcad cells
only induced N-cadherin expression, without any up-regulation of vimentin or loss of
β−catenin (Figure 6B). Furthermore, MCF7-shECad cells exhibited a 8-fold increase in cell
motility and a 3-fold increase in invasiveness, whereas MTdeltaEcad cells only displayed a
2.5-fold elevated motility but no increased invasiveness (Supplementary Figure S1A,B).
These data indicate that removal of E-cadherin can induce either a bona fide EMT (MCF7-
shEcad) or merely a “cadherin-switch” in the absence of a full EMT (MTdeltaEcad). Notably,
cell proliferation was diminished upon E-cadherin-depletion in all experimental systems
tested (Supplementary Figure S1C).
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Figure 6. E-cadherin loss in epithelial cell lines induces either a cadherin switch or full EMT.(A) NMuMG, MCF7 and
MTflEcad cells adapt a mesenchymal phenotype upon loss of E-cadherin by TGFβ treatment (+TGFβ), shRNA expression
(shEcad) or Cre-mediated deletion of the E-cadherin gene (+Cre). (B) Immunoblot analysis for E-cadherin (Ecad), N-
cadherin (Ncad), β-catenin, vimentin and NCAM expression in MCF7 and MTflEcad cells expressing E-cadherin (shCont
and MTflEcad) or depleted for E-cadherin expression by shRNA expression (shEcad) or Cre-mediated deletion of the E-
cadherin locus (MTdeltaEcad). Cell extracts were loaded on different gels and resolved proteins were visualized with
specific antibodies as indicated. Immunoblotting for vinculin was used as loading control. (C) NCAM expression is induced
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upon loss of E-cadherin function. NCAM mRNA levels were determined by quantitative RT-PCR in MCF7, MTflEcad and
NMuMG cells that have been depleted for E-cadherin (-E-cadherin) or not (+E-cadherin). For all values p<0.0001, unpaired
t-test. Data are shown as mean±SD. *Since NCAM is not expressed at detectable levels in MCF7 cells, its upregulated
expression in MCF-shEcad cells cannot be calculated as fold-induction. Instead the comparative Ct values (∆∆Ct) are given
in the lower row. (D) Immunoblot analysis for NCAM protein expression in NMuMG cells in the presence of TGFβ at the
indicated time points. Immunoblotting for vinculin was used as loading control. (E) NCAM mRNA levels were determined
by quantitative RT-PCR in NMuMG cells treated with TGFβ for the times indicated. *p=0.0134, **p<0.005; unpaired t-
test). Data are shown as mean±SD. (F) NCAM promoter activity is increased upon loss of E-cadherin expression. NMuMG
were transfected with a CAT reporter plasmid containing 1000 bp (∆Ssp) or 647 bp (∆Nde) of the NCAM promoter
sequence and treated or not with TGFβ for 6 days prior to the analysis of CAT activity (left panel; *p=0.0027 and **p=
0.0007, unpaired t-test). Data are shown as mean±SD. (G) NMuMG cells stably transfected with shControl or shSmad4 were
treated for 3 days with TGFβ and then analyzed for NCAM, E-cadherin (Ecad) and N-cadherin (Ncad) expression by
immunoblotting analysis. Immunoblotting for vinculin was used as loading control.
3.1.3.2. EMT induces NCAM expression
Gene expression profiling experiments and quantitative RT-PCR analysis comparing
NMuMG, MCF7 and MTflEcad cells before and after the loss of E-cadherin function
revealed that the expression of NCAM was significantly up-regulated upon loss of E-
cadherin expression in TGFβ-treated NMuMG, MCF7-shEcad and MTdeltaEcad cells
(Figure 6C). Immunoblotting analysis confirmed up-regulated expression of the 140 kD
isoform of NCAM (NCAM140) in comparison to the E-cadherin-expressing cells (Figure
6B). NCAM mRNA up-regulation was already detected 6 hours after TGFβ treatment of
NMuMG cells, and an increase in NCAM protein levels was observed 24 hours after TGFβ
treatment (Figure 6D,E), indicating that the upregulation of NCAM expression is an early
event upon loss of E-cadherin function and EMT. Ablation of E-cadherin by treatment of
MTflEcad cells with recombinant Cre recombinase protein carrying a HIV-Tat cell entry-
peptide resulted in the concomitant loss of E-cadherin expression with the gain of NCAM
expression, demonstrating that NCAM expression is upregulated by the loss of E-cadherin
without any additional TGFβ stimulation (Supplementary Figure S2B). Also in HEK293
cells, mesenchymal phenotype cells that expressed low levels of E-cadherin, shRNA-
mediated ablation of E-cadherin expression resulted in an elongated cell shape with increased
motility and an up-regulation of NCAM expression (Supplementary Figure S3A-C). Next, we
investigated the effect of loss of E-cadherin expression on NCAM gene promoter activity by
CAT-reporter assays. Utilizing DNA sequences of the NCAM gene promoter region either 1
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kb (ΔSsp) or 647 bp (ΔNdeI) upstream of the transcriptional start site (Boras and Hamel,
2002), TGFβ-treatment of NMuMG cells (Figure 6F) or ablation of E-cadherin expression in
MCF7 cells (Supplementary Figure S2A) provoked a significant increase in NCAM
promoter-reporter activity. It has been recently reported that Smad4-depleted NMuMG cells
(NMuMG-shSmad4) maintain an epithelial morphology upon TGFβ treatment (Deckers et
al., 2006). Consistent with this report, NMuMG-shSmad4 cells still expressed high levels of
E-cadherin after 3 days of TGFβ treatment, but only low levels of NCAM and N-cadherin in
comparison to Smad4-expressing NMuMG-shControl cells (Figure 6G). These results
indicate that Smad4-mediated signal transduction plays a critical role in the induction of
NCAM gene expression during TGFβ-induced EMT. To investigate whether NCAM up-
regulation also occurs in vivo, we crossed mice carrying LoxP-flanked conditional alleles of
the E-cadherin gene (Derksen et al., 2006) with Rip1Cre mice in which Cre-recombinase
was specifically expressed in β cells of the pancreatic islets of Langerhans (Ahlgren et al.,
1998). Despite the low constitutive expression of NCAM in islet cells of normal control mice
(Esni et al., 1999), β cells that upon successful recombination had lost E-cadherin expression
exhibited significantly higher levels of NCAM at their cell surface (Supplementary Figure
S4). Together, these data indicate that the loss of E-cadherin causes increased NCAM gene
expression in vivo and in vitro. 
3.1.3.3. NCAM is required for EMT
We next assessed whether increased NCAM levels were required for epithelial cells to
undergo EMT. Three murine NCAM-specific siRNAs (simNCAM1, 2 and 3) efficiently
down-regulated NCAM mRNA and protein levels in NMuMG cells in comparison to control
NCAM-mismatch-siRNA (siControl) transfected cells (Figure 7A,B). NCAM-depleted
NMuMG cells failed to undergo EMT and to upregulate the mesenchymal marker N-cadherin
upon TGFβ treatment, while siControl-transfected NMuMG cells readily converted to
mesenchymal cells indicating that NCAM is required for EMT to occur (Figure 7A,C).
Notably, ablation of NCAM expression in NMuMG cells, that after 13 days of TGFβ
treatment had undergone full EMT, lead to a reversion of EMT, with characteristic polarized
epithelial cell morphology. This morphological change was accompanied by an increase in E-
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cadherin expression and a decrease in N-cadherin expression, demonstrating that NCAM is
not only required for the initiation but also for the maintenance of EMT in NMuMG cells
(Figure 7D).
To investigate the role of NCAM in tumors undergoing EMT in vivo, we analyzed E-cadherin
expression during tumor progression in the Rip1Tag2 (RT2) transgenic mouse model of
pancreatic β cell carcinogenesis (Hanahan, 1985), either wildtype for NCAM expression or in
a NCAM knock-out background (RT2;NCAM+/+ and RT2;NCAM-/-, respectively; (Perl et
al., 1999). In wildtype RT2, the tumor areas showing downregulation of E-cadherin
expression exhibited significantly higher intensities of diffuse NCAM-specific fluorescence
staining at cell-cell contacts (Figure 7E). In contrast, in the absence of NCAM expression,
75% of the invasive carcinomas of RT2;NCAM-/- mice showed high levels of E-cadherin
expression (Figure 7F; p<0.0001, Fisher’s exact test). Altogether, these results indicate that
ablation of NCAM expression prevents EMT and E-cadherin loss in vitro and in vivo. 
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Figure 7. NCAM is required for EMT. (A) Immunoblot analysis of NCAM and N-cadherin (Ncad) in siControl and
siNCAM-transfected NMuMG cells. 24 hours after transfection, TGFβ was added to the medium for 48 hours.
Immunoblotting for vinculin was used as loading control. (B) Levels of NCAM mRNA were determined by quantitative RT-
PCR in NMuMG cells that have been transfected with siControl and siNCAM for 24 hours before treatment with TGFβ for
48 or 96 hours. For all values *p<0.002 compared to siControl-transfected cells, unpaired t-test. Data are shown as
mean±SD. (C) Phase contrast microscopy of siControl and siNCAM-transfected NMuMG cells treated or not with TGFβ for
48 hours. (D) NMuMG cells were treated for 13 days with TGFβ before transfection of a control (siControl) and or an
NCAM-specific siRNA (siNCAM3). 48 hours later phase-contrast images were taken (left panels). NCAM, N-cadherin
(Ncad) and E-cadherin (Ecad) expression levels were analyzed by immunoblotting (right panel). Antibodies against vinculin
were used as loading control. (E) Immunofluorescence staining for E-cadherin (red) and NCAM (green) on pancreatic
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sections from Rip1Tag2 mice. Lower panel: quantification of NCAM fluorescence in cell-cell junctions from E-cadherin-
positive cells or E-cadherin-negative cells (each n = 40) shows increased expression in cells that have lost E-cadherin
(*p<0.0001, unpaired t-test). Blue DAPI staining visualizes nuclei. (F) Immunofluorescence staining for E-cadherin (red) on
pancreatic sections from Rip1Tag2;NCAM+/+ (upper panels), Rip1Tag2;NCAM-/- (lower panels) and Rip1Tag2 mice (right
panels). Note that in contrast to carcinomas of Rip1Tag2;NCAM+/+ mice, E-cadherin expression is maintained in
carcinomas of Rip1Tag2;NCAM-/- mice. Blue DAPI staining visualizes nuclei. Ex, exocrine tissue; Tu, tumor tissue.
3.1.3.4. NCAM is sufficient to induce hallmarks of EMT
We next examined whether NCAM was able to induce EMT in epithelial cells. Ectopic
expression of NCAM induced cell death in NMuMG as well as in MCF7 cells, as previously
reported with other EMT regulators (Mani et al., 2007). We thus established several
independent clones of MDCK epithelial cells expressing NCAM140 (Figure 8A). Notably,
NCAM-expressing MDCK cells formed numerous foci on top of the confluent cell
monolayer, a feature that was not observed in control-transfected cells (Figure 8B). Under
sparse conditions, NCAM-expressing cells scattered and did not form cell-cell contacts, while
control MDCK cells formed small cell clusters (Figure 8B).
In heterogeneous populations of NCAM-expressing and non-expressing cells, the
majority of the NCAM-expressing cells delaminated from the cellular monolayer and
migrated on top of neighboring epithelial cells (Figure 8C). In the NCAM-expressing cells,
adherens junction proteins, such as β-catenin and E-cadherin, were undetectable (Figure 8C),
while N-cadherin expression was increased (Figure 8D). These results indicate that NCAM is
able to induce morphological and molecular changes representing typical hallmarks of EMT
in MDCK cells (shown here) and also in E-cadherin transfected fibroblastoid L cells (Esni et
al., 1999). 
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Figure 8. NCAM induces partial EMT. (A) Immunoblotting analysis of NCAM expression in MDCK cell clones either
transfected with empty vector (control) or with an NCAM expression vector (NCAM). Immunoblotting for vinculin was
used as loading control. (B) Phase-contrast microphotographs of confluent (upper panels) and sparse (lower panels) MDCK
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surface (left panel). The right panel shows a single NCAM-expressing cell that has lost E-cadherin expression and
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and on the right side of the panel. (D) Immunoblot analysis of N-cadherin (Ncad) in MDCK cells stably expressing NCAM.
Immunoblotting against vinculin was used as loading control.
3.1.3.5. NCAM induces focal adhesion assembly 
Since we previously had shown that NCAM was able to modulate β1 integrin-mediated cell-
matrix adhesion (Cavallaro et al., 2001), we compared control and NCAM-depleted cells for
their ability to spread on fibronectin-coated culture dishes. Cell spreading was significantly
reduced in TGFβ-treated NMuMG cells upon NCAM removal (Figure 9A,B). Furthermore,
cell spreading of TGFβ-treated, “mesenchymal” NMuMG cells could be repressed by
neutralizing antibodies against β1-integrin (Figure 9A), while spreading of non-treated
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epithelial NMuMG cells was unaffected (Figure 9B). Consistent with this notion, numerous
focal contacts were observed at the ventral surface of TGFβ-treated NMuMG cells in
comparison to their epithelial counterparts (Figure 9C), and cells undergoing EMT exhibited
increased amounts of phosphorylated FAK and paxillin and enhanced cell spreading (Figure
9D). Such TGFβ-mediated focal adhesion assembly as well as FAK phosphorylation was not
observed in NCAM-depleted NMuMG cells (Figure 9C,D). In a time course of mesenchymal
cell spreading, FAK was constantly phosphorylated suggesting a high stability of the focal
adhesions, whereas in NCAM-depleted cells, the levels of FAK phosphorylation oscillated,
indicating a high turnover of focal adhesions (Figure 9E). 
Transwell migration assays revealed a significantly higher chemotactic migration of
TGFβ-treated, siNCAM-transfected NMuMG cells as compared to TGFβ-treated, siControl-
transfected cells (Figure 9F). Moreover, NCAM-depleted TGFβ-treated NMuMG cells
migrated significantly faster in scratch wounding assays than NCAM-expressing control cells
(Supplementary Figure S5). However, adhesion assays performed to quantify stable matrix
attachment of cells independent of their spreading capacity did not reveal any differences
between NCAM-expressing and non-expressing cells (data not shown). These data suggest
that NCAM plays a critical role in focal adhesion assembly and turnover, rather than in
modulating the strength of cell matrix-adhesion.
NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin
- 71 -
0h 0.5h 2h 6h 8h
0h 0.5h 2h 6h 8h
siCont.
simNCAM1
p-FAK
Actin
D
E
NMuMG -TGFβ NMuMG +TGFβ NMuMG +TGFβC
Spreading
TGFβ 0h 48h
p-FAK
p-Paxillin
Vinculin
0h 48h
siCont. simNCAM1
siC
on
t.
sim
NC
AM
1
sim
NC
AM
2
siC
on
t.
sim
NC
AM
1
sim
NC
AM
2
-TGFβ +TGFβ
200
**
***
*
400
600
800
1000
1200
1400
M
ig
ra
tin
g 
ce
lls
 p
er
 fi
el
d
B
S
pr
ea
d 
ce
lls
 p
er
 fi
el
d
sim
NC
AM
2
sim
NC
AM
3
siC
on
t1.
siC
on
t2.
sim
NC
AM
2
sim
NC
AM
3
siC
on
t1.
siC
on
t2.
0
20
10
30
40
50
70
90
60
80
*
**
+IgG +β1-integrin blocking antibody
NMuMG - TGFβ
p-FAK
Actin
Spreading
F
NMuMG +TGFβNMuMG +TGFβ
siCont. simNCAM3
Phalloidin
FAK
A
sim
NC
AM
2
sim
NC
AM
3
siC
on
t1.
siC
on
t2.
sim
NC
AM
2
sim
NC
AM
3
siC
on
t1.
siC
on
t2.
+IgG +β1-integrin blocking antibody
*
*
*
**
*
0
20
10
30
40
50
70
90
60
80
S
pr
ea
d 
ce
lls
 p
er
 fi
el
d
NMuMG + TGFβ
Figure 9. NCAM is required for focal adhesion assembly during EMT. (A, B) TGFβ-treated NMuMG cells show a
markedly reduced cell spreading upon siRNA-mediated depletion of NCAM expression (simNCAM) as compared to
control-treated cells (siCont). Cell spreading is further reduced by the addition of neutralizing antibodies against β1-integrin
in TGFβ-treated NMuMG cells (A) but not in untreated cells (B). Data are shown as mean±SD. *p< 0.05, unpaired t-test.
(C) Immunofluorescence staining for actin (red) and p125FAK (green) in NMuMG cells in the presence or absence of TGFβ,
as indicated. Numerous focal adhesions are detected in TGFβ-treated cells (arrows, middle upper panel) as compared to
control cells (left panel). Higher magnification of the middle upper panel is shown on the right. Lower panels: NCAM-
depletion leads to impaired focal adhesion assembly in siCont- and siNCAM-treated NMuMG cells treated with TGFβ.
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Staining with DAPI (blue) visualizes nuclei. Size bars = 10 µm. (D) Immunoblotting analysis of NMuMG cells reveals an
increase in FAK and Paxillin phosphorylation upon EMT induction (left panel). Treatment with siRNA against murine
NCAM (simNCAM, right panel) represses the increase in EMT-induced FAK phosphorylation as observed in control-treated
cells (siCont; left panel). Immunoblotting for vinculin was used as loading control. (E) TGFβ-treated NMuMG cells were
transfected with control siRNA (siCont) or with siRNA targeting NCAM expression (simNCAM1), allowed to spread on the
culture dish for the indicated time points and levels of FAK phosphorylation were determined by immunoblotting with
antibodies specifically recognizing phosphorylated FAK. Immunoblotting for actin was used as loading control. (F)
Depletion of NCAM expression (simNCAM)significantly induces migration of NMuMG cells trough Transwell filters as
compared to control-siRNA-treated cells (siControl). *p=0.043, **p=0.013, ***p=0.0024, unpaired t-test. Data are shown as
mean±SD.
3.1.3.6. NCAM re-localizes into lipid rafts upon EMT
In neurons, it has been reported that a signaling complex between NCAM, p59Fyn and FAK is
formed upon homophilic NCAM-NCAM interactions, and that NCAM-mediated signaling
via p59Fyn depends on its localization to lipid rafts (Beggs et al., 1997; Niethammer et al.,
2002). Indeed, TGFβ treatment of NMuMG cells lead to increased phosphorylation of p59Fyn
(Figure 10A). Immunofluorescence analysis revealed that in TGFβ-treated NMuMG cells,
NCAM was predominantly localized in the junctions between cells and in focal plasma
membrane areas (Figure 10B, upper panels) where it co-localized with FAK (Figure 10b,
lower panels). Sucrose gradient density centrifugation experiments demonstrated that the low
levels of NCAM present in epithelial NMuMG cells were found exclusively in the detergent-
soluble protein fractions (Figure 10C). In contrast, in TGFβ-treated NMuMG cells a
substantial proportion of the high levels of NCAM were also detected in the top fractions of
the gradient (Figure 10C), indicating an association of NCAM with detergent-resistant lipid
rafts. FAK and phosphorylated p59Fyn were also found in the NCAM-containing lipid raft
fractions of the gradient. Disruption of lipid rafts by cholesterol depletion with methyl-β-
cyclodextrin (M-β-CD) completely impaired the formation of NCAM clusters in TGFβ-
treated NMuMG cells, while the actin cytoskeleton and cell shape remained largely
unaffected (Figure 10D, data not shown). These experiments indicate that a subset of NCAM
shifts its localization to p59Fyn/FAK containing lipid rafts upon the transition to a
mesenchymal phenotype. Since NCAM has been shown to physically associate with FGFR,
PLCγ and cortactin outside of lipid rafts (Cavallaro et al., 2001), we next assessed whether
these NCAM-containing signaling complexes were unchanged during EMT.
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Immunoprecipitation experiments with antibodies against NCAM revealed that FGFR2 was
found associated with NCAM regardless of TGFβ treatment of NMuMG cells. In contrast,
the signaling effectors PLCγ and cortactin co-immunoprecipitated with NCAM exclusively in
untreated epithelial NMuMG cells and not in TGFβ-treated “mesenchymal” NMuMG cells
(Figure 10E). These data suggest that during TGFβ-induced EMT of NMuMG cells NCAM
changes its subcellular localization and its signaling partners, which in turn leads to focal
adhesion stabilization.
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Figure 10. During EMT, NCAM localizes into lipid rafts together with p59Fynand FAK. (A) Immunoblotting analysis of
NMuMG cells reveals an increase in p59Fyn phosphorylation upon EMT induction (+TGFβ). Immunoblotting for total p59Fyn
was used as loading control. (B) Upper panels: Immunofluorescence staining for NCAM (green) in NMuMG cells in the
presence or absence of TGFβ. During EMT, NCAM is translocated from sites of cell-cell contacts to foci at the plasma
membrane (see higher magnification in top right panel). Lower panels: NCAM (red) and FAK (green) co-localize in TGFβ-
treated NMuMG cells. DAPI staining (blue) visualizes nuclei. Size bars = 20 µm. (C) NCAM140 associates with lipid rafts
upon induction of EMT. Lysates of TGFβ-treated or non-treated NMuMG cells were fractionated by sucrose gradient
centrifugation and proteins were resolved by SDS-gel electorphoresis. After blotting, membranes were cut in upper and
lower halves. The upper half was sequentially probed with antibodies against NCAM and FAK, the lower half was probed
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with antibodies against phosphorylated-p59Fyn and total p59Fyn. In mesenchymal cells (+TGFβ), NCAM, p59Fyn and FAK are
present in lipid rafts (lanes 1 to 3) as well as in the Triton X-100 soluble high-density fractions (lanes 4 to 6). In epithelial
cells (-TGFβ), they are only detected in the high-density fractions (lanes 4 to 6). (D) Immunofluorescence staining of NCAM
(red) in NMuMG cells treated with TGFβ. Upon methyl-β-cyclodextrin (M-β-CD) treatment lipid rafts are disorganized and
NCAM clusters disappear. Size bars = 20 µm. (E) NCAM forms a complex with FGFR2, PLCγ and cortactin in epithelial
cells. Lysates from NMuMG cells treated or not with TGFβ were immunoprecipitated with anti-NCAM antibodies (NCAM)
or unrelated isotype immunoglobulins (IgG). Total lysates and immunoprecipitates were resolved by SDS-gel
electrophoresis, and after protein transfer the blot was sequentially probed with antibodies specific for PLCγ, NCAM,
FGFR2 and vinculin. Cortactin was probed on a separate blot from a gel loaded with the same experimental cell extracts.
Note that NCAM precipitates PLCγ and cortactin only in untreated NMuMG cells but not in TGFβ-treated cells.
3.1.3.7. NCAM mediates focal adhesion assembly in various EMT systems
To assess whether NCAM exerts this critical function also during EMT in other experimental
systems, its expression was ablated in MCF7-shEcad, MTdeltaEcad and HEK293 cells by
transfection of specific murine or human siRNAs (Supplementary Figure S6A-D). In MCF7-
shEcad cells depleted from NCAM, a loss of neurite extensions was observed (Figure 11A),
an established hallmark of NCAM function (Cavallaro et al., 2001). In contrast, no obvious
morphological changes were observed in MTdeltaEcad cells upon NCAM depletion (data not
shown), suggesting that these cells were irreversible in their mesenchymal phenotype (note
that these cells carry a irreversible deletion of the E-cadherin gene). 
As observed in TGFβ-treated NMuMG cells, numerous focal contacts were observed
at the ventral surface of MTdeltaEcad and MCF7-shEcad cells (Figure 11B and data not
shown). Consistent with this observation, increasing amounts of phosphorylated FAK and
paxillin were observed in cells in MTdeltaEcad in comparison to their epithelial counterparts
(Figure 11C). Upon depletion of NCAM from MTdeltaEcad cells, FAK phosphorylation was
rapidly lost during cell spreading, while it remained constant in control cells (Figure 11D).
As a consequence, cell spreading of NCAM-depleted MCF7-shEcad, MtdeltaEcad and
HEK293 cells were reduced (Figure 11E and data not show). Notably, phosphorylation of
paxillin was unaffected by the presence or absence of NCAM, indicating that paxillin
phosphorylation is mediated by an NCAM-independent pathway (Figures 11D, 9C,D). 
Comparable to NMuMG cells, in HEK293 cells NCAM localization also shifted from
non-lipid raft to lipid raft membrane fractions upon loss of E-cadherin (Figure 11F).
Consistent with this observation, disruption of lipid rafts by cholesterol depletion with M-β-
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CD completely impaired the formation of NCAM clusters in HEK293-shEcad and
MTdeltaEcad cells (Figure 11F and data not shown). Forced, inducible expression of NCAM
in HEK293 cells resulted in the translocation of a subset of NCAM into lipid rafts,
demonstrating that increased levels of NCAM protein mediate its translocation to lipid rafts
and that the loss of E-cadherin is not necessarily required for this process (Supplementary
Figure S7). 
Immunoprecipitation experiments revealed that in E-cadherin-deficient HEK293-shEcad cells
the high levels of NCAM associated with p59Fyn, an interaction that could not be detected in
control cells expressing low levels of NCAM (Figure 11G). Similarly to TGFβ-treated
NMuMG cells, in HEK293 cells NCAM associated with PLCγ only in the presence of E-
cadherin (Figure 11G). These results indicate that, upon loss of E-cadherin function, NCAM
ceases to associate with PLCγ and cortactin and a subset of NCAM protein re-localizes to
lipid rafts where it binds to p59Fyn. 
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Figure 11. NCAM expression control focal adhesion assembly in various mesenchymal cells. (A) Quantification of neurites
in MCF7-shECad cells reveals that the number of neurites per cell is significantly decreased in siNCAM-transfected cells
compared to siControl-transfected cells (lower panel, *p=0.0133 and **p=0.0087, unpaired t-test). Data are shown as
mean±SD. (B) Immunofluorescence staining for actin (red) and p125FAK (green) on MTflEcad cells with and without Cre-
recombinase expression. Numerous focal adhesions are detected in E-cadherin-depleted cells (arrows, middle panel) as
compared to control cells (left panel). Higher magnifications of the middle panels are shown on the right. Staining with
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DAPI (blue) visualizes nuclei. Size bars = 10 µm. (C) Immunoblotting analysis of MTflEcad and MTdeltaEcad cells reveals
an increase in FAK and paxillin phosphorylation upon mesenchymal transition. Immunoblotting for vinculin was used as
loading control. (D) MTdeltaEcad cells were transfected with siControl or siNCAM SiRNA, allowed to spread for the
indicated times and the levels of phosphorylation of FAK and paxillin were determined by immunoblotting analysis. Cell
lysates were resolved by SDS gel electrophoresis, and after protein transfer blots were sequentially probed with antibodies
against phosphoryalated FAK and phosphorylated paxillin. (E) Cell spreading of MCF7-shEcad and HEK293 cells
transfected with different siRNAs targeting NCAM (sihNCAM2 and 3) on plastic culture dishes is reduced as compared to
control-treated cells (siCont). (*p=0.0021, unpaired t-test). Data are shown as mean±SD. (F) NCAM140 associates with
lipid rafts upon loss of E-cadherin expression. Upper panels: Lysates of HEK293-shECad and HEK293-shCont cells were
fractionated by sucrose gradient centrifugation and analyzed by immunoblotting for NCAM, β-catenin and vinculin as
loading control. In E-cadherin-depleted cells (shEcad), NCAM is present in lipid rafts (fractions 1 and 2) as well as in the
Triton X-100 soluble high-density fractions (fractons 5 and 6). In the presence of E-cadherin (shCont), NCAM is only
detected in the high-density fractions (fractions 5 and 6). Lower panels: Immunofluorescence staining of NCAM (red) in
HEK293-shECad cells treated with methyl-β-cyclodextrin (M-β-CD). Upon treatment, lipid rafts are disorganized and
NCAM clusters disappear. Size bars = 20 µm. (G) HEK293-shEcad (shEcad +) and HEK293-shCont (shEcad -) cell lysates
were immunoprecipitated with antibodies against NCAM or an unrelated immunoglobulin isotype (IgG). NCAM
precipitated p59Fyn (arrow) only in the absence of E-cadherin, and PLCγ only in the presence of E-cadherin. Vinculin was
used as loading control. The asterisk indicates immunoglobulin heavy chain.
3.1.3.8. Expression of NCAM in human and mouse tumors 
We next determined whether up-regulated NCAM expression was also observed in E-
cadherin-negative cancer cells in vivo. NCAM and E-cadherin expression were analyzed by
immunohistochemical staining of tumor tissue from a recently published mouse model of
lobular breast carcinogenesis, in which mice carrying LoxP-flanked alleles of the p53 gene
(Trp53F) were crossed with keratin14 gene-promoter-Cre recombinase mice (K14-Cre) and
with mice carrying LoxP-flanked alleles of E-cadherin (EcadF/F; (Derksen et al., 2006). In E-
cadherin-expressing tumors (K14-Cre;Trp53F/F;EcadF/+), E-cadherin was expressed at the
membrane of most tumor cells (Figure 12A), while NCAM could only be detected in large
blood vessels of the surrounding fat or muscle tissue and in the basal layer of the epidermis
(Figure 12A,E). In contrast, in tumors of K14-Cre;Trp53F/F;EcadF/F mice, E-cadherin
expression was efficiently ablated (Figure 12A,C), yet NCAM expression was now detectable
at varying intensities in tumor cells (Figure 12A,D). In particular, cells within invasive tumor
fronts displayed significant NCAM expression, for example at the interface between tumors
and subcutaneous myocytes and adipocytes, as well as in disseminated tumor cells (Figure
12A,E and F). 
We next assessed NCAM expression in human cancers by immunohistochemical staining of
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multi-tissue arrays containing 39 different human cancer types and corresponding 22 normal
tissues. Depending on availability, between 5 and 50 samples per cancer type were analyzed.
A particular strong up-regulation of NCAM was observed in neuroendocrine tumors,
including small-cell lung cancer (SCLC, 35 of 43 patients, p < 0.001, Fisher’s exact test) and
intestinal carcinoids (33 of 44 patients, p < 0.001, Fisher’s exact test), cancer types known to
lose E-cadherin expression during tumor progression (Salon et al., 2004). Staining of serial
histological sections of a human intestinal neuroendocrine carcinoid revealed expression of
NCAM predominantly in the invasive cancer cells of the tumor with low or no E-cadherin
expression, while NCAM was not found to be expressed in the E-cadherin-positive,
differentiated compartments of the tumor (Figure 12B). These results indicate that NCAM is
upregulated upon loss of E-cadherin function in certain types of human cancers.
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Figure 12. NCAM is up-regulated in E-cadherin-negative tumors. (A) Serial histological sections from breast tumors of
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K14-Cre;Trp53F/F mice expressing E-cadherin (Ecad F/+) or deficient in E-cadherin expression (Ecad F/F) were stained
with antibodies against E-cadherin (a and c) and NCAM (b, d, e and f). NCAM is absent in E-cadherin-expressing tumor
cells (a, b). In contrast, NCAM is expressed in tumors that have lost E-cadherin expression (c, d). NCAM is predominantly
expressed on the invasive front of E-cadherin-negative tumors at the interphase between tumor cells and myocytes (e) or
adipocytes of the skin (f). Disseminated tumor cells in the stroma (indicated by arrows in e) also display strong NCAM
staining. Inserts represents higher magnifications of the respective sections. Size bars = 100 µm. (B) Serial histological
sections from a human patient neuroendocrine carcinoid were stained with antibodies against E-cadherin (a-d) and NCAM
(e,f). NCAM is not expressed in E-cadherin-positive, differentiated cancer cells, whereas NCAM is expressed in invasive
cancer cells with reduced E-cadherin expression. Morphological structures are marked for orientation. Size bars = 200 µm.
3.1.4. Discussion
We have employed cellular experimental systems, transgenic mouse models and patient
biopsies to investigate how the loss of E-cadherin function contributes to tumor progression.
Notably, E-cadherin depletion in cultured cells in vitro leads to increased expression of the
cell adhesion molecule NCAM. A comparable NCAM up-regulation is also observed in
transgenic mouse models of malignant insulinoma and lobular breast carcinoma and in
human small-cell lung cancer and intestinal carcinoids, where a loss of E-cadherin and a gain
of mesenchymal markers have been previously implicated in tumor progression (Salon et al.,
2004). Interestingly, expression of L1, a close relative of NCAM, is also observed in E-
cadherin-negative cells of the invading tumor front, for example in colorectal cancer (Gavert
et al., 2005).
The molecular mechanisms underlying the regulation of NCAM gene expression
during EMT are the focus of intense investigations in our laboratory. Here, we have assessed
the functional contribution of upregulated NCAM expression to EMT. In the tumor
progression models employed here, NCAM is found in two distinct complexes: in the
presence of E-cadherin low levels of NCAM localize outside of lipid rafts and associate with
FGFR, PLCγ and cortactin. Upon loss of E-cadherin function, NCAM expression levels are
increased, and a subset of NCAM protein translocates to lipid rafts, where it associates with
p59Fyn. Subsequent phosphorylation and activation of p59Fyn and its effector substrate FAK
result in the stabilization of β1 integrin-mediated focal adhesions and increased cell spreading
and migration (Figure 13). On the other hand, FGFR transmits NCAM-dependent and
NCAM-independent signals: NCAM-mediated activation of FGFR leads to the activation of
PLCγ and via the Raf-kinase PKCβII to sustained MAPK activation and increased cell
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adhesion. In contrast, stimulation of FGFR by FGFs activates PLCγ/PKCα and Ras/Raf/
MAPK signaling pathways and promotes cell adhesion and proliferation (Francavilla et al.,
2007); Figure 13). Thus, loss of E-cadherin affects the nature of NCAM-mediated signal
transduction by inducing NCAM gene expression and by changing NCAM’s subcellular
localization. Forced expression of NCAM also resulted in its translocation to lipid rafts even
in the presence of E-cadherin, indicating that the levels of NCAM proteins determine its
subcellular localization and thus its signaling qualities (Supplementary Figure S7). It is
interesting to note that NCAM is a haploinsufficient gene, indicating that NCAM gene dosage
plays a critical role in development and disease (Esni et al., 1999; Perl et al., 1999). Our
results may provide a biochemical explanation for this gene dosage effect. The results also
substantiate findings in neurons, where it has been demonstrated that NCAM140 localized in
membrane compartments outside of lipid rafts binds and stimulates FGFR via its fibronectin
type III domains, which in turn activates PLCγ and MAPK signaling pathways (Doherty and
Walsh, 1996; Niethammer et al., 2002). In contrast, when situated within lipid rafts, NCAM
associates with p59Fyn and activates FAK kinase-mediated signaling (Beggs et al., 1997;
Niethammer et al., 2002). 
Apparently, NCAM expression plays an essential role in mesenchymal cell motility as
characterized by the formation of β1-integrin-dependent focal adhesions. We have previously
shown that the genetic ablation of NCAM gene expression results in the loss of β1-integrin
activation (Cavallaro et al., 2001) and that ablation of NCAM or β1-integrin leads to reduced
tumorigenicity of tumor cells (Kren et al., 2007). Here we demonstrate that, after loss of E-
cadherin function and gain of NCAM expression during EMT, phosphorylated FAK is
stabilized and β1-integrin-mediated cell spreading is enhanced. In contrast, in epithelial cells,
FAK phosphorylation has a high turnover, very few focal adhesions are detected, and cell
spreading is slow and largely β1-integrin-independent.
Based on the data presented, we conclude that the loss of E-cadherin, among many other
molecular consequences, induces up-regulated expression of the NCAM gene. As a result,
increased levels of NCAM localize to lipid rafts and via p59Fyn induce the formation of focal
adhesions and integrin-dependent mesenchymal cell migration and invasion. The correlation
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between the loss of E-cadherin and the gain of expression of NCAM and other Ig-domain
adhesion molecules in specific human cancer types and mouse models of carcinogenesis
indicate that these molecular pathways play a critical role in malignant tumor progression and
metastasis and, thus, warrant further investigation.
Figure 13. NCAM upregulation leads to a functional switch. Depicted is a working model of the molecular mechanisms
underlying the change in NCAM subcellular localization and its interacting partners during EMT. In epithelial cells, low
levels of NCAM form a complex with FGFR and PLCγ leading to the activation of the Raf-kinase PKCβII and thus to a
sustained activation of the MAPK pathway and cell adhesion. Upon loss of E-cadherin function during EMT, NCAM is
highly expressed, and a subset localizes to lipid rafts where it associates with p59Fyn, leading to FAK phosphorylation, focal
adhesion assembly and cell migration. Both NCAM-mediated signaling pathways are required for neurite outgrowth. In
contrast, FGF-induced stimulation of FGFR results in PLCγ-mediated activation of PKCα and a short pulse activation of the
Ras/Raf/MAPK pathway resulting in cell adhesion and proliferation. FGF-induced signaling is overruled by the NCAM-
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mediated signals (Cavallaro et al., 2001; Francavilla et al., 2007).
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3.1.5. Supplementary Figures
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Figure S1. Increased migration of MCF7 and MTflEcad cells upon loss of E-cadherin (shEcad and MTdeltaEcad,
respectively). *p<0.0001 and **p= 0.0236, unpaired t-test. Data are shown as mean±SD. (B) shRNA-mediated depletion of
E-cadherin (shEcad) induces invasion of MCF7 cells. ***p=0.0186, two sided t-test. Data are shown as mean±SD. (C)
Epithelial-mesenchymal transition reduces the proliferation rates of NMuMG, MCF7 and MTflEcad NMuMG cells. Cell
numbers were measured using an MTT assay.
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Figure S2. NCAM promoter activity is increased upon loss of E-cadherin. (A) MCF7 cells expressing E-cadherin or
depleted for E-cadherin expression were transfected with a CAT reporter plasmid containing 1000 bp (DSsp) or 647 bp
(DNde) of the NCAM promoter sequence, and CAT activity was determined 48 hours after transfection (*p = 0.0114 and
**p = 0.0374). Data are shown as mean±SD. (B) MTflEcad cells carrying floxed alleles of the E-cadherin gene were treated
with purified recombinant Cre-recombinase fused to a HIV-Tat entry peptide to ablate the E-cadherin alleles by
recombination/excision. RNA was extracted at the time points of treatment as indicated, and the relative expression levels of
NCAM and E-cadherin were determined by quantitative RT-PCR.
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Figure S3. Loss of E-cadherin expression in HEK293-shEcad cells. (A) Phase contrast micrographs of HEK293 cells stably
expressing a control shRNA (shCont, left panel) or an E-cadherin-specific shRNA (right panel). (B) Immunoblotting
analysis of E-cadherin (Ecad), NCAM, b-catenin, and vimentin expression in HEK293-shCont and HEK293-shEcad cells.
Immunoblotting for vinculin was used as loading control. (C) Scratch wounding assay on confluent layers of HEK293-
shCont and HEK293-shEcad cells. 42 hours after wounding, phase contrast microphotographs were taken. Note that within
this period, HEK293-shEcad cells had almost closed the gap, while HEK293-shCont cells had migrated less.
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Figure S4. E-cadherin deletion in b cells of the islets of Langerhans leads to increased NCAMexpression in normal tissues.
Immunofluorescence staining for E-cadherin (green; A, D, E) and for NCAM (red; C, D, F) in a pancreatic section from a E-
cad F/F;RipCre mouse as indicated. E and F represent higher magnifications of the boxes in panels A and C, respectively.
Single b cells that have lost E-cadherin expression and gained high levels of NCAM expression are indicated by arrows.
Nuclei are stained with DAPI (blue).
NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin
- 88 -
0h 24h
siCont.
simNCAM1
simNCAM2
Figure S5. NCAM depletion increases cell migration Scratch wounding assay on confluent layers of NMuMG cells
transfected with siControl or siNCAM siRNA and treated with TGFβ. 24 hours after wounding, phase contrast
microphotographs were taken. Note that within this time period, siNCAM-transfected cells had almost closed the gap, while
the siControl cells had migrated less. 
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Figure S6. Characterization of siRNA targeting mouse and human NCAM. (A) Immunoblotting analysis of MTdeltaEcad
cells transfected for 48 hours with mouse NCAM-specific siRNA targeting NCAM or with mismatch control siRNA.
Immunoblotting for vinculin was used as loading control. (B and C) HEK293 and HEK293-shEcad and MCF7-shEcad cells
(D) were transfected for the indicated times with 3 independant siRNA targeting human NCAM or with mismatch control
siRNA (siCont) and analyzed by immunoblotting (upper panels) or quantitative RT-PCR (lower panels) for NCAM
expression. Mouse riboprotein L19 primers were used for normalization, and fold induction was calculated against
siControl-treated cells using the comparative Ct method (∆∆Ct). *p<0.01, unpairedt-test. Data are shown as mean±SD.
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Figure S7. High levels of NCAM140 associate with lipid rafts. (A) HEK293 cells expressing NCAM under the control of
the Tetracycline-inducible system (HEK293-FlpInTrex-NCAM) were either grown in the absence of Doxycycline (non-
induced) or in the presence of Doxycycline (induced) to induce expression of NCAM. Lysates of the cells were fractionated
by sucrose gradient centrifugation and analyzed by immunoblotting for NCAM, phosphorylated-p59Fyn, p59Fyn and
vinculin, as indicated. In cells expressing high levels of NCAM (induced), NCAM, p59Fyn and FAK are present in lipid
rafts (0 and 20% sucrose) as well as in the Triton X-100 soluble high-density fractions (30, 35, and 40% sucrose). In cells
expressing low levels of NCAM, they are only detected in the high-density fractions (30, 35, and 40% sucrose).(B)
Expression levels of E-cadherin remain unchanged upon induced expression of NCAM. HEK293-FlpInTrex-NCAM and
HEK293-FlpInTrex-GFP cells were induced with doxycycline to express NCAM and GFP, respectively, and NCAM and E-
cadherin levels were determined by immunoblotting at the time points indicated. Tubulin served as loading control.
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3.1.6. Material and Methods
Reagents and antibodies 
Mouse NCAM-Fc (20 µg/ml) was a gift from U. Cavallaro (IFOM, Milano, Italy). TGFβ:
R&D Systems (Abingdon, UK). Antibodies: anti-α-actin (Abcam, Cambridge, UK), anti-E-
cadherin (for immunoblotting), anti-pY397FAK, anti-FAK, anti-p-Paxillin, anti-pY528p59Fyn
(BD Transduction Laboratories, Allschwil, Switzerland), anti-E-cadherin (for
immunostaining; Zymed, San Diego, CA), anti-vinculin N-19, and anti-hNCAM 123C3
(Santa Cruz Biotechnology, Heidelberg, Germany), anti-vimentin clone V9, anti-β-catenin
and anti-hNCAM OB-11 (Sigma, Basel, Switzerland), anti-β1-integrin MAB2253Z
(Millipore, Volketswil, Switzerland), anti-FGFR2 C-17, anti-cortactin 4F11, anti-PLCγ and
anti-p59Fyn (Upstate Biotechnology, Lake Placid, NY), anti-murine NCAM 5B8
(immunoblotting and immunofluorescence), anti-NCAM 13 (immunoprecipitation; BD
Transduction Laboratories) and anti-N-cadherin (Takara Biomedicals, Tokyo, Japan).
Cells and cell lines
A subclone of NMuMG cells (NMuMG/E9; hereafter NMuMG) expressing E-cadherin has
been previously described (Maeda et al., 2005). MDCKII, NMuMG, HEK293 and MCF7
cells were cultured in DMEM supplemented with glutamine, penicillin, streptomycin, and
10% FCS (Sigma). Oligonucleotides (Suppl. data, Table S1) were annealed and inserted into
the pSUPER-retro-neo vector (OligoEngine, Seattle, WA) to generate pSUPER-Ecad-shRNA
and pSUPER-Cont-shRNA. MCF7 and HEK293 cells stably transfected with pSuperRetro-
Ecad-shRNA (shEcad) and pSuperRetro-mNCAM-shRNA (sh-cont) and MDCKII cells
stably transfected with NCAM140 expression vectors were selected in G418. NMuMG-
shSmad4 and NMuMG-shCont were obtained from P. ten Dijke (Leiden University Medical
Center, The Netherlands; (Deckers et al., 2006). TGFβ treatment of NMuMG cells was
performed without serum deprivation, and TGFβ was replenished every 3 days. MTflEcad
cells were established from a mammary gland tumor isolated from an MMTV-Neu mouse
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(Muller et al., 1988) crossed with EcadF/F mice (Derksen et al., 2006). To establish the
MTflEcad-Cre cell line, MTflEcad cells were infected with LZRSpBMN retroviral vector
expressing Cre-IRES-GFP. After infection, GFP-expressing cells were sorted by FACS.
hNCAM and mNCAM siRNAs were purchased from Invitrogen (Stealth siRNA duplex
oligoribonucleotides; Table S1). Transfections with LipofectAMINE RNAiMAX
(Invitrogen) were performed according to the manufacturer's instructions. Total cell lysates,
immunoblots, and immunofluorescence experiments were performed as previously described
(Wicki et al., 2006). Depending on the species origin of antibodies, immunoblots were either
probed sequentially or on multiple membranes. Adobe Photoshop has been used to excise the
relevant portion of the immunoblots from the original scans of X-ray films exposed to
chemiluminescence visualization of specific proteins, as indicated by black frames in the
figures. 
Migration and invasion assays
Cell migration was determined in a modified two-chamber migration assay (pore size: 8 µm;
Falcon BD, Franklin Lakes, NJ). For invasion assays, membranes were coated with 20 µl of a
2.5 mg/ml solution of Matrigel (Falcon BD). For both assays, 105 cells were seeded in 1%
fetal calf serum/DMEM (Sigma) in the upper chamber and the lower chamber was filled with
10% fetal calf serum/DMEM. After 24h incubation at 37°C, cells in the upper chamber were
carefully removed with a cotton swap and the cells that had traversed the membrane were
fixed in 4% paraformaldehyde/HBS-Ca2+, stained with crystal violet (0.5% in 20% methanol)
and counted.
Cell spreading assay
To quantify cell spreading, cells were plated on a plastic culture dish, and 30 minutes after
seeding the medium was changed to eliminate unattached cells. Cells were incubated at 37°C
and counted in regular intervals in four independent experiments. In cases where β1-integrin
blocking antibodies were used, cells were incubated for 30 minutes with 100 µg/ml mouse
IgG or anti-β1-integrin antibodies prior to seeding.
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In vitro wounding assay
A scratch wound was generated using a 200 µl pipette tip on confluent cell monolayers in a
6-well culture plates in 10% serum containing DMEM-medium (Sigma, St. Louis, Missouri).
Cells were then washed with fresh medium to remove floating cells. Microphotographs were
taken at different time points.
Quantitative RT-PCR
Total RNA was prepared using Trizol (Invitrogen), reverse transcribed with M-MLV reverse
transcriptase RNAse (H-) (Promega, Wallisellen, Switzerland), and transcripts were
quantified by PCR using SYBR-green PCR MasterMix (Applied Biosystems, Rotkreuz,
Switzerland) and the primers indicated in Table S1. Human or mouse riboprotein L19
primers were used for normalization. PCR assays were performed in triplicates, and fold
induction was calculated against control-treated cell lines using the comparative Ct method
(ΔΔ Ct).
CAT assays 
NMuMG cells were transfected with ΔNde and ΔSsp NCAM-CAT reporter constructs(Boras
and Hamel, 2002) and treated with TGFβ for 6 days. CAT assays were performed using the
CAT Enzyme Assay System (Promega). CAT activities were normalized relative to co-
transfected control luciferase activities.
Immunoprecipitations
Cells were lysed in RIPA-plus buffer. Equal amounts of proteins were incubated overnight
with either mouse IgG or with anti-NCAM antibodies. Protein G sepharose beads (Sigma)
were incubated with the immune complexes for 30 minutes, washed in cold lysis buffer and
boiled in 2x SDS-PAGE loading buffer.
Flotation assays
Cells were lysed in cold lysis buffer for 30 minutes (1% Triton X-100, 25 mM Tris-HCl pH
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7.5, 10% sucrose, 1 mM CaCl2, 1 mM MgCl2 containing 1 mM NaF, 2 mM Na3VO4, 0.1 mM
PMSF, 1 mM DTT and protease inhibitor cocktail), and isolation of Triton X-100-insoluble
membrane fractions by sucrose gradient density centrifugation was performed as described
(Oliferenko et al., 1999). 
Histological analysis 
Mice with a deletion of both E-cadherin alleles specifically in the β cells of the islets of
Langerhans were generated by crossing mice carrying E-cadherin alleles flankes by loxP sites
(E-cadfl/fl; (Derksen et al., 2006) with RipCre mice (Ahlgren et al., 1998). Mice were
sacrificed at the age of 56 days. The preparation of frozen tissue sections and
immunofluorescence and immunohistochemical analysis was performed as described
previously (Perl et al., 1998); (Wicki et al., 2006). In case of mouse-anti-mouse antibodies,
background was reduced by additional blocking with the m.o.m kit (Vector Laboratories,
Burlingame, California) according to the manufacturer’s recommendations. The following
primary antibodies were used at a 1:100 dilution: rat anti-mouse E-cadherin (Zymed), mouse
anti-human E-cadherin (BD), anti-mouse NCAM 5B8 (a gift from U. Cavallaro), and mouse
anti-human NCA (OB11, Sigma). Stainings were evaluated on an AxioVert microscope and
on a LSM 510 META confocal microscope (Zeiss, Oberkochen, Germany). Human cancer
samples were obtained with the consent of the Ethical Committee of the Kantons beider
Basel.
Statistical analysis
Statistical analysis and graphs were generated using the GraphPad Prism software (GraphPad
Software Inc, San Diego, CA). All statistical analysis were done by unpaired, two-sided t-
test. Normality testing was performed using the Kolmogorov-Smirnov test with Dallal-
Wilkinson-Lillie for p-values.
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3.2. Dlx2 protects NMuMG cells from TGFβ induced cell-cycle arrest and apoptosis
Mahmut Yilmaz and Gerhard Christofori. Manuscript in preparation.
3.2.1. Abstract
Resistance against TGFβ-induced growth inhibition is a pre-requisite for tumor progression
and metastasis formation. Tumor cells evade TGFβ-mediated growth inhibition by
attenuating canonical TGFβ signaling and by undergoing an epithelial-mesenchymal
transition (EMT). 
Here, we demonstrate that the transcription factor distal-less homeobox 2 (Dlx2) is
upregulated during EMT by canonical TGFβ signaling. Dlx2 induces the transcriptional
repression of the transforming growth factor receptor II (TGFβRII), leading to attenuated
canonical TGFβ signaling and thus reduced expression of TGFβ target genes, such as cyclin-
dependent kinase inhibitor p21CIP1. Simultaneously, Dlx2 promotes survival and proliferation
via epidermal growth factor receptor (EGFR)-mediated activation of the mitogen-activated
protein kinase (MAPK) and phosphoinositide-3 kinase (PI3K) signaling pathways. Ablation
of Dlx2 expression during EMT decreases survival and impairs the ability of B16 melanoma
cells to grow into primary tumors in transplanted syngeneic mice and to metastasize to the
lung. Conversely, increased expression of Dlx2 during EMT promotes survival and correlates
with the invasiveness and metastatic potential of human cancers.
These results establish a mechanistic link between Dlx2 expression, resistance against TGFβ-
mediated growth inhibition and promotion of cell survival and invasion. 
3.2.2. Introduction
The chemokine TGFβ plays a central role in various biological processes such as
development, tissue homeostasis and cancer. During gastrulation or neural crest formation
TGFβ induces motility and invasiveness, enabling cells to migrate to distant sites within the
developing embryo. In contrast, in differentiated epithelial tissue TGFβ primarily maintains
tissue homeostasis by inducing growth arrest and apoptosis, functioning as a tumor-
suppressor (Derynck et al., 2001; Siegel and Massague, 2003; Massague, 2008). 
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This ambivalent nature of TGFβ signaling plays also a critical role in cancer development
and progression. At early stages of tumorigenesis TGFβ functions as a tumor-suppressor by
inducing cell cycle arrest and apoptosis. In contrast, during late stage tumorigenesis, TGFβ
functions as an oncogene by inducing a transition of non-invasive epithelial cells into
invasive mesenchymal cells, a process named epithelial-mesenchymal transition (EMT)
(Roberts and Wakefield, 2003; Thiery and Sleeman, 2006; Pardali and Moustakas, 2007;
Massague, 2008; Yang and Weinberg, 2008). 
The hallmarks of EMT, namely the loss of epithelial markers such as E-cadherin, the gain of
mesenchymal markers such as N-cadherin, the transition into mesenchymal cell shape
accompanied by increased motility and invasiveness are all reminiscent of early steps of
metastasis. Hence, EMT evolved to an attractive model to describe early steps of single cell-
based cancer invasion and several reports identified EMT in the invasive front of human
tumors (Oft et al., 1998; Rosivatz et al., 2002; Usami et al., 2008). The modulation of TGFβ
signaling from a tumor-suppressor to an EMT-inducer plays an critical role during tumor
progression and is achieved by two major modification namely, attenuation of the apoptotic
TGFβ signaling and activation of survival ensuring, mitogenic phosphoinositide 3-kinase
(PI3K) and mitogen-activated protein kinase (MAPK) signaling pathways. The tumor-
suppressive, canonical TGFβ signaling is mediated the by receptor associated Smad proteins
(R-Smads). Upon ligand binding the R-Smads (Smad2/3) are phosphorylated, dissociate from
the TGFβ-receptor complex, interact with the common mediator Smad4, translocate into the
nucleus and control the expression of various genes. Cell-cycle inhibitory genes such as
p15INK4B and p21CIP1 are transcriptionally activated by canonical TGFβ signaling while genes
such as the mitogenic c-Myc are repressed (Massague, 2004). Tumors attenuate apoptotic
canonical TGFβ signaling and bypass cell-cycle arrest by repressing transforming growth
factor receptor II (TGFβRII) expression or via mutational inactivation of Smad proteins (Kim
et al., 2000; Osada et al., 2001; Venkatasubbarao et al., 2001; Munoz et al., 2006; Yamashita
et al., 2008b). By inhibiting its tumor-suppressive function, tumor cells utilize TGFβ to drive
proliferation and survival by non-canonical signaling-mediated activation of the MAPK and/
or the PI3K pathways (Gotzmann et al., 2002; Janda et al., 2002; Dumont et al., 2003;
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Jechlinger et al., 2006; Lee et al., 2007). Total loss of TGFβ signaling impairs tumor
progression and metastasis formation (Oft et al., 1998; Moustakas and Heldin, 2005). 
Here, we introduce the homeobox transcription factor distal-less homeobox 2 (Dlx2) as a
gene upregulated during EMT, which protects epithelial, non-transformed NMuMG cells
from TGFβ-induced cell-cycle arrest and apoptosis. We show that Dlx2 expression is induced
by canonical TGFβ signaling and functions in a negative feedback loop by inducing the
transcriptional repression of the TGFβRII gene. This leads to reduced TGFβRII proteins
levels, decreased Smad 4 activity and finally, to decreased expression of TGFβ target genes,
such as the cell-cycle inhibitor p21CIP1, and stabilization of the mitogenic c-Myc protein.
Simultaneously, Dlx2 promotes, in cooperation with the epidermal growth factor receptor
(EGFR), survival and proliferation by activating the MAPK and PI3K pathways, which are
both essentially required for resistance against TGFβ-induced cell-cycle arrest and apoptosis. 
3.2.3. Results
3.2.3.1. EMT induces Dlx2 expression
For the identification of genes critical in the regulation of EMT, we performed genes
expression profiling and quantitative RT-PCR experiments on three independent in vitro
EMT model systems before and after EMT, namely (i) MTdeltaECad cells, a MMTV-neu
breast tumor-derived cell line, in which EMT was induced by Cre-recombinase mediated
deletion of the E-cadherin gene (Lehembre et al., 2008) (ii) MFC7-shECad cells, a human
breast cancer cell line, in which EMT was induced by shRNA-mediated downregulation of E-
cadherin (Lehembre et al., 2008) and (iii) NMuMG cells, a murine mammary epithelial cell
line, in which EMT was induced upon treatment with TGFβ (Piek et al., 1999). Screening for
genes that are regulated in all three experimental systems, we identified the homeobox
transcription factor Dlx2 as a commonly upregulated gene (MFC7-shECad 50x,
MTdeltaECad 4x, NMuMG + TGFβ 3.5x upregulated). In NMuMG cells, Dlx2 is most
upregulated after 6 days of TGFβ treatment (Figure 14A). To assess whether Dlx2 is a target
of either canonical or non-canonical TGFβ signaling, we followed Dlx2 mRNA expression in
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stable Smad4 knockdown NMuMG cells (shSmad4-NMuMG) treated with TGFβ (Deckers et
al., 2006). In TGFβ-treated shSmad4-NMuMG cells Dlx2 expression is significantly less
upregulated, indicating that Dlx2 is a target of Smad-dependent, canonical TGFβ signaling
(Figure 14B). Thus, Dlx2 is upregulated during TGFβ-induced EMT as a target of canonical
TGFβ signaling.
3.2.3.2. Dlx2 is not required for EMT
We next assessed whether Dlx2 expression is critical for TGFβ-induced EMT in NMuMG
cells. Therefore, we transfected NMuMG cells with siRNA against Dlx2 and followed
changes in cell morphology and epithelial or mesenchymal marker expression. TGFβ-treated,
siDlx2-expressing NMuMG cells underwent a bona fide EMT, showing no phenotypic
differences to control cells undergoing EMT (Figure 14C). Furthermore, expression of the
epithelial marker E-cadherin and mesenchymal markers N-cadherin and NCAM were
comparable to control cells, underlining that Dlx2 function is not required for EMT
(Supplementary Figure S8). Interestingly, the number of surviving cells was significantly
reduced in TGFβ-treated siDlx2-NMuMG cells, due to increased apoptosis and decreased
proliferation (Figure 14D-F). This was confirmed by a significantly reduced cell growth of
TGFβ treated NMuMG cells in which Dlx2 expression was ablated due to an shRNA-
mediated knock-down (shDlx2-NMuMG) (Figure 14G). Thus, Dlx2 function is required for
survival and proliferation of NMuMG cells undergoing EMT, yet not for the actual
morphogenic process of EMT.
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Figure 14. Dlx2 is a target of canonical TGFβ signaling and promotes survival during TGFβ-induced EMT. (A) Dlx2
is upregulated during TGFβ-induced EMT. Dlx2 mRNA levels were determined by quantitative RT-PCR in NMuMG cells
treated with TGFβ for days indicated. (B) Dlx2 is upregulated by Smad-dependent, canonical TGFβ signaling. Dlx2 mRNA
levels were determined by quantitative RT-PCR in stable Smad4 knockdown (shSmad4) and control (shCTR) NMuMG cells
treated with TGFβ for days indicated. (C) Dlx2 function is not required for TGFβ-induced EMT. Phase-contrast
microphotographs reveal a bona fide EMT of Dlx2-depleted (siDlx2) and control (siCTR) NMuMG cells treated with TGFβ
for 6 days. (D) Loss of Dlx2 function reduces survival during TGFβ-induced EMT. Dlx2-depleted (siDlx2) and control
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(siCTR) NMuMG cells were treated with TGFβ for days indicated. Viable cells were counted by trypan blue exclusion using
a Neubauer chamber. (E) Loss of Dlx2 function reduces proliferation during TGFβ-induced EMT. Dlx2-depleted (siDlx2)
and control (siCTR) NMuMG cells were treated with TGFβ for days indicated. Proliferation was assessed by BrdU
incorporation and FACS analysis. (F) Loss of Dlx2 function increases apoptosis during TGFβ-induced EMT. Dlx2-depleted
(siDlx2) and control (siCTR) NMuMG cells were treated with TGFβ for days indicated. Apoptosis was assessed by Annexin
V staining and FACS analysis. (G) Loss of Dlx2 function decreases cell growth during TGFβ-induced EMT. NMuMG cells
stably infected with three independent shRNA against Dlx2 (shDlx2 I-III) and control shRNA (shCTR) were treated with
TGFβ for days indicated and counted using a Neubauer chamber. Data are means of three independent experiments.
Statistical values are calculated by using an unpaired, two-tailed t-test. p-value ≤ 0.05 indicated with (*), p-value ≤ 0.01
indicated with (**).
3.2.3.3. Dlx2 is not sufficient to induce EMT
To investigate whether expression of Dlx2 by itself induces EMT, we stably infected
NMuMG cells with lentiviral particles encoding N-terminal HA-tagged murine Dlx2 and
used cell pools for further analysis. Dlx2 is exclusively expressed in the nucleus of stably
infected NMuMG cells and does not induce EMT, as the cells are neither elongated nor
flattened and do not reveal increased motility shown by Boyden chamber-based migration
assay (Figure 15A, Supplementary Figure S9). To investigate whether expression of Dlx2
induces a loss of epithelial and a gain of mesenchymal markers, we analyzed the expression
of the epithelial marker E-cadherin and the mesenchymal markers N-cadherin and NCAM.
Western Blot analysis revealed a decreased expression of E-cadherin in Dlx2-expressing
NMuMG cells, whereas N-cadherin and NCAM expression remained unchanged (Figure
15B). The repression of E-cadherin gene expression in Dlx2-expressing NMuMG cells was
confirmed by immunofluorescence staining for E-cadherin and by the reduction in E-cadherin
mRNA levels (Figure 15C, 16D). Reduced expression of E-cadherin is mediated on the
transcriptional level, as shown by an E-cadherin promoter reporter assay (Figure 15D). Yet,
considering that the remaining E-cadherin protein is localized in functional cell-cell junctions
suggests that it is sufficient to prevent detachment and scattering of Dlx2-expressing
NMuMG cells. 
In summary, Dlx2-expressing NMuMG cells show a decrease in E-cadherin protein levels,
but no mesenchymal morphology, increased motility nor upregulation of the mesenchymal
markers N-cadherin or NCAM, thus failing to show any hallmarks of bona fide EMT. Thus,
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Dlx2 is not sufficient to induce EMT.
3.2.3.4. Dlx2 enables TGFβ-resistant growth
We next investigated whether expression of Dlx2 affects proliferation and/or apoptosis of
EMT undergoing NMuMG cells. Dlx2-expressing NMuMG cells revealed a significantly
increased cell growth in comparison to control cells and displayed no sensitivity towards
TGFβ-mediated growth inhibition (Figure 15E). To investigate whether this is due to
increased proliferation or decreased apoptosis, we compared the rates of proliferation (BrdU
incorporation) and apoptosis (Annexin V staining) of control and Dlx2-expressing NMuMG
cells under TGFβ treatment. In comparison to control cells, Dlx2-expressing NMuMG cells
reveal an increased proliferation and decreased apoptosis rate in presence of TGFβ (Figure
15F, G). Thus, the accelerated and TGFβ resistant growth of Dlx2-expressing NMuMG cells
relies on both increased proliferation and decreased apoptosis during TGFβ-induced EMT. 
In summary, loss of function and gain of function experiments confirm that Dlx2 is required
for cell survival and proliferation during TGFβ-induced EMT. 
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Figure 15. Dlx2 expression leads to increased proliferation and resistance towards TGFβ-induced apoptosis. (A, left
panel) Dlx2 is exclusively localized in the nucleus of NMuMG cells. Confocal laser scanning microcopy NMuMG cell
stably expressing N-terminal HA-tagged Dlx2 (green). Dlx2 was detected by anti-HA immunofluorescence staining. Blue
DAPI staining visualizes nuclei. Size bar = 50µm. (A, right panel) Dlx2 expression is not sufficient to induce EMT. Phase-
contrast microphotographs of Dlx2-expressing and control NMuMG cells. Note that Dlx2-expressing NMuMG cells are not
individual nor flattened, showing no hallmarks of mesenchymal cells. Size bar = 50µm. (B) Dlx2 expression is not sufficient
to increase expression of mesenchymal markers. Immunoblotting analysis for the epithelial marker E-cadherin and the
mesenchymal markers NCAM and N-cadherin in Dlx2-expressing and control NMuMG cells. Immunoblotting against
vinculin was used as a loading control. (C) Dlx2 expression reduces expression of the epithelial marker E-cadherin.
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Confocal laser scanning microcopy analysis of E-cadherin in Dlx2-expressing and control NMuMG cells (red). Note that E-
cadherin expression is reduced but still present in intercellular adhesions. Blue DAPI staining visualizes nuclei. Size bar =
50µm. (D) Dlx2 mediates transcriptional repression of the E-cadherin gene. Dlx2-expressing and control NMuMG cells
were transfected with a luciferase reporter plasmid containing 423 bp of the E-cadherin promotor sequence. Values were
normalized to Renilla luciferase activity. (E) Dlx2 expression promotes accelerated cell growth which is resistant to TGFβ-
mediated growth inhibition. Dlx2-expressing and control NMuMG cells were treated with or without TGFβ for days
indicated and counted using a Neubauer chamber. (F) Expression of Dlx2 decreases apoptosis during TGFβ-induced EMT.
Dlx2-expressing and control NMuMG cells were treated with TGFβ for days indicated. Apoptosis was assessed by Annexin
V staining and FACS analysis. (G) Expression of Dlx2 increases proliferation during TGFβ-induced EMT. Dlx2-expressing
and control NMuMG cells were treated with TGFβ for days indicated.Proliferation was assessed by BrdU incorporation and
FACS analysis. Data are means of three independent experiments. Statistical values are calculated by using an unpaired,
two-tailed t-test. p-value ≤ 0.05 indicated with (*), p-value ≤ 0.01 indicated with (**).
3.2.3.5. Dlx2 attenuates TGFβ-induced EMT
We next investigated whether expression of Dlx2 has an impact on EMT induction and/or
progression in NMuMG cells. Control and Dlx2-expressing NMuMG cells were treated with
TGFβ and changes in cell morphology, invasion and molecular marker expression were
followed. In contrast to control cells which exhibit a bona fide EMT upon TGFβ-treatment
(Figure 16A, upper panel), the Dlx2-expressing NMuMG cells showed a less flattened and
less elongated, but more compact cell morphology (Figure 16A, lower panel). Hence, we
analyzed whether Dlx2-expressing NMuMG follow EMT-associated changes in cell
adhesion and/or cytoskeletal composition. For this, we performed a immunofluorescence
staining for phosphorylated focal adhesion kinase (pFAK), the intermediate filament
vimentin and actin stress fibers (phalloidin). As shown, Dlx2-expressing NMuMG cells when
treated with TGFβ display reduced staining for pFAK and vimentin accompanied by reduced
actin-based stress fibers formation, indicating that Dlx2-expressing NMuMG cells do not
undergo a bona fide EMT upon treatment with TGFβ. To further validate that Dlx2
expression attenuates TGFβ-induced EMT, we analyzed invasion of the control and Dlx2-
expressing NMuMG cells into collagen I matrix in the presence of TGFβ. In contrast to
control cells which invade into the collagen I matrix, the Dlx2-expressing NMuMG cells fail
to form invasive protrusions, thus confirming that Dlx2 expression prevents EMT (Figure
16C). Next, we quantified the loss of epithelial marker and gain of mesenchymal marker
expression in TGFβ-treated control and Dlx2-expressing NMuMG by quantitative RT-PCR.
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The loss of the epithelial marker E-cadherin is accelerated in TGFβ-treated Dlx2-expressing
NMuMG cells, whereas NCAM induction is comparable to controls (Figure 16D, E).
Interestingly, Dlx2-expressing NMuMG cells reveal no upregulation of the mesenchymal
marker N-cadherin (Figure 16F). In summary, Dlx2-expressing NMuMG do not undergo a
bona fide TGFβ-induced EMT. In comparison to control cells, Dlx2-expressing cells display
(i) reduced stress fibers formation (ii) reduced expression of vimentin (iii) reduced focal
adhesion (iv) no formation of invasive protrusions in a 3D collagen I matrix and (v) reduced
expression of mesenchymal marker N-cadherin. Moreover, although loss of E-cadherin is
accelerated, NCAM induction is comparable to control cells illustrating the Dlx2 expression
provokes a partial EMT.
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Figure 16. Dlx2-expression prevents a bona fide EMT. (A) Dlx2 expressing NMuMG cells do not undergo a bona fide
EMT. Phase-contrast microphotographs of 10 days TGFβ-treated Dlx2-expressing and control NMuMG cells. Note that
TGFβ-treated Dlx2-expressing cells have a less elongated and flattened cell morphology. Size bar = 50µm. (B, upper
panel) Dlx2 expression prevents TGFβ-induced actin stress fiber formation. Confocal laser scanning microcopy of Dlx2-
expressing and control NMuMG cells treated for 8 days with TGFβ. Actin fibers were visualized by phalloidin staining. Blue
DAPI staining visualizes nuclei. Size bar = 50µm. (B, middle panel) Dlx2 expression prevents phosphorylation of focal
adhesion kinase (FAK). Confocal laser scanning microcopy of Dlx2-expressing and control NMuMG cells treated for 8 days
with TGFβ. Phosphorylated FAK was visualized by immunostaining (green), actin stress fiber by phalloidin staining (red).
Blue DAPI staining visualizes nuclei. Size bar = 50µm. (B, lower panel) Dlx2 expression prevents upregulation of the
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mesenchymal intermediate filament vimentin. Confocal laser scanning microcopy of Dlx2-expressing and control NMuMG
cells treated for 8 days with TGFβ. Vimentin was visualized by immunostaining (red) and vimentin positive cells were
counted: CTR-NMuMG cells were 96%, Dlx2-expressing NMuMG cells were 26% positive for vimentin. Size bar = 50µm.
(C) Dlx2 expression prevents EMT-mediated invasion into collagen I. Dlx2-expressing and control NMuMG cells were
embedded in collagen I and treated with or without TGFβ for 3 days. Actin cytoskeleton was stained by phalloidin (green)
and visualized by confocal laser scanning microcopy. (D) Dlx2 expression accelerates loss of E-cadherin expression during
TGFβ-induced EMT. E-cadherin mRNA levels were determined by quantitative RT-PCR in NMuMG cells treated with
TGFβ for times indicated. Values were normalized to endogenous RPL19 levels. (E) Dlx2 expression does not prevent
induction of NCAM during TGFβ-induced EMT. NCAM mRNA levels were determined by quantitative RT-PCR in
NMuMG cells treated with TGFβ for times indicated. Values were normalized to endogenous RPL19 levels. (F) Dlx2
expression prevents upregulation of N-cadherin during TGFβ-induced EMT. N-cadherin mRNA levels were determined by
quantitative RT-PCR in NMuMG cells treated with TGFβ for times indicated. Values were normalized to endogenous
RPL19 levels. Data are shown as mean ± SD and are representative of three independent experiments. Statistical values are
calculated by using an unpaired, two-tailed t-test. p-value ≤ 0.05 indicated with (*), p-value ≤ 0.01 indicated with (**), p-
value ≤ 0.001 indicated with (***).
3.2.3.6. Dlx2 inhibits canonical TGFβ signaling 
Tumor cells are well known to escape from TGFβ-mediated growth inhibition by attenuating
the apoptotic, canonical TGFβ-signaling. This is shown to be achieved by repression of the
TGFβ receptor II (TGFβRII) levels or by inactivating mutations of Smad proteins
(Chakravarthy et al., 1999; Gobbi et al., 1999; Gobbi et al., 2000; Buck et al., 2004). To
investigate whether attenuation of the apoptotic, canonical TGFβ signaling pathway is
responsible for the TGFβ resistant cell growth of Dlx2-expressing NMuMG cells, we
determined the presence and activities of different canonical TGFβ signaling molecules.
Protein levels of the TGFβRII were decreased in Dlx2-expressing NMuMG cells, whereas
Smad4 protein levels were unchanged (Figure 17A). Decreased TGFβRII promoter reporter
activity accompanied by reduced TGFβRII mRNA levels illustrated that repression of
TGFβRII is mediated on the transcriptional level (Figure 17B, C). Consequently, following
the reduction of TGFβRII protein levels, phosphorylation of the effector protein Smad2 was
reduced along with the activity of the common mediator Smad4, as illustrated by western blot
and decreased Smad4 luciferase reporter activity (CAGA box reporter), respectively (Figure
17D, E). Finally, decreased TGFβ signaling lead to reduced transcriptional control of TGFβ
target proteins, as shown by reduced expression of the cyclin-dependent kinase inhibitor
p21CIP1 and stabilization of the mitogenic c-Myc protein (Figure 17F, 18A lower panel). We
Dlx2 protects NMuMG cells from TGFβ-induced cell cycle arrest and apoptosis
- 108 -
found no upregulation of inhibitory Smads such as Smad7 nor upregulation of the Smad
specific E3 ubiquitin protein ligase 1 (Smurf1) which were shown to inhibit TGFβ receptor
signaling and promote TGFβ receptor degradation, respectively (Data not shown) (Di
Guglielmo et al., 2003; Zhang et al., 2007). 
In summary, expression of Dlx2 leads to a transcriptional repression of the TGFβRII gene,
reduced Smad activity, reduced expression of the cell-cycle inhibitor p21CIP1 and stabilization
of the mitogenic c-Myc protein, thus inhibiting the apoptotic, canonical TGFβ signaling
pathway.. 
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Figure 17. Dlx2 expression attenuates apoptotic, canonical TGFβ signaling. (A) Dlx2 expression reduces TGFβRII
expression in NMuMG cells. Immunoblotting analysis of Dlx2-expressing and control NMuMG cells. Immunoblotting
against vinculin was used as a loading control. (B) Dlx2 mediates transcriptional repression of the TGFβRII gene. Dlx2-
expressing and control NMuMG cells were transfected with a luciferase reporter plasmid containing 255 bp of the TGFβRII
promotor sequence and treated with or without TGFβ for 3 days. Values were normalized to Renilla luciferase activity.(C)
Dlx2 expression reduces TGFβRII mRNA levels in NMuMG cells. TGFβRII mRNA levels were determined by quantitative
RT-PCR. Values were normalized to endogenous RPL19 levels. (D) Dlx2 expression provokes reduced phosphorylation of
Smad2 proteins. Immunoblotting analysis of Dlx2-expressing (Pools and Dlx2 high expressing clones 1, 2) and control
NMuMG cells. Immunoblotting against GAPDH was used as a loading control. (E) Dlx2 expression in NMuMG cells
decreases Smad 4 activity. Dlx2-expressing and control NMuMG cells were transfected with a luciferase reporter plasmid
Dlx2 protects NMuMG cells from TGFβ-induced cell cycle arrest and apoptosis
- 110 -
containing repetitive elements of Smad4 binding motifs and treated with or without TGFβ for 3 days. Values were
normalized to Renilla luciferase activity. (F) Dlx2 expression decreaeses expression of the cell cycle inhibitor p21CIP1.
Immunoblotting analysis of Dlx2-expressing and control NMuMG cells treated for 6 days with TGFβ. Immunoblotting
against actin was used as a loading control. Data are shown as mean ± SD and are representative of three independent
experiments. Statistical values are calculated by using an unpaired, two-tailed t-test. p-value ≤ 0.05 indicated with (*), p-
value ≤ 0.01 indicated with (**), p-value ≤ 0.001 indicated with (***).
3.2.3.7. Dlx2 promotes MAPK and PI3K activation
The MAPK and PI3K pathways are well known to be interactively engaged upon TGFβ
signaling to ensure survival and proliferation (Janda et al., 2002; Lee et al., 2007). Hence, we
investigated if these pathways were also active in Dlx2-expressing NMuMG cells. In order to
follow MAPK activity we analyzed the phosphorylation of the MAPK Erk1/2. As shown,
Erk1/2 phosphorylation levels are constantly higher in Dlx2-expressing NMuMG cells in the
absence as well as presence of TGFβ (Figure 18A). Assessing whether increased MAPK
signaling is responsible for the accelerated and TGFβ-resistant growth of Dlx2-expressing
NMuMG cells, we treated both control and Dlx2-expressing NMuMG cells with an inhibitor
for the MAPKK MEK1/2 (PD98059) and quantified cell growth in the absence or presence of
TGFβ. Treatment with PD98059 for 4 days lead to an increased growth reduction of Dlx2-
expressing NMuMG cells (-54%) as compared to control cells (-20%), indicating that Dlx2-
mediated accelerated cell growth relies partially on MAPK activity (Figure 18B). Notably,
PD98059 treatment of Dlx2-expressing NMuMG cells did not normalize cell growth to
control levels, indicating that MAPK activity was not solely responsible for Dlx2-mediated
accelerated proliferation. Combined treatment with TGFβ and PD98059 for 4 days lead to
further growth reduction of Dlx2-expressing NMuMG cells (-60%), whereas control cell
growth completely collapsed (-96%) (Figure 18B). Thus, increased MAPK activity is
important for the accelerated cell growth of Dlx2-expressing NMuMG cells but is not
essential for TGFβ resistant proliferation. 
To investigate whether the PI3K pathway is cooperating with the MAPK pathway to ensure
accelerated and TGFβ resistant cell growth of Dlx2-expressing NMuMG cells, we assessed
the phosphorylation of the PI3K target protein kinase B (PKB). PKB is increased in
phosphorylation in Dlx2-expressing NMuMG cells on both activation sites (Thr308 and
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Ser473) in the presence as well as absence of TGFβ (Figure 18A). To investigate to what
extent PI3K signaling is required for TGFβ resistant growth of Dlx2-expressing NMuMG
cells, we treated both control and Dlx2-expressing NMuMG cells with the PI3K inhibitor
ZSTK474 for 4 days in the presence or absence of TGFβ and determined cell growth. In
contrast to control cells whose growth slightly declines after 4 days treatment with ZSTK474
(-10%), the growth of Dlx2-expressing NMuMG cells was strongly reduced and almost
normalized to control cell growth (-61%) (Figure 18C). Furthermore, combined treatment
with TGFβ and ZSTK474 for 4 days resulted in further significant growth reduction of both
control (-88%) and Dlx2-expressing NMuMG cells (-76%) (Figure 18C). Thus, comparable
to MAPK signaling, the PI3K plays an important role for Dlx2-mediated acceleration of
growth, but is not solely responsible for TGFβ-resistant proliferation. Comparing the
magnitude of inhibition mediated by either PD98059 and ZSTK474, we assume that PI3K
activity plays a pivotal role in Dlx2-mediated TGFβ resistant growth. In summary, Dlx2-
mediated TGFβ-resistant cell growth relies on the cooperative activity of the MAPK and the
PI3K pathways. 
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Figure 18. Dlx2 promotes resistance against TGFβ-mediated growth inhibition via cooperated activation of the
MAPK and PI3K signaling pathways. (A) Dlx2 expression increases phosphorylation of the MAPK Erk1/2 and the PI3K
target protein PKB at both activation sites (Serine473/Threonine308). Immunoblotting analysis of Dlx2-expressing and
control NMuMG cells treated with or without TGFβ for 4 days. Immunoblotting against GAPDH was used as a loading
control. (B) Dlx2-mediated TGFβ-resistant growth relies on MAPK activity. Dlx2-expressing and control NMuMG cells
were treated with TGFβ for 4 days in combination with the MAPK inhibitor PD98059 (9.35µM) or DMSO (solvent control)
and counted using a Neubauer chamber. (C) Dlx2-mediated TGFβ-resistant growth relies on PI3K activity. Dlx2-expressing
and control NMuMG cells were treated with TGFβ for 4 days in combination with the PI3K inhibitor ZSTK474 (0.239µM)
or DMSO (solvent control) and counted using a Neubauer chamber. (D) Dlx2-mediated increased proliferation does not
depend on an autocrine TGFβ-loop. Dlx2-expressing and control NMuMG cells were treated with the TGFβRI inhibitor
SB431542 (3µM) or DMSO (solvent control) and counted using a Neubauer chamber. (E) Dlx2-mediated TGFβ-resistant
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growth relies on EGFR activity. Cells were treated with TGFβ for 4 days in combination with the EGFR inhibitor AG1478
(0.775 µM) or DMSO (solvent control) and counted using a Neubauer chamber. (F) Inhibition of EGFR activity reduces
MAPK Erk1/2 and PKB phosphorylation in Dlx2-expressing NMuMG cells. Immunoblotting analysis of Dlx2-expressing
and control NMuMG cells treated with the EGFRi AG1478 (1.55µM) for 6 hours. Immunoblotting against GAPDH was
used as a loading control. Data are shown as mean ± SD and are representative of three independent experiments. Statistical
values are calculated by using an unpaired, two-tailed t-test. p-value ≤ 0.05 indicated with (*), p-value ≤ 0.01 indicated with
(**), p-value ≤ 0.001 indicated with (***).
3.2.3.8. Dlx2 engages EGFR for TGFβ resistant growth
Invasive tumor cells are known to promote growth and invasion by utilizing TGFβ within an
autocrine, positive feedback loop (Park et al., 2000; Dumont et al., 2003). This is known to
be achieved by activation of the MAPK and/or PI3K pathways through non-canonical TGFβ
signaling (Lee et al., 2007, Bakin et al., 2000). Hence, we assessed whether Dlx2-mediated
accelerated growth was driven by an autocrine, positive feedback loop of TGFβ. Control and
Dlx2-expressing NMuMG cells were treated with an inhibitor for TGFβRI (SB431542) and
cell growth was quantified. Treatment of both control or Dlx2-expressing NMuMG cells with
SB431542 for 4 days did not reveal any significant difference in cell proliferation, revealing
that the accelerated growth of Dlx2-expressing NMuMG cells is not caused by an autocrine
TGFβ loop (Figure 18D). 
ErbB family members are known to prevent TGFβ-induced cell-cycle arrest and apoptosis by
activating the PI3K pathway (Fabregat et al., 1996; Fabregat et al., 2000; Murillo et al., 2005;
Del Castillo et al., 2006). Furthermore, neuronal transit-amplifying cells, which were positive
for Dlx2, were shown to be highly responsive to epidermal growth factor (EGF) stimulation.
In developing olfactory bulb interneurons, Dlx1 and Dlx2 were shown to control the
expression of ErbB4, indicating that Dlx2 could engage ErbB family members to drive
proliferation and survival during TGFβ-mediated selection (Doetsch et al., 2002; Long et al.,
2007). Therefore, we investigated whether inhibition of EGFR signaling impaired
accelerated, TGFβ-resistant growth of Dlx2-expressing NMuMG cells. For this purpose, we
treated control and Dlx2-expressing NMuMG cells with the EGFR inhibitor AG1478 and
assessed cell growth. Treatment with AG1478 for 4 days lead to an reduced growth of Dlx2-
expressing NMuMG cells (-54%) as compared to control cells (-20%), indicating that Dlx2-
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mediated accelerated cell growth relied on EGFR activity (Figure 18E). Combined treatment
with the AG1478 and TGFβ for 4 days induced growth arrest and apoptosis of both control
cells (-97%) and Dlx2-expressing NMuMG cells (-90%), demonstrating that Dlx2-mediated
TGFβ resistant growth relied on the EGFR activity (Figure 18E). Interestingly, the
magnitudes of growth inhibition mediated by AG1478 in the presence as well as in the
absence of TGFβ resembled ZSTK474-mediated PI3K inhibition, pointing towards a
functional relationship between EGFR and PI3K activity. To address whether inhibition of
the EGFR affects MAPK and/or PI3K signaling, we analyzed the phosphorylation of the
MAPK Erk1/2 and PKB in control and Dlx2-expressing NMuMG cells after AG1478
treatment. Treatment of Dlx2-expressing NMuMG cells with AG1478 lead to reduced
phosphorylation of PKB and Erk1/2, thus showing that EGFR is required for the activation of
both pathways (Figure 18F). To confirm that EGF induces PI3K and MAPK activation, we
stimulated starved control and Dlx2-expressing NMuMG cells with recombinant EGF (rEGF)
and followed Erk1/2 and PKB phosphorylation. Treatment of starved Dlx2-expressing
NMuMG cells with rEGF lead to increased and sustained phosphorylation of PKB and
MAPK Erk1/2 (Supplementary Figure S10). 
Thus, EGFR activation leads to increased PI3K and MAPK activity in Dlx2-expressing
NMuMG cells which is required for survival and proliferation during TGFβ-induced EMT. 
3.2.3.9. Dlx2 is required for tumor growth and metastasis
EMT and resistance towards TGFβ-mediated growth inhibition plays an important role in
tumor progression and metastasis formation of melanomas (Silye et al., 1998; Sanders et al.,
1999; Poser et al., 2001; Teicher, 2001; Kuphal and Bosserhoff, 2006; Boone et al., 2008).
Hence, we investigated whether knockdown of Dlx2 expression in B16 melanomas cells
impairs their ability to form a tumor and to metastasize. First, we analyzed whether Dlx2 is a
target of TGFβ signaling in melanoma cells, by treating B16 melanoma cells for 4 days with
TGFβ and assessing Dlx2 expression. Dlx2 mRNA is 6x upregulated in 4 days TGFβ-treated
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B16 melanomas, confirming that Dlx2 is a target of TGFβ signaling (Figure 19A). Next we
investigated whether knockdown of Dlx2 impairs the ability of B16 melanoma cells to form a
tumor and to metastasize, by performing subcutaneous injections of three independent stable
Dlx2 knockdown B16 melanoma cells (shDlx2-B16 I-III) into C57BL/6 mice and quantifying
tumor growth and metastasis to the lung. Knockdown of Dlx2 in B16 melanomas cells
resulted in a significant reduction in primary tumor growth, showing that Dlx2 played an
important role in primary tumor formation (Figure 19B). To investigate whether the potential
to metastasize is impaired in shDlx2-B16 melanomas, we quantified micro-metastatic lesions
in the lung of C57BL/6 mice injected subcutaneously with shDlx2-B16 melanoma cells. The
number of micro-metastatic lesion was significantly decreased in C57BL/6 mice injected
with shDlx2-B16 melanoma cells, showing that Dlx2 expression was important for the
metastatic spread of B16 melanoma cells (Figure 19C, D). In summary, suppression of Dlx2
in B16 melanoma cells resulted in decreased primary tumor growth and metastasis formation,
indicating that Dlx2 is required for efficient tumor growth and metastasis formation. 
Next we investigated whether increased expression of Dlx2 correlated with the ability of
human tumors to grow, progress and to metastasize. Surveying gene expression profiles of
human cancer biopsies using the NextBio.com database, we found a positive and significant
correlation of increased Dlx2 expression and the potential of melanoma and lung cancer to
metastasize. (Table 1). In prostate and lung cancer, also a positive and significant correlation
of increased Dlx2 expression and advances in tumor stage was detected, indicating that Dlx2
may play a significant role in primary tumor formation (Table 1). Treatment of human glioma
cells with an inhibitor for TGFβRI results in a significant downregulation of Dlx2, indicating
that Dlx2 is also a target of TGFβ signaling in gliomas and could have an impact on tumor
growth and metastasis formation (Table 1). Interestingly, for all these tumors, in particular in
melanomas, it is well known that the resistance towards TGFβ-mediated growth inhibition
and EMT plays an essential role for their metastatic spread, supporting the hypothesis that
Dlx2 has a protective function during human tumor-progression and metastasis formation . 
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Figure 19. Dlx2 is required for primary tumor growth and metastasis to the lung. (A) Treatment of B16 melanomas
cells with TGFβ induces upregulation of Dlx2. B16 melanoma cells were treated with TGFβ for 6 days and Dlx2 mRNA
levels were determined by quantitative RT-PCR. Values were normalized to endogenous RPL19 levels. (B) Loss of Dlx2
function impairs tumor growth of B16 melanoma cells. B16 melanoma cells were ablated for Dlx2 by shRNA mediated
knockdown using three independent Dlx2-specific shRNA sequences (shDlx2 1-3). Cells were injected into both flanks in
C57/Bl6 mice and tumor weight was measured after 2 weeks of incubation time. N=18. (C) Loss of Dlx2 function impairs
metastatic potential of B16 melanoma cells. B16 melanoma cells were ablated for Dlx2 by shRNA mediated knockdown
using three independent Dlx2-specific shRNA sequences (shDlx2 1-3). Cells were injected into both flanks in C57/Bl6 mice
and micrometastatic lesions in the lung were counted after 2 weeks of incubation time. (D) Micrometastatic lesion in the
Dlx2 protects NMuMG cells from TGFβ-induced cell cycle arrest and apoptosis
- 117 -
lung of C57/Bl6 mice. Serial histological sections of lungs from C57/Bl6 injected subcutaneously with shDlx2-1 and
shControl B16 melanomas cells were stained with hematoxylin/eosin. N=5. Size bar = 100 µm. Data are shown as mean ±
SD and are representative of three independent experiments. Statistical values are calculated by using an unpaired, two-tailed
t-test. p-value ≤ 0.05 indicated with (*), p-value ≤ 0.01 indicated with (**), p-value ≤ 0.001 indicated with (***).
Cancer type Bioset name p-value foldupregulation
NCBI-GEO
accession number
Melanoma
tumors
Intermediate metastatic potential
melanoma vs. Foreskin melanocyte
normal
0.0451 4.19 GSE4845
High metastatic potential melanoma vs.
Foreskin melanocyte normal
0.0361 4.93 GSE4845
Intermediate metastatic potential
melanoma vs. Low metastatic potential
melanoma
0.0196 2.52 GSE4845
High metastatic potential melanoma vs.
Low metastatic potential melanoma
0.0028 3.03 GSE4845
High metastatic potential melanoma vs.
Low metastatic potential melanoma
0.0067 2.96 GSE4845
Metastatic melanoma vs. normal
melanocytes
0.0021 18.8 GSE4570
Lung cancer
Stage 4 vs. Stage 1 0.0123 3.847 GSE2109
Distant metastasis vs. no metastasis 0.0064 3.045 GSE2109
Stage 4 vs. Stage 1 0.012 3.087 GSE2109
Stage 2A vs. Stage 1b 0.0351 3.29 GSE3141
Prostate cancer State 4 vs. stage 2 0.0039 3.27 GSE6919
Glioma
TGFβ inhibition leads to Dlx2
downregulation
0.0037 -21.9
(Bruna et al., 
2007)
Table 1. Dlx2 expression in human cancers. Expression of Dlx2 correlates significantly with advanced tumor progression
and metastatic potential of melanoma, glioma, lung and prostate cancers. Microarray data are accessible at NCBI Gene
Expression Omnibus (GEO) database.  
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3.2.4. Discussion
Overcoming TGFβ-mediated growth inhibition at early stages of tumor development and to
use it at later stages as a pro-invasive factor, plays an essential role in tumor progression and
metastasis formation (Roberts and Wakefield, 2003; Thiery and Sleeman, 2006; Pardali and
Moustakas, 2007; Massague, 2008; Yang and Weinberg, 2008). Hence, to understand the
molecular mechanisms enabling cancer cells to prevail TGFβ-induced cell-cycle arrest and
apoptosis plays an important role in cancer therapy. In vitro EMT models, such as the non-
transformed NMuMG cells used here, provide experimental systems which can be used to
dissect to molecular mechanism promoting resistance against TGFβ-mediated growth arrest
and EMT. 
In the present study, we performed gene expression profiling experiments and quantitive RT-
PCR analysis of different in vitro EMT model systems to identify the transcription factor
Dlx2 as a commonly upregulated gene during EMT. By utilizing the established NMuMG
cells as an TGFβ-induced EMT-model system, the B16 mouse melanoma model and human
cancer gene expression databases we identified Dlx2 as a transcription factor promoting
tumor growth and metastasis.
Dlx2 is upregulated by canonical TGFβ signaling and loss of function as well as gain of
function studies in NMuMG cells revealed that Dlx2 function is not required and its
expression is not sufficient to induce EMT. Instead, we found that Dlx2 function is crucial for
the protection from TGFβ-induced cell-cycle arrest and apoptosis. This is achieved by two
major modifications, namely the inhibition of the apoptotic TGFβ signaling pathway and the
simultaneous activation of the mitogenic and survival-ensuring MAPK and PI3K pathways,
respectively (Figure 20): 
The Dlx2-mediated attenuation of the canonical TGFβ signaling pathway is a consequence of
a transcriptional repression of the TGFβ receptor II (TGFβRII) gene, leading to reduced
TGFβRII protein levels, decreased activation of the signal transducers Smad2/4 and thus
reduced transcriptional repression and/or activation of TGFβ target genes, such as the
mitogenic c-Myc protein or the cell-cycle inhibitor p21CIP1, respectively. Whether Dlx2 binds
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directly to the TGFβRII promotor to repress its transcription remains elusive. Since no
consensus binding motif for Dlx2 has been defined, we was not possible to perform any in
silico studies. The Dlx2-driven mitogenic and proliferative signals are mediated by the
EGFR, which activates the MAPK and the PI3K pathways to guarantee survival and
proliferation in the presence of TGFβ (Figure 20). This goes in line with studies showing that
EGF protects from TGFβ-induced apoptosis by stimulating PI3K activity and that neuronal
transit amplifying cells, which are overexpressing Dlx2, are found to be highly responsive to
epidermal growth factor (EGF) stimulation (Doetsch et al., 2002; Murillo et al., 2005; Del
Castillo et al., 2006; Uttamsingh et al., 2008). We found no upregulation of the EGFR nor
increased production of its ligand EGF in Dlx2-expressing NMuMG cells. Hence, the
mechanism how Dlx2 triggers EGFR signaling to promote survival and proliferation remains
elusive and is under current investigations in our laboratory. 
As a tribute to reduced canonical TGFβ signaling, Dlx2-expressing NMuMG cells do not
undergo a bona fide TGFβ-induced EMT, as the cells reveal no typical mesenchymal cell
morphology, no formation of stress fiber, no invasion into collagen and less upregulation of
mesenchymal markers like N-cadherin or vimentin. Still, the loss of E-cadherin is accelerated
in Dlx2-expressing NMuMG cells and NCAM induction is comparable to TGFβ-treated
control cells. Thus, depending on the expression levels of Dlx2, cells may undergo only a
partial EMT, which could explain why the detection of full EMT is rare in human cancer
biopsies (Tarin et al., 2005; Thompson et al., 2005). 
Supporting the importance of Dlx2 function during tumor development and progression, we
performed loss of function studies by generating stable Dlx2 knockdown B16 melanoma cells
which were subcutaneously injected into syngeneic C57/Bl6 mice. Quantifying primary
tumor growth and micrometastatic lesions in the lung, we found that loss of Dlx2 function
significantly impairs the ability of B16 melanomas to form primary tumors and metastasis in
the lung. Furthermore, surveying gene expression database of human cancer biopsies have
revealed that Dlx2 expression significantly correlates with tumor progression and the
metastatic potential of human melanoma, prostate and lung cancers. Interestingly, for these
cancers the resistance towards TGFβ-mediated growth inhibition plays an essential role
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during tumor progression and metastasis formation (Heredia et al., 1996; Guo et al., 1997;
Derynck et al., 2001; Lucke et al., 2001; Buck et al., 2004; Ao et al., 2006; Hoek et al., 2006;
Biswas et al., 2007; Borczuk et al., 2008; Jeon et al., 2008). 
In summary, we identified the transcription factor Dlx2 as an upregulated target gene of
canonical TGFβ signaling, which functions in a negative feedback loop to attenuate apoptotic
TGFβ signaling, thereby enabling cells to survive and to undergo EMT. The correlation
between the gain of Dlx2 expression and the metastatic capacity of human and murine tumors
indicate that Dlx2 has a critical function in malignant tumor progression and metastasis and,
thus, warrant further investigation. 
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Figure 20. Dlx2 upregulation protects from TGFβ induced cell-cycle arrest and apoptosis. A working model of the
molecular mechanisms underlying Dlx2-mediated protection from TGFβ-induced cell-cycle arrest and apoptosis is depicted.
Binding of TGFβ to the TGFβ receptor induces phosphorylation and activation of the receptor associated signal transducers
Smad2/3. Activated Smad2/3 forms with Smad4 a trimeric complex and enters the nucleus to induce expression of TGFβ-
target genes such as the cell cycle inhibitor p21CIP1 or the transcription factor distal-less homeobox 2 (Dlx2). Dlx2 expression
promotes the transcriptional repression of the TGFβRII gene (dashed lines). This leads to reduced TGFβ receptor expression,
reduced Smad2/3 activation and decreased expression of cytostatic genes such as p21CIP1. Simultaneously, Dlx2 promotes
epidermal growth factor receptor (EGFR) mediated activation of the mitogenic and pro-survival MAPK and PI3K pathways,
leading to MAPK Erk1/2 and PKB phosphorylation, respectively. Thus, the transcription factor Dlx2 ensures survival during
TGFβ-induced EMT by attenuating the apoptotic TGFβ signaling pathway and by activating mitogenic and survival
promoting MAPK and PI3K pathways, respectively.
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3.2.5. Supplementary Figures
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Supplementary Figure S8: Dlx2 is not required for EMT. Immunoblotting analysis for the epithelial marker E-cadherin and
the mesenchymal markers N-cadherin and NCAM in Dlx2-depleted (siDlx2) and control (siCTR) NMuMG cells treated with
TGFβ for 6 days. Immunoblotting against GAPDH was used as a loading control. 
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Figure S9: Dlx2 expression does not increase motility of NMuMG cells. Boyden chamber-based motility assay of Dlx2-
expressing and control NMuMG cells. 
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Figure S10. Dlx2 expression leads to increased EGFR activity. Immunoblotting analysis of Dlx2-expressing and control
NMuMG cells treated with recombinant murine EGF (rEGF, 10ng/ml) for times indicated. Note that PKB Serine473
phosphorylation is increased and sustained in Dlx2-expressing NMuMG cells. Immunoblotting against GAPDH was used as
a loading control. 
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3.2.6. Material and Methods
Reagents and antibodies
Recombinant human TGFβ (#240-B, Becton&Dickinson), recombinant murine EGF
(#PMG8041, Invitrogen). Antibodies: E-cadherin for immunfluorescence (#13-1900,
Zymed), for western blot (#610182, Transduction Laboratories), N-cadherin for
immunfluorescence (#33-3900, Zymed) for western blot (#M142, Takara), NCAM (5B8, gift
from U. Cavallaro), Vimentin (#V2258, Sigma-Aldrich), Vinculin (#V9131, Sigma-Aldrich),
GAPDH (#ab9485, Abcam), TGFβRII (#sc-220, Santa Cruz), Smad4 (#sc-7154, Santa Cruz),
Smad2 (#3103, Cell Signaling), pSmad2 (#3101, Cell Signaling), p21CIP1(#556430,
Pharmingen), c-Myc (# 06-340, Upstate Biotechnology), pPKB Threonine (#5106, Cell
Signaling), pPKB Serine (#9271, Cell Signaling), pErk (#M-8159, Sigma-Aldrich), Erk
(#M7927, Sigma-Aldrich), pFAK (#611806, Becton&Dickinson), HA.11 (#MMS-101R,
Covance), anti-BrdU-FITC (# 347583, Becton&Dickinson). Inhibitors: MEK1/2 Inhibitor
PD98,059 (#ALX-385-023, Alexis Biochemicals), TGFβRI inhibitor SB431542 hydrate
(#S4317, Sigma-Aldrich), PI3K inhibitor ZSTK474 (#ALX-270-454, Alexis Biochemicals),
PDGFR inhibitor Thyphostin AG1296 (#ALX-270-037, Alexis Biochemicals), PI3K
Inhibitor AG1478 (#ALX-270-036, Alexis Biochemicals).
Cells and cell lines
A subclone of NMuMG cells (NMuMG/E9; hereafter NMuMG) expressing E-cadherin has
been previously described (Maeda et al., 2005). MTdeltaEcad and MCF7-shEcad have been
described (Lehembre et al., 2008). Cells were cultured in DMEM supplemented with
glutamine, penicillin, streptomycin, and 10% FCS (Sigma). NMuMG-shSmad4 and
NMuMG-shCont were obtained from P. ten Dijke (Leiden University Medical Center, The
Netherlands; Deckers et al., 2006). TGFβ treatment of NMuMG cells was performed without
serum deprivation, and TGFβ was replenished every 3 days (2 ng/ml). mDlx2 siRNA (ON-
TARGET plus, SmartPool, L-043273-01-005, mouse Dlx2) was purchased from Dharmacon.
mDlx2 shRNAs were purchased from Sigma-Aldrich. Transfections with LipofectAMINE
RNAiMAX (Invitrogen) were performed according to the manufacturer's instructions. Total
cell lysates, immunoblots, and immunofluorescence experiments were performed as
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previously described (Lehembre et al., 2008). Depending on the species origin of antibodies,
immunoblots were either probed sequentially or on multiple membranes. Adobe Photoshop
has been used to excise the relevant portion of the immunoblots from the original scans of X-
ray films exposed to chemiluminescence visualization of specific proteins, as indicated by
black frames in the figures. 
Production of lentivirus containing Dlx2 and shDlx2 short hairpin RNA. 
Murine Dlx2 shRNAs (shDlx2 #1-3, TRCN0000070598-600) and control shRNA (shCTR,
SHC002, Mission Non-Target shRNA Control Vector) were purchased from Sigma-Aldrich.
Dlx2 (kindly provided by Prof. Dr. Peter Farlie) was tagged N-terminally with HA-tag and
cloned into the lentiviral expression vector pWPXL. Lentiviral particles were produced by
transfecting HEK293T cells with the lentiviral expression vectors in combination with the
packing vector pR8.91 and the envelope encoding vector pVSV using Fugene HD. After two
of virus production, lentivirus containing supernatants were harvested, filtered (0.45 µm) and
added to target cells in presence of polybrene (8 ng/ml). Infections were performed twice a
days for two days.
Quantitative RT-PCR
Total RNA was prepared using Trizol (Invitrogen), reverse transcribed with M-MLV reverse
transcriptase RNAse (H-) (Promega, Wallisellen, Switzerland), and transcripts were
quantified by PCR using SYBR-green PCR MasterMix (Applied Biosystems, Rotkreuz,
Switzerland) and the primers indicated in Table S1. Human or mouse riboprotein L19
primers were used for normalization. PCR assays were performed in triplicates, and fold
induction was calculated against control-treated cell lines using the comparative Ct method
(ΔΔ Ct). Following primer were used: 
murine E-cadherin: 
fwd: 5'-TTTACCCAGCCGGTCTTTGA-3', rev: 5'-TCCTGGAACAGCGCCTTCT-3';
murine N-Cadherin 
fwd: 5'-CTGCCATGACTTTCTACGGAGA-3', 5'-CAATGACGTCCACCCTGTTCT-3';
murine Dlx2 
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fwd: 5'-GGCCTCACCCAAACTCAGGT-3', rev: 5'-GTATCTCGCCGCTTTTCCAC-3'; 
TGFβR2 
fwd: 5'-GGCTCTGGTACTCTGGGAAA-3', rev: 5'-AATGGGGGCTCGTAATCCT-3'; 
murine RPL19: 
fwd: 5'-ATCCGCAAGCCTGTGACTGT-3', rev: 5'-TCGGGCCAGGGTGTTTTT-3'
Reporter Assay
NMuMG cells were transfected with 200 ng reporter and 5 ng Renilla encoding plasmids
using Lipofectamine 2000. After 2 days of transfection, cell were analyzed using the Dual-
Luciferase Reporter Assay System (#E1960, Promega) and the Berthold Luminometer
LB960. Measured luciferase values were normalized to internal Renilla control. Smad4
promotor construct kindly provided by Peter ten Dijke (Dennler et al., 1998). TGFβRII
promotor reporter kindly provided by Seong-Jin Kim (Hahm et al., 1999). E-cadherin
promotor reporter kindly provided by Kirstin Verschueren (van Grunsven et al., 2003)
Cell growth curves
1x104 cells were seeded in each well of 24-well plate and cell number was assessed by using
a Neubauer counting chamber.
Migration assays
Cell migration was determined in a modified two-chamber migration assay (pore size: 8 µm;
Falcon BD, Franklin Lakes, NJ). 105 cells were seeded in 1% fetal calf serum/DMEM
(Sigma) in the upper chamber and the lower chamber was filled with 10% fetal calf serum/
DMEM. After 24h incubation at 37°C, cells in the upper chamber were carefully removed
with a cotton swap and the cells that had traversed the membrane were fixed in 4%
paraformaldehyde/HBS-Ca2+, stained with crystal violet (0.5% in 20% methanol) and
counted.
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Proliferation assay (BrdU incorporation)
Cells were incubated with 10µM BrdU for 2h at 37C. Fixed in 70% ice-cold Ethanol. Treated
with 2N HCL/0.5% Triton X-100 solution for 30 min at RT. Resuspended in 0.1 M
Na2B4O7 pH 8.5 for 2min at RT. Washed with 0.5%Tween-20/1% BSA/PBS. Incubated
with FITC labeled anti-BrdU AB (#347583, BD) for 30 min RT. Washed with
0.5%Tween-20/1% BSA/PBS. Resuspended and incubated in PBS with 5µg/ml PI for at least
1h RT. Filtered and analyzed by FACSCanto II using DIVA software.
Apoptosis assay (Annexin assay)
Cells were washed twice with cold PBS and resuspended in 1X Binding Buffer at a
concentration of 1 x 105 cells/ml. 5 µl of Cy5 Annexin V was added to cells and incubated for
15 min at RT (25°C) in the dark. After 15 min incubation at RT, cells were analyzed on a
FACSCanto II using DIVA software. 
Subcutaneous injections
Cells were harvested by trypsinization and resuspended in PBS to a final concentration of
4x105 cells/200µl. 8 weeks old C57/Bl6 mice were injected in the flank with 200 µl for each
cell line, and tumors were allowed to form for 14 days. Mice were sacrificed when the tumors
reached a diameter of 1 cm. These experiments were repeated 2 times, using 5–8 mice per
tumor group. 
Collagen gel assay
Cells trypsinized from tissue culture plates were washed with PBS and counted. 1 x 105 cells
in 333 µl media cell were mixed with 74 µl MEM, 37 µl Sodium Bicarbonate (# S8761,
Sigma-Aldrich) and 555 µl PureCol (#5409, Inamed Biomaterials). The mixtures were
distributed in chamber of 8-well CultureSlides (#354118, Becton&Dickinson) and allowed to
solidify into gel for 1 hour at 37C. Subsequently, collagen gels were overlaid with complete
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DMEM with or without TGFβ (2ng/ml). The medium with respective growth factors was
changed every second day.
Histological analysis 
The preparation of immunohistochemical analysis was performed as described previously
(Perl et al., 1998). Stainings were evaluated on an AxioVert microscope and on a LSM 510
META confocal microscope (Zeiss, Oberkochen, Germany).
Statistical analysis
Statistical analysis and graphs were generated using the GraphPad Prism software (GraphPad
Software Inc, San Diego, CA). All statistical analysis were done by unpaired, two-sided t-
test. Normality testing was performed using the Kolmogorov-Smirnov test with Dallal-
Wilkinson-Lillie for p-values.
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